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“Begin at the beginning,” the King said gravely, “and go on till you come to the end: then stop.”  
 
Uit ‘Alice’s Adventures in Wonderland’, Lewis Carroll. 
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Hereditary deafness and hearing loss 
Hearing loss and deafness are major health issues; it has been estimated that over 70,000,000 
people worldwide are unable to participate in normal verbal communication due to auditory 
handicaps (Tekin et al., 2001). The prevalence of severe hearing loss and deafness amongst 6-
12 year olds in the Netherlands was 0.74 per 1000 in 1996, making the estimated total number 
of deaf and hard of hearing in the Dutch population 11,400 (de Graaf et al., 1998).  
Considering either phenotypic manifestation or aetiology, there are many ways to classify 
hearing loss; for instance phenotypically, congenital early onset hearing loss can be discerned 
from congenital late onset, mild hearing loss from profound and conductive hearing loss from 
sensorineural (Tekin et al., 2001). 
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Figure 1.1: The peripheral auditory system is represented on the left, a cross section of the cochlear scala media 
containing the organ of Corti is represented on the right (adapted from van den Broek and Feenstra, 2007). 
Conductive hearing loss is caused by defects located distally from the cochlea, whereas sensorineural hearing 
loss is caused by defects of the cochlea or the central auditory pathways.  
IHC = Inner Hair Cell, OHC = Outer Hair Cell, PC = Pillar Cell, TM = Tectorial Membrane 
 
The etiological classification is based on a distinction made between environmental and 
genetic cause (or a combination of these) of hearing loss. Environmental and genetic factors 
have often been described to cause equal numbers of cases (Bitner-Glindzicz, 2002; Resendes 
et al., 2001). The proportion of environmental (or sporadic) as compared to genetic cases of 
hearing loss, however, in the Western world, appears to be decreasing over the last decades; 
this is possibly due to a better control of some environmental causes. For example, 
vaccination schemes and antibiotics reduce the incidence and severity of infectious diseases 
that may cause hearing loss. 
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Marazita et al. found, analysing a large group of deaf children that 37.2% were sporadic cases, 
the remaining 62.8% being 15.7% dominant and 47.1% recessive genetic cases (Marazita et 
al., 1993). A commonly used classification of genetic hearing loss is syndromic versus non-
syndromic. Syndromic causes comprise 30% of genetic deafness and hearing loss, non-
syndromic causes 70% (Resendes et al., 2001). 
Rapid advancement in identification of genes involved in hearing loss and deafness is made, 
due to progress in the Human Genome Project, cochlea specific cDNA libraries and studies of 
murine models for hearing loss (Petit, 2006). Today, over 130 loci and 40 genes for non-
syndromic hearing loss have been described, and new loci and genes are identified and 
characterized almost on a monthly basis (an up-to-date overview can be found on the 
hereditary hearing loss homepage: http://webh01.ua.ac.be/hhh/). 
Non-syndromic hearing loss may be caused by a variety of pathophysiological mechanisms: 
for example by involvement of gene products in structural integrity, transportation of ions 
across membranes and regulation of transcription factors (Tekin et al., 2001). Denotation of 
non-syndromic hearing impairment is systematic: ‘DFNA’ indicating dominant loci, ‘DNFB’ 
recessive loci, ‘DFN’ X-linked loci and ‘DFNM’ modifying loci (Bitner-Glindzicz, 2002; 
Resendes et al., 2001). 
Severity of hearing loss, caused by a single gene, may be very variable. Various factors 
influence the clinical outcome, such as the mutation itself, environmental factors and 
interacting genes. Mechanisms of gene interaction are; production of proteins interacting with 
normal gene products, genes providing alternative pathways and genes encoding transcription 
factors (Steel, 1999). 
Some genes are involved in both syndromic and non-syndromic hearing loss, e.g. PDS 
(Pendred syndrome and non-syndromic deafness, respectively) and MYO-7A (Usher 
syndrome and non-syndromic deafness, respectively). One single gene can be involved in 
both dominant and recessive non-syndromic hearing loss (e.g. MYO-7A, TECTA and GJB2). 
Finally, phenotypic similarities are not necessarily caused by the same genetic condition 
(Resendes et al., 2001; Steel, 1999; Smith, 1995). 
 
Today, several hundreds of syndromes comprising hearing loss have been described. The 
focus of this thesis will be on one of these syndromes: HDR syndrome. This clinical entity is, 
in its most classical form, characterized by hypoparathyroidism, deafness and renal dysplasia. 
Before addressing the syndrome in detail and defining the overall goals of this thesis, we will 
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review the more prevalent ‘hearing loss – renal abnormalities association’ and the rare 
‘hearing loss – hypoparathyroidism association’. 
  
Hearing loss associated with renal abnormalities 
Nowadays a wide range of syndromes is known in which the hearing loss and kidney 
anomalies co-occur. These syndromes are caused by an almost equally wide range of 
underlying patho-physiological mechanisms, several of which remain to be unravelled.1 
Mutations in the JAGGED1 gene cause Alagille syndrome, a complex malformative disorder 
that was initially described as the association of 5 major features: paucity of interlobular bile 
ducts, peripheral pulmonary artery stenosis, butterfly-like vertebral arch defect, posterior 
embryotoxon and a peculiar facies. Today, individuals with 3 out of the 5 main features are 
considered to have the syndrome (Crosnier et al., 2000). In addition to these main features, 
minor features such as skeletal defects, high-pitched voice, mental retardation, growth 
retardation, arterial stenosis, small bowel atresia and diabetes have been described (Crosnier 
et al., 2000). Patients often present with a variety of both developmental and functional renal 
abnormalities, ranging from renal cysts to hypoplastic kidneys (Crosnier et al., 2000). Another 
common feature is (mixed) hearing loss, that often is mild to severe in nature and 
predominantly affects the middle frequencies (Caignec et al., 2002). Pathophysiologically the 
disease is explained by the strong expression of JAGGED1 during embryo-and fetogenesis in 
the vascular system, and other mesenchymal and epithelial tissues. The gene encodes a 
transmembrane protein, which is a ligand of the NOTCH receptors, which are implicated in 
the determination of cell fate (Crosnier et al., 2000; Kiernan et al., 2001; Li et al., 1997). 
Alport syndrome is among the most prevalent auditory syndromes, its incidence being 
approximately 1:200,000 (Smith, 1995). Its main characteristics are: progressive nephropathy 
(hematuria progressing to renal failure), sensorineural hearing loss and ocular abnormalities 
(anterior lenticonus and perimacular flecks). Leiomyomatosis of the esophagus and the 
tracheobronchial tree, mental retardation and haematological abnormalities are symptoms 
sporadically associated with the disease. The phenotypic heterogeneity of Alport syndrome 
has long been recognized. However, in spite of this heterogeneity, all phenotypes are caused 
by mutations of type IV collagen α chains, which are expressed in basement membranes 
involved in the disease (glomerular basement membrane, anterior lens capsule, Descemet’s 
membrane, Bruch’s membrane, the cochlear basilar membrane, and the basement membranes 
                                                 
1 A synopsis of characteristics of underlined syndromes described in this paragraph can be found in Table 1.1.  
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of the spiral prominence, the spiral limbus and the stria vascularis). The X-linked form of the 
syndrome affects approximately 80-85% of patients. This form of Alport syndrome is caused 
by mutations - several hundreds of which have been identified today - in the COL4A5 gene 
(Xq22). Typically, males are more severely affected by renal disease than females. The 
remaining patients are for the greater part affected by autosomal recessive Alport syndrome, 
caused by mutations in COL4A3 or COL4A4 (2q35-37), and only a small minority is affected 
by autosomal dominant Alport disease, possibly arising from mutations in COL4A3 or 
COL4A4 (Hudson et al., 2003; Kashtan, 2000; Lemmink et al., 1997). Patients with early 
renal failure can be treated with angiotensin-converting-enzyme inhibitors and 
antihypertensive drugs, aiming to delay progression of the disease. The only available 
treatment for end-stage renal failure associated with the syndrome today is renal 
transplantation. Unfortunately, however, 1-5% of post-transplantation Alport patients develop 
specific anti-GBM nephritis, leading to renal graft loss (Hudson et al., 2003; Lemmink et al., 
1997). 
The autosomal recessive Alström syndrome is characterized by retinal pigmentary 
degeneration, early-onset truncal obesity, non-insulin-dependent diabetes mellitus, acanthosis 
nigricans, slowly progressive bilateral sensorineural hearing loss and chronic nephropathy. 
Renal failure usually commences between the second and fourth decades of life, the severity 
of the renal failure is an important determinant of prognosis regarding survival. Additional 
features are plenty and include cardiomyopathy, advanced bone age, developmental delay, 
asthma, hypothyroidism, hyperinsulinaemia, alopecia, hypertension, hypertriglyceridemia, 
elevation of hepatic enzymes, male hypogonadism, short stature, kyphosis, hyperostosis 
frontalis interna and scoliosis (Benso et al., 2002; Marshall et al., 1997). Mutations of the 
ALMS1 gene on chromosome 2p13 bring about this rare disorder. In spite of structural 
similarities between ALMS1 and mucin genes, the exact function of the former gene is as yet 
unknown (Hearn et al., 2002). 
Defective salt transport by the thick ascending limb of Henle is the main feature of a group of 
autosomal recessive disorders known as Bartter syndrome. Five variants of the syndrome 
exist, sharing characteristic clinical features such as renal salt wasting with normal or lowered 
blood pressure, hypokalemic metabolic alkalosis, hypercalciuria and normotensive 
hyperreninemic hyperaldosteronism (e.g. Herbert, 2003; Shalev et al., 2003). In addition some 
patients show a typical facial appearance with a prominent forehead, triangular faces, 
drooping mouth and large eyes and pinnae (Vollmer et al, 2000). Sensorineural hearing loss is 
specific for Bartter’s syndrome type IV. This variant is caused by mutations in the BSND or 
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Barttin gene on chromosome 1p (Birkenhäger et al., 2001;Vollmer et al., 2000). Barttin is 
essential for the proper functioning of chloride channels ‘ClC-Kb’ at the basolateral side of 
the thick ascending loop of Henle and ‘ClC-Ka’ at the basolateral side of the thin ascending 
loop of Henle. Interestingly, Barttin is also essential for chloride efflux at the basolateral side 
of the marginal cells of the stria vascularis, and defective chloride transport may influence the 
potassium secretion and endolymphatic potassium concentration -leading to impaired 
cochlear function and hearing loss-, and it may impede the generation of a high endocochlear 
potential – necessary for the sensory transduction of sounds by hair cells- (Naesens et al., 
2004). Individuals with (antenatal) Bartter syndrome benefit from treatment with 
indomethacin (a cyclooxygenase inhibitor) (Herbert, 2003). 
Branchio-Oculo-Facial (BOF) syndrome is a rare autosomal dominant disorder, bearing some 
similarities to the more prevalent BOR syndrome (see below). For this reason, although an 
exact gene locus has not been identified, it has been suggested that its locus may be expected 
to be on chromosome 8q. Phenotypically patients are affected by distinctive craniofacial, 
cervical, auricular, ophthalmologic and oral anomalies. Auricular abnormalities are common 
(low set, rotated ears, external auditory canal stenosis, preauricular pit, cochlear dysplasia) 
and 71 % of patients suffer from a conductive hearing loss. Sensorineural hearing loss is rare, 
but has been described in several patients (Raveh et al., 2000). Renal abnormalities are found 
in 37% of patients (Raveh et al., 2000). 
Mutations in the eyeless (EYA1) transcription factor gene, as well as mutations in SIX1 and 
SIX5 (Hoskins et al., 2007; Ruf et al., 2004), lead to the most common (autosomal dominant) 
syndrome with an association of hearing impairment and renal abnormalities, namely 
Branchio-Oto-Renal (BOR) syndrome. Incidence is approximately 1:40.000 (Smith, 1995). 
Major phenotypic features of the syndrome are early-onset hearing loss, dysmorphology of 
the ears, branchial clefts and renal abnormalities (Bitner-Glindzicz, 2002; Steel, 1999; Tekin 
et al., 2001). Approximately 90% of patients are affected by hearing loss, which can be 
mixed, conductive or sensorineural in origin (Smith et al., 1998; Stinckens et al., 2001). Renal 
abnormalities range from vesico-ureteric reflux, ureteral pelvic junction obstruction, 
hydronephrosis, pelviectasis, calyectasis and bifid kidneys with double ureters to kidney 
agenesis, hypoplasia and dysplasia (Pierides et al., 2002; Smith et al., 1998). 
No more than eight patients with Burn-McKeown syndrome have been described so far. 
Patients were characterized by bilateral choanal stenosis or atresia and a typical facial 
phenotype with hypertelorism, short palpebral fissures, lower eyelid coloboma, thin lips and 
prominent ears, as well as a prominent nasal bridge. Other features, such as cardiac defects, 
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hearing loss, cleft lip/palate (with oronasal fistula), micrognathia, short stature, pre-auricular 
tags, hypomimic face and (unilateral) kidney hypoplasia may be present. The facial phenotype 
seems to change significantly with age. Intrafamilial there may be a remarkable variation in 
phenotypic expression. It has been suggested that the syndrome may inherit in a X-linked 
recessive mode, however the causative gene(s) remain to be identified (Wieczorek et al., 
2003). 
CHARGE-syndrome (ocular Coloboma, Heart defects, Atretic choanae, Retarded growth or 
development, Genital hypoplasia and Ear anomalies or hearing loss) has an estimated birth 
incidence of 1:12,000 (Kallen et al., 1999). It is often caused by mutations in the CHD7 gene 
(Vissers et al. 2004), but in a subset of patients mutations in SEMA3E may play a role in the 
pathogenesis of the disease (Lalani et al., 2004). The syndrome may reflect a polytropic 
developmental field defect involving neural crest cells or the neural tube. Sensorineural or 
mixed hearing loss affects the majority of patients, whereas renal anomalies occur in 15-25% 
of patients (Edwards et al., 2002; Tellier et al., 1998; Wang et al., 2001). 
Based on a review of 140 cases, Nance et al. defined the requirements for the clinical 
diagnosis of classical Cockayne syndrome (CS I). According to these authors the diagnosis 
can be made in patients who are affected by 1) growth failure with (near) normal birth weight 
and 2) neurodevelopmental or neurological dysfunction, combined with at least three of the 
following five features 3) cutaneous photosensitivity, with or without thin or dry skin or hair, 
4) progressive pigmentary retinopathy, and/or cataracts, optic disc atrophy, miotic pupils or 
decreased lacrimation, 5) sensorineural hearing loss, 6) dental caries and 7) cachectic 
dwarfism. In infants or toddlers the diagnosis may be more difficult; it based on the presence 
of the two obligatory features in combination with one of the five other criteria and additional 
biochemical evidence (i.e. fibroblast sensitivity to UV light) (Nance et al., 1992). Other 
symptoms compatible with the diagnosis are hypertension, renal dysfunction, hepatomegaly, 
serum transaminase elevation, undescended testes and anhidrosis. The mean age of death in 
reported cases was 12.3 years (Nance et al., 1992; Sato et al., 1988). Patients with CS II have 
a more severe and earlier onset of symptoms, they usually die by the age of 6 or 7 (Nance et 
al., 1992). The syndrome inherits in an autosomal recessive way. It is caused by the CSA and 
CSB genes, located on genes 5 and 10 respectively (Fryns et al., 1991; Henning et al., 1995). 
The ATP6(V1)B1 gene encodes the B1 subunit of H+-ATPase, one of the key membrane 
transporters for acid secretion in the α-intercalated cells of the medullary collecting duct in 
kidneys (Feldman et al., 2006; Hahn et al., 2003; Ruf et al., 2003). Mutations in ATP6V1B1 
cause Distal Renal Tubular Acidosis (DRTA) with sensorineural hearing loss; metabolic 
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acidosis of varying severity -accompanied by inappropriately alkaline urine- that if untreated 
may result in dissolution of bone, leading to osteomalacia and rickets. Other features of the 
disease include low serum potassium, elevated urinary calcium, growth failure, 
nephrocalcinosis and nephrolithiasis that may present as ‘Steinstrasse’ on abdominal X-ray 
(Peces, 2000). A final characteristic of the disease is early onset, sensorineural hearing loss, 
which is probably caused by defective endolymph pH homeostasis. The hearing loss is 
progressive and does not respond to the treatment of DTRA with alkali supplementation by 
sodium bicarbonate, Shoul solution, potassium citrate or other alkali preparations (Hahn et al., 
2003). Interestingly, it has recently been demonstrated that mutations in another gene, 
ATP6V0A4 cause DRTA associated with older onset, mild to moderate sensorineural hearing 
loss (Stover et al., 2002). 
For a description of Duane- Radial Ray Syndrome see Okihiro syndrome. 
Neuropathic pain, caused by nerve fiber degeneration due to lipid accumulation, is the clinical 
hallmark of Fabry disease (a.k.a. Anderson-Fabry disease), affecting as much as 77% of 
patients. The pain typically increases during exercise or overheating. Other common features 
are: angiokeratoma (71%), CVA, TIA, renal disease resulting in renal dialysis and renal 
transplant, left ventricular hypertrophy (88%), heart valve anomalies (29%), hypohidrosis 
(56%), gastrointestinal symptoms (abdominal pain, nausea and vomiting) and hearing loss 
(MacDermot et al., 2001). Approximately 50% of Fabry patients complain of hearing 
symptoms. Hearing loss may be uni- or bilateral, is moderate to severe and often has a sudden 
onset in childhood that may be preceded by tinnitus (Conti et al., 2003; Keilmann, 2003). 
Histological analysis of four temporal bones of Fabry patients demonstrated hyperplastic 
mucosa, strial and spiral ligament atrophy, basal hair cell loss and a reduced number of spiral 
ganglion cells, however glycosphingolipid accumulation (see below) could not be 
demonstrated (Schachern et al., 1989). Dysmorphic features, such as thick lips, bulbous nose 
and thickening of the nasolabial folds, are present in approximately 50% of patients. A birth 
frequency of 1: 100,000 makes Fabry disease the second most common glycospingolipid 
storage disorder. The disease is caused by a deficiency of X-linked lysosomal hydrolase, α-
galactosidase, leading to the accumulation of uncleaved glycosphingolipids (especially Gb3) 
(MacDermot et al., 2001). Lipid deposits may be found in cortical and brain stem structures, 
in autonomic ganglia, in cardiac muscle and conducting fibres, in renal glomeruli and tubules, 
and in the endothelium and media of small vessels. Since Fabry disease is an X-linked 
disorder it predominantly affects males, although carrier females can, dependent on their X-
chromosomal inactivation, also be affected to a mild or more severe degree (Jardim et al., 
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2004). Current therapy involves symptomatic medical management, dialysis, enzyme 
replacement therapy, kidney transplantation and gene therapy (Inderbitzin et al., 2005). 
Agalsidase alfa therapy possibly even brings about a reversal of hearing deterioration in 
affected patients (Hajioff et al., 2003). The median cumulative survival of a cohort of UK 
patients was 50 years (MacDermot et al., 2001).  
Fanconi anemia is a rare chromosome instability syndrome characterized by aplastic anemia, 
cancer and leukemia susceptibility and, at cellular level, a hypersensitivity to DNA cross-
linking agents. Detection of increased chromosome breakage in cultured peripheral blood 
lymfocytes, following exposure to clastogenic agents, confirms the diagnosis (De Kerviler et 
al., 2000). The prevalence is 1-5/1,000,000, but as high as 1/22,000 in white South Africans. 
Patients typically develop bone marrow failure during the first decade of life, and by the age 
of 40 90% of patients are affected by it. By that age 33% of patients will have developed 
hematologic and 28% nonhematologic neoplasms (e.g. head and neck squamous carcinoma, 
gynecologic squamous cell carcinoma, esophageal carcinoma, liver tumors, brain tumors, skin 
tumors and renal tumors) (Taniguchi et al., 2006). In two thirds of cases the disease is 
associated with congenital malformations that may involve every organ system. Common 
features are skin pigmentation abnormalities, growth retardation, facial abnormalities, radial 
ray deformities, gastrointestinal deformities, microcephaly, eye abnormalities and congenital 
cardiopathies (De Kerviler et al., 2000). Hearing loss is present in 17.4-19% of patients, and is 
usually conductive in nature (Santos et al., 2002). Sensorineural hearing loss is rare, but has 
been described (Chevalier, 1983). External auditory canal stenosis (12%) and pinna 
deformations (6%), with low ear implant are not uncommon (Santos et al., 2002). The urinary 
system is affected in approximately 30% of patients, and hypo- or aplastic kidneys, ectopic or 
pelvic kidneys, horseshoe and sigmoid kidneys may be found (De Kerviler et al., 2000). 
Fanconi anemia comprises at least 12 complementation groups (A, B, C, D1, D2, E, F, G, I, J, 
L and M) and today 11 of the 12 responsible genes have been identified. Although progress 
has been made in the molecular understanding of the disease - FA proteins appear to 
cooperate with several other proteins in a pathway leading to the recognition and repair of 
damaged DNA- some pathophysiological aspects remain to be clarified (Taniguchi et al., 
2006). 
Fechtner syndrome is a macrothrombocytopenia associated with sensorineural hearing loss, 
cataracts, nephritis and characteristic leucocyte inclusion bodies (Moxey-Mims et al., 1999). 
The disease bears resemblance to, and may even be a variant of, Alport syndrome; 
ultrastructually, renal biopsy findings are alike. Fechtner syndrome is associated with a mild 
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bleeding tendency, and in case of surgery, it may be necessary to administer DDAVP 
preoperatively to affected patients (Matzdorff et al., 2001). The gene responsible for the 
disease was linked to 22q11-q13 (Cusano et al., 2000), and it has been proposed that 
mutations in the MYH9 gene in this region may result in Fechtner syndrome, the May-Hegglin 
anomaly or Sebastian syndrome (Seri et al., 2000). 
Isolated microtia/anotia, oculoauriculovertebral spectrum (OAVS) and Goldenhar syndrome 
are often considered to be appearances of increasing severity of the same anomaly. The latter 
two forms comprise a variety of abnormalities in structures derived from the first and second 
branchial arches. Cases are usually sporadic. Albeit that nomenclature is not completely 
decisive, the combination of epibulbair dermoids, preauricular tags/pits, microtia and facial 
asymmetry due to an unilateral small jaw is usually termed OAVS, whereas this combination 
is known as Goldenhar syndrome when accompanied by thoracic hemivertebrae and cleft lip 
and/or palate (Wang et al., 2001). Apart from the obvious conductive hearing loss, 
sensorineural hearing loss affects 11% of patients suffering from hemifacial microsomia 
(Carvalho et al., 1999). Prevalence of renal malformations has been reported to be as high as 
11% in isolated anotia and or microtia, and 70% in Goldenhar syndrome (Harris et al., 1996; 
Ritchey et al., 1994).  
It has been estimated that Klippel-Feil syndrome occurs in approximately 1:40,000-42,000 
births. The syndrome is characterized by the presence of a congenital fusion of either some or 
all cervical vertebrae, depending on the subtype (1-3). This fusion may lead to a classic triad 
of symptoms; a short neck, a low posterior hairline and limited range of motion of the neck. 
An immense and variable spectrum of anomalies is known to be associated with the syndrome 
– e.g. congenital scoliosis (>50% of patients), rib abnormalities (33%), Sprengel’s deformity 
(20-30%), synkinesia (15-20%), cervical ribs (12-15%), cardiovascular abnormalities (4-
29%), craniofacial abnormalities, vocal impairment, psychomotor retardation, hypothyroidism 
and polydactyly (da Silva et al., 1993; Papagrigorakis et al., 2003; Tracy et al., 2004). 
Genitourinary abnormalities occur in 25-35% of patients (Tracy et al., 2004). Hearing loss is 
present in 30% of patients, and may be sensorineural, mixed or occasionally conductive 
(Papagrigorakis et al., 2003; Tracy et al., 2004). Inheritance is either autosomal recessive 
(types 1 and 3) or dominant (type 2). It has been suggested that the locus for type 2 Klippel-
Feil syndrome lies on chromosome 2, 5, 8 or 15 (Papagrigorakis et al., 2003), but no Klippel-
Feil genes have been identified so far. 
The very rare Levy Hollister syndrome is characterized by dysplasia of different organ 
systems. Commonly found anomalies are radial ray defects of the upper limbs, which often 
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are associated with radioulnar synostosis and lacrimal malformations. Other features are 
xerostomia (due to aplasia of major salivary glands), dysplasia of the auricles (cup ears), 
dental anomalies, hearing loss (either sensorineural, conductive or mixed) and malformations 
of the kidneys (ranging from agenesis to sclerosis). Although it has been recognised that the 
disorder inherits in an autosomal dominant way, the exact underlying genetic cause remains to 
be elucidated (Fierik et al., 2003, Kreutz et al., 1988). 
The combination of progressive sensorineural hearing loss, cognitive impairment, facial 
dysmorphism, late onset pancytopenia and variable renal and genitourinary abnormalities 
inheriting in an X-linked recessive way, is known as Martin-Probst syndrome. Additional 
features such as microcephaly, short stature, teleangiectasias and dermatoglyphics may be 
present. Although no exact underlying genetic cause has been identified today, skewed X-
inactivation has been demonstrated in carrier females, and the disorder has been mapped to 
Xq1-21 (Martin et al., 2000; Probst et al., 2004). 
Muckle-Wells Syndrome (MWS) is a dominantly inherited autoinflammatory disease, closely 
related to other associations such as Familial Cold autoinflammatory Syndrome (FCS) and 
Neonatal Onset Multisystem Inflammatory Disease (NOMID). MWS is characterized by 
rashes, fever, arthralgia, progressive sensorineural hearing loss and the frequent development 
of systemic AA amyloidosis (amyloidosis derived from the inflammatory serum amyloid-
associated protein) (Hawkins et al., 2004). Occasionally ophthalmologic features may be 
present. Active inflammatory symptoms and visual loss respond well to subcutaneous 
injections of anakinra, a recombinant human IL-1 receptor antagonist (Alexander et al., 2005; 
Hawkins et al., 2004). The disease was linked to chromosome 1q44 and is probably caused by 
mutations in the NALP3/CIAS1/PYPAF1 gene (Cuisset et al., 1999; Hawkins et al., 2004). 
The exact pathophysiology underlying the very rare, Treacher Collins resembling, Nager 
syndrome (acrofacial dysostosis) remains unknown today. The paired related homeobox 
genes Prrx1 and Prrx2 (encoding DNA binding transcription factors essential for cellular 
differentiation and embryonic patterning), have been suggested to play a role in causing the 
syndrome. Although no mutations in the open reading frames of the genes have been found, 
mutations altering regulation of the genes have not yet been excluded (Norris et al., 2000). 
Patients affected by Nager syndrome have craniofacial features similar to those seen in 
Treacher Collins syndrome (e.g. downslanting palpebral fissures, hypoplasia of the maxilla, 
mandibular hypoplasia and external ear anomalies – causing conductive hearing loss), 
however in addition they suffer from defects of the upper, and sometimes the lower, limb 
(ranging from thumb hypoplasia to absence of the radial ray) (Friedman et al., 1996; Hunt et 
  21
al., 2002; Paladini et al., 2003). Wang et al. reviewed literature on Nager syndrome and found 
renal malformations in 9% of affected individuals (Wang et al., 2001). 
The most characteristic features of Okihiro syndrome (or Duane- Radial Ray Syndrome) are 
radial ray defects and Duane anomaly (limitation of abduction of the eye and narrowing of the 
palpebral fissure with retraction of the globe on adduction). The phenotypic expression of 
Okihiro syndrome is variable. An extensive range of associated features has been reported, 
embracing anal stenosis, pigmentary anomalies, facial asymmetry, cardiac lesions (ASD, 
VSD), choanal atresia, renal malformations, external ear malformations and hearing loss 
(Kohlhase et al., 2003). The disease is inherited in an autosomal dominant way and results 
from mutations in the putative zinc finger transcription factor gene SALL4 on chromosome 20 
(Borozdin et al., 2004a; Kohlhase et al., 2003). Mutations in the same gene – that without 
exception produce preterminal stop codons - also have been shown to cause acro-renal-ocular 
syndrome, Holt-Oram syndrome and suspected thalidomide embryopathy. Although these 
disorders may all be part of a phenotypic spectrum caused by SALL4 mutations, a clear 
genotype-phenotype correlation has not been established so far (Borozdin et al., 2004b; 
Kohlhase et al., 2005). 
The autosomal recessively inherited Refsum’s disease (Phytanic Acid Storage Disease, 
Heredopathia Atactica Polyneuritiformis) is characterised by the inability to metabolise 
dietary phytanic acid (by the primary α-oxidation pathway), resulting in excessive 
accumulation of phytanic acid in serum triglycerides and all fatty tissues (e.g. myelin sheaths, 
liver and kidneys). Patients are usually asymptomatic until the age of 20 to 30 years, when 
they are typically initially affected by night blindness. The ‘full-blown’ syndrome is 
characterised by the tetrad of retinitis pigmentosa, cerebellar ataxia, peripheral demyelinating 
neuropathy and high CSF protein. Other frequent findings are anosmia, vestibular 
impairment, pupillary abnormalities, shortened distal phalanges and broad short fingernails, 
lens opacities, ichtyosis, cardiac arrythmias and renal failure. A progressive sensorineural 
hearing loss affects up to 80 % of the patients. Usually this hearing loss commences 
asymmetrical in the second decade, whereas by the fourth decade its severity increases. The 
inner ear rather than the central nervous system is affected by the disease. Interestingly OHC 
function is normal and IHC function and/or auditory nerve function are impaired. The 
mainstay of management of Refsum’s disease consists of dietary restriction of phytanic acid 
(dairy products, meats and ruminant fats) aiming to prevent acute attacks of the disease and 
progression of organ impairment. Therapeutic plasma exchange rapidly reduces plasma 
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phytanic levels during acute attacks. (Oysu et al., 2001; Weinstein, 1999). The Refsum 
disease gene was localized to chromosome 10p (Nadal et al., 1995). 
The clinical presentation of Townes-Brocks syndrome is very variable, however 
characteristically anorectal abnormalities, abnormalities of hand and feet, deformities of the 
outer ear, preauricular tags and a sensorineural hearing loss occur. The hearing loss is slowly 
progressive, and apart from the predominant sensorineural component usually comprises a 
small conductive component. 27% of patients are affected by renal abnormalities (including 
renal hypoplasia, dysplasia, unilateral renal agenesis, horseshoe kidney, ureterovesical reflux, 
posterior urethral valves and meatal stenosis). The syndrome is caused by mutations in the 
SALL1 gene encoding a zinc finger transcription factor, possibly involved in urological, renal, 
limb, ear, brain and liver development (Kohlhase, 2000; Powell et al., 1999; Rossmiller et al., 
1994; Salerno et al., 2000).  
Finally, Wolfram syndrome is a progressive, neurodegenerative condition, with an estimated 
prevalence of 1/770,000 in the UK. The syndrome is also known as DIDMOAD (Diabetes 
Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness). Diabetes mellitus usually is the 
first sign of the disease, it is followed in time by optic atrophy and diabetes insipidus (Minton 
et al., 2003; Piccoli et al., 2003). Urologic features, such as uretero-hydronephrosis and 
bladder dysfunction are present in the majority of patients. The features usually become 
manifest during late teenage-years (Ankotché  et al., 1998; Cremers et al., 1977; Piccoli et al., 
2003). A high frequency sensorineural hearing loss affects up to 62% of patients. A subgroup 
of Dutch female patients was recently identified, showing an exceptionally high degree of 
mid- and high frequency hearing impairment (Pennings et al., 2004). Other complications 
include psychiatric disorders (suicide), gastro-intestinal dysmotility, primary gonadal atrophy, 
olivo-ponto-cerebellar ataxia and anosmia (e.g  Minton et al., 2003). The disease is usually 
caused by inactivating mutations in WSF1, whereas non-inactivating mutations in the same 
gene can be found in DFNA6/14 families (Cryns et al., 2003). 
(A synopsis of the above syndromes is given in table 1.1) 
 
Apart from the list of well-described syndromes above, that most likely will not be fully 
complete and will gradually expand, casuistic reports on the concurrence of renal problems 
and hearing loss are not uncommon. Sometimes the association could be incidental, for 
example in a boy affected by complete bilateral nerve deafness combined with familial 
iminoglycinuria (Rosenberg et al., 1968), in two brothers with sensorineural hearing loss, 
nephropathy, diabetes mellitus, premature atherosclerosis and progressive neurological
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deterioration with photomyoclonic epilepsy (Feigenbaum et al., 1994) and in two sibs affected 
by Senior Loken syndrome (nephronophthisis and retinal dystrophy) and moderate 
sensorineural hearing loss (Clarke et al., 1992), but some of these associations may turn out to 
be new clinical (syndromic) entities in the future.  
Crew et al. for example describe two sibs with a single nucleotide insertion in exon 5 of 
CD151 (11p15.5) with end stage renal failure, sensorineural hearing loss, pretibial 
epidermolysis bullosa and β-thalassemia minor (Crew et al., 2004), whereas Hussain et al 
describe the combination of infantile hyperinsulinism, severe enteropathy, profound 
sensorineural deafness and renal tubulopathy, due to a 122 kb deletion of the short arm of 
chromosome 11, also deleting 26 exons of the USH1C gene (Hussain et al., 2004). The 
acronym BRESEK/BRESHECK was used by Reish et al. to describe a potential new X-linked 
syndrome affecting two maternally related half brothers. The clinical phenotype comprised 
brain anomalies, retardation, ectodermal dysplasia, skeletal deformities, Hirschsprung disease, 
eye anomalies, cleft palate, cryptorchidism, ear anomalies, mixed hearing loss and kidney 
dysplasia (Reish et al., 1997). 
Bilateral macular colobomas combined with apical dystrophy of the hands and feet is known 
as Sorsby syndrome; another very rare, autosomal dominantly inherited condition. In one 
affected family sensorineural hearing loss was found in a young male patient with no kidney 
abnormalities and mixed hearing loss was found in his mother, who, like two other family-
members had only a single kidney (Thompson et al., 1988). 
The overlap in symptomatolgy between Melnick-Needles syndrome and several other 
syndromes has led to some controversy regarding nomenclature in recent decades. The 
existence of a fronto-otopalatodigital-osteodysplasty syndrome has been suggested, after 
clinical evidence indicated an overlap of frontometaphyseal dysplasia (FMD), oto-palato-
digital (OPD) syndrome type I and II and Melnick-Needles syndrome (MNS). Common 
features in affected patients are (severe) skeletal dysplasia and characteristic facial features 
(FMD, MNS), but urogenital anomalies and hearing loss may also be part of the clinical 
spectrum (Kristiansen et al., 2002; Morova et al., 2003; Robertson et al., 1997). Serpentine 
fibula – polycystic kidney syndrome, or Hadju-Cheney syndrome bears a lot of similarities to 
Melnick-Needles syndrome, and multiple papers have addressed the question whether or not 
the syndromes are mere variants of one syndrome or whether they represent distinct clinical 
entities. An elongated curved, or serpentine, fibula present in the former seems to be the 
distinguishing feature (Exner, 1988; Majewski et al., 1993; Ramos et al., 1998).   
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Diagnosis of many of the above syndromes is often difficult for several reasons. First, all 
symptoms do not necessarily occur simultaneously. Secondly, often different symptoms are 
not equally apparent. And, finally, the rarity of many of these syndromes unavoidably leads to 
ignorance considering the syndromes in question, causing misdiagnosis or underdiagnosis.  
Awareness amongst medical specialists may lead to a reduction in mis- and underdiagnosis as 
may targeted diagnostic tests. Malformations of the external ear (such as pre-auricular pits 
and tags, anotia or microtia, lop or cup ears) are associated with an increased incidence of 
renal anomalies of clinical significance – e.g. in CHARGE syndrome, Townes-Brocks 
syndrome, oculoauricolovertebral spectrum, BOR syndrome, BOF syndrome, Nager 
syndrome, Levy Hollister syndrome and Fanconi anemia (e.g. Wang et al., 2001) -, we 
therefore believe that these malformations when present, and especially when combined with 
hearing loss warrant renal ultrasound. 
 
Hearing loss associated with hypoparathyroidism 
The combination of hearing loss with hypoparathyroidism is much less common than that 
with renal abnormalities. Still some papers devoted attention to the subject. Some of these 
propose a causal connection, some a common (genetic) cause for the hypoparathyroidism-
hearing loss association. 
Garty et al. demonstrated sensorineural hearing loss in 3 out of 17 patients affected by 
idiopathic hypoparathyroidism (and conductive hearing loss in 2 out of 17) and hereafter 
proposed hearing impairment to be either a complication or an associated feature of 
hypoparathyroidism (Garty et al., 1994). Likewise, sensorineural hearing loss was found in 7 
out of 21 Japanese patients with untreated hypoparathyroidism or chronic hypocalcaemia. 
Ikeda et al. suggested that a low calcium level in the inner ear fluid or the direct effect of 
vitamin D deficiency on the inner ear was responsible for the malfunctioning of these inner 
ears, and thus for the sensorineural hearing loss found in these patients (Ikeda et al., 1987). 
Unfortunately neither paper states explicitly if and how other causes of hearing loss were 
excluded. Therefore other possible causes of hearing loss might have been overlooked. Indeed 
for some of the cases described, a syndromic etiology might be considered.  
As early as in 1983 a connection has been suggested between non-hypoparathyroidism 
induced vitamin D deficiency (and its resulting deficiency of calcium) and hearing loss. 
Brookes described 10 patients with progressive bilateral hearing loss and vitamin D 
deficiency. Different pathophysiological mechanisms for the coming about of the hearing loss 
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were proposed, e.g. disruption of the neurosensory epithelium or the supporting bone 
structure of the otic capsule and calcium dependent disturbances in membrane permeability 
and neuromuscular excitability (Brookes, 1983). Since -to our knowledge- until now the 
above hypotheses have not been tested systematically, a causative role for hypocalcaemia in 
hearing loss cannot be excluded in hypoparathyroidism-hearing loss associations.  
Several distinct genetic (mitochondrial) defects have been described, causing a clinical 
phenotype in which hearing loss and hypoparathyroidism co-occur. The best known of these 
is probably Kearns-Sayre Syndrome, a neurological disorder with variable 
encephalomyopathic symptoms amongst which hearing loss. Less than 10% of Kearns-Sayre 
patients suffer from hypoparathyroidism, hyperaldosteronism, hypomagnesemia or thyroid 
dysfunction. However, hearing loss and hypoparathyroidism may be the initial major 
manifestations of the syndrome. If so, there is an association with pleioplasmic mitochondrial 
DNA rearrangements. It has been suggested that ATP deficiency is involved in the 
pathogenesis of both the hearing loss and PTH deficiency (Wilichowski et al., 1997). An 
A3243G mutation of mitochondrial DNA was found in a 54-year old woman with diabetes 
mellitus, hearing loss, muscle weakness and hypocalcaemia due to idiopathic 
hypoparathyroidism. Point mutations at the 3243 position are known to cause maternally 
inherited diabetes mellitus and deafness (MIDD), but hypoparathyroidism is a rare finding in 
this association. Once again, since the parathyroids require high-energy supply, it is not 
unthinkable that the hypoparathyroidism in this patient is caused by a disturbed mitochondrial 
oxidative phosphorylation (Tanaka et al., 2000). Finally, Hameed et al., describe a 6 year old 
boy with focal segmental glomerulosclerosis, hypoparathyroidism and sensorineural deafness, 
who after developing progressive neurological deterioration, was diagnosed with 
mitochondrial myopathy and neuropathy (see also next paragraph). 
In some other patients affected by both hearing loss and hypoparathyroisim, although a 
genetic or syndromic cause was suspected, no distinct genetic or chromosomal defects could 
be demonstrated.  Six members of one family were affected by autosomal dominant familial 
hypoparathyroidism and sensorineural deafness, without renal dysplasia. The proband had a 
normal 46, XY karyotype, without microdeletions in chromosome 22q11.2 as tested by FISH 
(Watanabe et al., 1998). Unfortunately, the authors do not describe the mitochondrial DNA, 
or chromosome 10p (see next paragraph). Finally, the existence of a familial idiopathic 
hypoparathyroidism – familial progressive sensorineural deafness – human leucocyte antigen 
syndrome was proposed by Yumita et al., after describing 3 cases from two families with 
these characteristics (Yumita et al., 1986). 
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Hypoparathyroidism, Deafness, Renal dysplasia (HDR) syndrome  
In 1977 Bakarat et al. described two male siblings with hypoparathyroidism, ‘nerve deafness’ 
and nephrotic syndrome, both of whom died of renal failure during childhood. The authors 
suggested that this combination of symptoms might comprise a new association, possibly 
inheriting in an autosomal recessive way (Bakarat et al., 1977). However, it was not until 
several years later, in 1992 to be exact, when a larger family, affected by a distinct autosomal 
dominant syndrome of hypoparathyroidism, sensorineural hearing loss and renal dysplasia, 
was described (Bilous et al., 1992), that the triad of symptoms was recognized as a distinct 
clinical entity, that only since 1997 has been known by its acronym ‘HDR syndrome’ 
(Hasegawa et al., 1997).  
The clinical presentation of HDR patients has been very diverse, their most prominent 
symptoms and signs ranging from seizures due to hypocalcaemia (this thesis; Beetz et al., 
1997) and generalized psoriasis (Aksoylar et al., 2004), to recurrent cerebral infarctions  
(Fujimoto et al., 1999), and severe mental retardation, autism and calcifications of the basal 
ganglia (Verri et al., 2004). The variability in phenotypic expression may sometimes delay 
(Ishida et al., 2001) or even prevent diagnosis of HDR syndrome. The latter may hold true for 
a small number of patients, presented in medical literature over the last decades (Hameed et 
al., 2001; Shaw et al., 1991; Yumita et al., 1986) (see Table 1.2 for details, ** indicates 
patients that were never diagnosed with HDR syndrome). 
 
Genetic cause of HDR syndrome 
DiGeorge syndrome is a developmental field defect, characterized by facial dysmorphysms, 
congenital conotruncal heart defects, hypoparathyroidism and thymushypo- or aplasia (or T 
cell defects). Most patients are affected by a microdeletion in chromosome 22q11 (DGCRI). 
However in a small minority of patients the syndrome is caused by partial deletion of 
chromosome 10p (DGCRII). In the late 1990’s several papers reported patients with Di-
George or velo-cardio-facial like syndromes, lacking congenital heart disease but suffering 
from additional features such as renal malformations and sensorineural hearing loss. In some 
of these patients chromosomal aberrations telomeric from the DGCRII were detected (e.g. van 
Esch et al., 1999a). In a large retrospective review study, van Esch et al., compared the 
classical DiGeorge phenotype to the so-called 10p deletion syndrome, and found that in the 
latter in addition to the classical DiGeorge features severe mental retardation, sensorineural 
hearing loss, renal anomalies and severe growth retardation were commonly found (van Esch
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et al., 1999b). Recently, it has been suggested that BRUNOL3 may be responsible for heart 
and thymus defects associated with partial monosomy 10p (Lichtner et al., 2002) However, to 
remain within the scope of this thesis, from here on the focus will be mainly on HDR 
syndrome. 
In 1997 Hasegawa et al. had already suggested that the putative gene(s) responsible for HDR 
syndrome should be located at a 10pter→p13 region, after demonstrating a terminal deletion 
of chromosome 10 (Del(10)(p13)) in one Japanese patient with HDR syndrome (Hasegawa et 
al., 1997). Three years later an HDR syndrome locus was officially mapped distal to the 
DiGeorge Critical Region on 10p13/14 (Lichtner et al., 2000), and shortly hereafter, van Esch 
et al. demonstrated that the syndrome is caused by haploinsufficiency of the GATA3 gene 
(van Esch et al., 2000). Further evidence of this was provided by Muroya et al., demonstrating 
GATA3 abnormalities in seven out of nine Japanese families with the HDR syndrome 
(Muroya et al., 2001). 
An extensive analysis of different GATA3 mutations in HDR syndrome, is given in a 2004 
review paper (Nesbit et al., 2004). In this paper Nesbit et al. draw attention to the curious fact 
that a correlation between the GATA3 mutations and the observed HDR phenotype has not 
been established so far; the same mutation in different families (or even within a single 
family) may lead to different phenotypes. Two new mutations have been identified since the 
appearance of Nesbit’s review paper leading to a total of 21 mutations known today (Mino et 
al., 2005; Zahirieh et al., 2005). It is not unreasonable to expect that more mutations will be 
identified in the future: in fact we describe a new mutation identified in a Dutch HDR patient 
in Chapter 5 of this thesis. 
 
Transcription factor GATA3 
In mammals immature, multipotent precursor cells develop into single cell lineages. Lineage 
specific transcription factors play an important role in this cellular differentiation. A specific 
group of transcription factors consists of several zinc finger proteins, characterized by a 
GATA element (A/T GATA A/G), which together constitute the so-called “GATA family”. 
As compared to other families of transcription factors, that may include dozens to hundreds of 
members, the GATA family is relatively small with three to four factors found in Drosphila 
and up to eleven in Caenorhabditis elegans. Six GATA factors have been identified in 
vertebrates, these are expressed in different tissues; GATA1 in haematopoietic progenitor 
cells, different blood cells and testes, GATA2 in haematopoietic progenitor cells, different 
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blood cells, endothelial cells and embryonic brain, GATA4 in heart, intestinal epithelium, 
primitive endoderm and gonads, GATA5 in heart, lung, gut and spleen and GATA6 in heart, 
lung, gut, liver and gonads. GATA3 is expressed in T-lymphocytes, endothelial cells, 
placenta, kidney, adrenal gland, embryonic brain, adult CNS and adult PNS (Patient et al., 
2002; Simon, 1995). 
The human GATA3 gene was cloned in 1994 by Labastie et al., who demonstrated that the 
gene contains six exons distributed over 17 kb of DNA (Labastie et al., 1994). The two zinc 
fingers are encoded by two different exons. ZnF2 (or the C-terminal zinc finger) binds DNA, 
whereas this binding is stabilized by the N-terminal zinc finger (ZnF1). Besides, ZnF1 
interacts with other multitype zinc finger proteins, e.g. the friends of GATA (FOG) (Nesbit et 
al., 2004).   
Although the exact target genes of GATA3 remain unknown today, a recent extensive 
microarray study indicated no less than 261 possible target genes, grossly belonging to two 
groups; genes involved in transcription regulation and genes involved in cellular signaling 
(Airik et al., 2005). 
The broad distribution of GATA3 and the large number of possible target genes, suggest the 
gene to be involved in a great variety of processes. Indeed over time it has been shown that 
GATA3 is –to name only a few examples- involved in the development of serotonergic 
neurons in the caudal raphe nuclei  (van Doorninck et al., 1999), cellular proliferation in the 
thymus and development of T-cell progenitors (Hendriks et al., 1999). Mouse embryos, that 
are entirely deficient in Gata3 die at 11 days post conception, due to noradrenaline deficiency 
of the sympathetic nervous system (Lim et al., 2000), massive internal bleeding, marked 
growth retardation, severe deformities of the brain and spinal cord and gross aberrations in 
fetal liver haematopoiesis (Pandolfi et al., 1995). In contrast, mice heterozygous for the Gata3 
mutation survive, being even fertile (Pandolfi et al., 1995). 
During early developmental stages Gata3 is expressed inside the otocyst and the surrounding 
periotic mesenchyme as well as in a population of neurons in rhombomere 4, where it is 
involved in morphogenesis of the ear and pathfinding of efferent neuron axons that navigate 
to the ear respectively. An elongated cyst is what remained of the entire ear in Gata3 mutant 
embryo’s (E13) (Karis et al., 2001). In 1998 Rivolta and Holley found downregulation of 
Gata3 in the mouse cochlea during hair cell differentiation, leading them to suggest that Gata3 
could act as a repressor of genes involved in cell differentiation in the organ of Corti – 
enabling formation of the adult cellular pattern (Rivolta et al., 1998). In chapter 3 of this 
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thesis we contradict this suggestion by demonstrating Gata3 expression in adult murine 
cochleae.  
With increasing knowledge about this transcription factor, GATA3 seems to be an 
increasingly ‘hot-topic’. It has been suggested that GATA3 variants may contribute to 
tumorigenesis in ESR1-positive breast tumors, through their involvement in growth control 
and maintenance of a differentiated state in epithelial cells (Usary et al., 2004). Moreover, 
GATA3 has also been subject of recent otological publications. It is a well-known fact that in 
contrast to mammalian cochlear hair cells, avian cochlear hair cells have the capacity to 
regenerate after being damaged. Interestingly, it has been demonstrated that GATA3 is 
amongst the up-regulated genes in regenerating avian cochleas (Hawkins et al., 2003).  
 
Audiometry in mouse models of hearing loss 
Great structural similarities exist between the ears of almost all (equatrian) mammals; this 
also applies to the murine and human ear. All structures found in the human ear are present in 
the murine ear as well. There are, however, some differences. One of those is the presence of 
a persistent stapedial artery in mice, a condition that is only very rarely found in man. In 
humans the inner ear lies within the bony trabeculations of the mastoid, whereas in mice the 
cochlea protrudes into the tympanic bulla, a 3.5 x 5.0 mm air-filled cavity. Another distinction 
is the length of the cochlear duct; 2.5 turns in man, as compared to, 1.5-2 turns in the mouse 
(Bohne et al., 1997; Jero et al., 2001b). The length of the mouse cochlea varies both within 
and across mouse strains (Ou et al., 2000).  
Although previously the mouse was not considered an ideal animal model for studying 
hearing loss, due to disadvantages related to its small size, it is now rapidly becoming the 
animal of choice for several reasons. Great progress has been made in mouse genomics and 
several mouse models of hearing loss have been developed. As stated earlier, there is great 
similarity between murine and human ears. Finally, breeding characteristics of mice, where 
big litters are born after a relatively short gestation, make this animal an ideal model for 
studying genetic defects. 
 
Preyer’s reflex / Acoustic Startle Response 
A method that has been extensively used (in the past) for the evaluation of hearing in 
laboratory mice is Preyer’s reflex; the observation of a startle response elicited by a loud 
auditory stimulus. This method has certain advantages; it is easy and it can be rapidly 
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performed in large number of animals, and there’s no need for any equipment to elicit the 
response. There are however some limitations; the test is based on a subjective observation of 
the animal by the investigator, and based on the test outcome no distinction between 
sensorineural and conductive hearing loss can be made. When categorizing mice as being 
genetically deaf or not, animals could easily be misclassified due to (possibly) self-resolving 
middle-ear problems. Furthermore the method is not very sensitive; Jero et al. found that 
animals with an ABR threshold equal to or under 76 dB SPL had positive reflexes. They 
suggested that the Preyer’s reflex should only be used for rough screening of hearing in mice 
(Huang et al., 1995; Jero et al., 2001a).  
 
Auditory Brainstem Response 
Auditory Evoked Potentials (AEP’s) are electrical potentials occurring in response to auditory 
stimulation, recorded at various levels of the auditory system. Already in 1974 Picton et al. 
categorized   various   types   of   Auditory   Evoked   Potentials  as  ‘long  latency  responses’   
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Figure 1.2: The ascending pathways of the auditory system in man (adapted from van den Broek and Feenstra, 
2007).  
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- probably representing widespread activation of the frontal cortex-, ‘middle latency 
responses’ – representing the auditory thalamus and cortex - and ‘early responses’ – 
representing activation of the cochlea and the auditory nuclei of the brainstem – (Picton et al., 
1974). Of these the early responses, and more specifically the Auditory Brainstem Response 
(ABR), have proved to be most useful, both in clinical practice and in experimental research.   
In man Auditory Brainstem Responses (ABRs) are commonly used to screen for retrocochlear 
pathology (e.g. Godey et al, 1998; Rupa et al, 2003), to test hearing in newborns being at high 
risk for hearing impairment (e.g. Watson et al., 1996) and to objectively determine hearing 
thresholds, when subjective hearing evaluation is impossible. 
The origins of the different ABR-peaks, in anaesthetised laboratory mice, were described by 
Henry in 1979. Based on lesion techniques and local recordings he concluded that PI 
corresponds with the cochlea and the action potential from the auditory nerve, and that PII-V 
originate from the ipsilateral cochlear nucleus, the contralateral olivary nuclei and the nucleus 
of the trapezoid body, a source between the cochlear nuclei and inferior colliculi and from the 
lateralmost portion of the contralateral inferior colliculus, respectively (Henry, 1979). Several 
years later an anatomical frequency-place map for the mouse organ of Corti was developed, 
by comparing noise-induced cochlear lesions with ABR-thresholds shifts in C57BL/CBA F1 
mice (Ou et al., 2000). Nowadays, the recording of ABRs by subcutaneous needle electrodes, 
has become a routine method for hearing evaluation in laboratory mice.  
 
Distortion Product Otoacoustic Emissions  
In 1978 Kemp was the first to describe an acoustic phenomenon present in healthy ears, but 
absent in ears with cochlear hearing loss. He suggested that the non-linear acoustic responses 
to auditory stimulation he recorded in the external acoustic meatus originated in the cochlea, 
and depended on normal functioning of the cochlear transduction process (Kemp, 1978). 
Today these responses are known to be by-products of the active motility of outer hair cells, 
serving as amplifiers of the displacement of the cochlear partition. Various subgroups of these 
so-called otoacoustic emissions are recognised, occurring both spontaneous (SOAE’s – 
Spontaneous Otoacoustic Emissions-) and after stimulation (Evoked Otoacoustic Emissions; 
TEOAE’s – Transient Evoked Otoacoustic Emissions-, CEOAE’s – Continuous Evoked 
Otoacoustic Emissions-, DPOAE’s – Distortion Product Otoacoustic Emissions- and 
SFOAE’s – Stimulus Frequency Otoacoustic Emissions-) (e.g. van Zanten et al., 2002).      
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Interestingly, nowadays (evoked) otoacoustic emissions (OAE’s) represent the most accurate 
measure for testing OHC function (Schrott et al., 1991), with a broad range of applications in 
neonatal hearing screening, clinical practice and scientific research. In murine auditory 
research otoacoustic emissions have been used to study (amongst others) age related hearing 
loss (Jimenez et al., 1999; Parham, 1997; Parham et al., 1999), noise induced hearing loss – 
NIHL - (Jimenez et al., 2001; Vazquez et al., 2001), effects of gender on hearing (Guimaraes 
et al., 2004), effects of hypothyroidism on OHCs (Li et al., 1999) and the effects of genetic 
mutations on the auditory system (Huang et al., 1995; Huang et al., 1998; Konrad-Martin et 
al., 2001) – see also chapter 4 of this thesis. 
 
Apart from the above-mentionted, commonly used techniques, other specific acoustic tests 
such as ECochG and patch clamp studies of central auditory nuclei may provide additional 
useful electrophysiological information on specific parts of the auditory pathway (in 
laboratory animals). However, discussion of these techniques is beyond the scope of this 
thesis. 
 
Scope of this thesis 
In recent years great progress has been made in the understanding of genetically induced 
hearing impairment. Papers of great interest on this subject are published frequently. In this 
thesis the nature of hearing loss in Hypoparathyroidism, Deafness and Renal dysplasia 
syndrome is studied with a variety of different techniques. 
Hearing acuity in laboratory mice is often assessed by measuring Auditory Brainstem 
Responses (ABR) under general anesthesia. Some anesthetics are known to cause an increase 
in ABR-peak latencies in laboratory animals such as gerbils and rats. In chapter 2 we 
evaluate the possibility of hearing assessment in alert mice. The possible effects of general 
anesthesia on peak and interpeak latencies and on ABR-thresholds are studied. In addition we 
look into the effects of varying post stimulus time frame duration, and stimulus repetition rate.  
In chapter 3 and chapter 4 we assess whether the auditory system of heterozygous Gata3 
mice may serve as model for the auditory system of patients affected by the HDR syndrome. 
Hearing in the mouse model is evaluated by ABR-recordings and distortion product 
otoacoustic emissions (DPOAE)-measurements, whereas cochlear histology is analyzed by 
light microscopical examination of cochlear quarter turns and of semithin slices of the organ 
of Corti and by electron microscopical examination of cochlear hair cells. Chapter 3 also 
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addresses the expression patterns of Gata3 in both the inner ear and the auditory parts of the 
central nervous system. Using the combined results of the abovementioned experiments we 
evaluate the nature of the hearing loss and postulate a hypothesis on the pathogenesis of the 
hearing loss in HDR syndrome. 
A link between the basic scientific experiments, described in the previous chapters and 
clinical research is tentatively made in chapter 5. The hearing of two patients affected by 
HDR syndrome is described in detail. Human and murine audiometrical data are compared. 
Experimental data described in chapters 2 to 5 are discussed in chapter 6.  In this chapter 
some new developments in mouse auditory research are discussed, that may lead to directions 
for future research. 
The main goal of this PhD study is to contribute new knowledge to the field of genetic 
hearing impairment, and more specifically to elucidate the underlying mechanisms causing 
hearing loss in HDR syndrome. In addition it is tried to bridge the gap between basic 
scientific and clinical research by comparing results of auditory tests performed in mice and 
men. 
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“Don’t spend time beating on a wall, hoping to transform it into a door. ”  
 
Coco Chanel. 
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Summary 
Anesthesia is known to affect the Auditory Brainstem Response, ABR, in animals often used 
in hearing research. This study describes the differences in ABRs, between awake and 
anesthetized FVB/N mice. Intracranial electrodes connected to a head fixation pedestal were 
used for click-evoked ABR recordings. This pedestal served to immobilize mice, either awake 
or under anesthesia, in a ‘free’ sound field.  
The presence of myogenic noise in the awake condition obviously increases recording time. 
However it is demonstrated that recording times can be significantly reduced by increasing 
the stimulus repetition rate from 23 up to 80 impulses per second. This causes only a small 
but significant increase in absolute peak latencies in the awake condition, but has no 
significant effect on the overall ABR-waveform, nor on the ABR-threshold, nor on the ABR 
interpeak latencies, nor on the absolute peak latencies in the anesthetized condition.  
Anesthesia with ketamine/xylazine caused a significant prolongation of ABR-peak latencies 
and interpeak latencies as well as a significant upward shift (8.0 ± 1.8 dB) of ABR-thresholds 
as compared to the awake condition. Under anesthesia the measurement accuracy of peak 
latencies, interpeak latencies and thresholds decreases. In conclusion, the awake condition is 
preferable for more accurate measurements of ABR characteristics, in spite of the myogenic 
noise concomitant with this condition.  
 
Keywords: ABR, anesthesia, awake, mouse 
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Introduction  
The mouse is often used as a model to study effects of various genetic deficits on hearing. 
Anatomically the mouse cochlea is similar to that of the human (Steel and Bock, 1983) and, 
analogues between murine and human hereditary abnormalities in hearing are well established 
(Brown and Steel, 1994, Call and Morton, 2002; Steel, 1995; Tekin et al., 2001). 
Assessment of hearing acuity in mice is done in many studies (e.g. Ou et al, 2000; Rusch et al, 
2001; Trune et al., 1996; Zheng et al., 1999) by measuring the Auditory Brainstem Response 
(ABR) thresholds. Invariably those assessments are done in anesthetized animals. The 
combination of ketamine and xylazine is often used to effectuate narcosis in mice during ABR 
measurements (Henry, 2002; Huang et al., 1995; Jero et al., 2001; Miller et el., 1998; Ou et 
al., 2000). Several studies have demonstrated that ketamine increases peak latencies in gerbil 
and rat, while ABR thresholds remained unchanged (Church and Gritzke, 1987; Smith and 
Mills, 1989; Smith and Mills, 1991). Here we evaluate the possibility of hearing assessment 
by ABR in awake mice. ABR recording in awake animals is obviously more time consuming 
than in anesthetized mice because of myogenic noise, which triggers the artifact-rejection 
mechanism of the recording system. On the other hand, recording time can be reduced, 
possibly without significantly affecting the ABR, by increasing the stimulus repetition rate to 
values exceeding the often-used range of up to 20 per second. For eliciting the ABRs we 
simply used click stimulation as we do expect anesthesia to influence the various frequency 
regions in the cochlea alike.  
 
The questions to be answered in this study are: 
1) Is it possible to measure ABR thresholds in the awake mouse? ; 2) Does anesthesia with 
ketamine/xylazine affect the ABR waveform? ; 3) What is the accuracy of threshold 
measurements in both conditions? ; 4) Do peak latencies and thresholds of the responses 
significantly differ between awake and anesthetized animals? ; 5) Do these differences, if 
present, significantly depend on stimulus repetition rate? 
 
Material and Methods 
Mice  
Twelve mice (7 females, 5 males) of the FVB/N strain were included in this study. At 
recording time their age range was 12-16 weeks.  
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Experiments were performed in accordance with the "Principles of laboratory animal care" 
(NIH publication No. 86-23, revised 1985) and the guidelines approved by the Erasmus 
University animal care committee (DEC; protocol No. 138-01-03). No (apparent) signs of 
distress (such as weight loss, stereotypical behavior, squeaking, scratching or eye-blinking) 
were observed in our mice during or after experiments. 
Surgical technique 
For the purpose of fixation of the animal in the experimental set-up and for connection of 
electrode leads, each mouse was operated upon approximately one week before ABR 
measurements. Animals were anesthetized with a mixture of O2, N2O and 2% halothane. Two 
platinum wires, serving as reference electrodes, were placed in hand-drilled holes in both left 
and right occipital bones at the level of Crus2 of the cerebellum. A stainless steel screw, 
which served as the active electrode, was fixed to the skull between the two parietal bones, as 
close as possible to the sagittal suture. Finally, another stainless steel screw, serving as 
common ground electrode, was drilled into either the left or the right frontal skull. All 
electrodes and wires as well as four other screws, placed solely for the purpose of fixation, 
were covered with dental cement, in which a four-poled connector was fixed. Total time of 
surgery was approximately 45 minutes. Morbidity and mortality were low. 
ABR-recording 
The active electrode was connected with the positive inputs of a 2-channel physiological 
amplifier and the reference electrodes to the negative inputs. ABR recording was carried out 
with help of custom-made equipment. We used the EUPHRA-I system (Erasmus University 
Physiological Response Averager) for stimulus control and response recording. This 2-
channel response averaging system consists of a PC combined with components for stimulus 
presentation and response acquisition and averaging (DSP Motorola 56002, 32 MHz). The 
filter bandpass was 20-8000 Hz. Artifact rejection was used during averaging, the rejection 
criterion being ±40 µV. Stimulus clicks were generated by the DSP board (duration 100 µs; 
repetition rates 23 up to 80 per second). Five hundred accepted sweeps were averaged per 
response. 
Clicks of alternating polarity were binaurally presented in a frontal free field condition with a 
one-tweeter loudspeaker (Radio Shack Super Tweeter 40-1310B) at a constant 40 mm 
distance between the cone tip of the tweeter and the external auditory canals of the animal. In 
subsequent peak latency determinations the 0.117 ms acoustic delay was not corrected for. A 
Bruel & Kjaer sound level meter (2218 with 1613 octave filter set and a ½ inch 4134 
microphone) was used for acoustic calibration in dBpeSPL.  
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Response peaks were labeled with roman numerals I through V. As response waveforms 
appear to be strain dependent (see waveforms reported in (Le Calvez et al., 1998, Zheng et al., 
1999)) we adopted a naming convention, for the anesthetized condition as much in 
correspondence with existing literature as possible, e.g. Figures 2.2 and 2.3. 
Response thresholds were determined by decreasing the stimulus level with 20 dB steps from 
80 or 90 dBpeSPL until no response peaks were detectable, and by subsequently increasing 
the level with 5 dB steps until the peaks reappeared (Huang et al., 1995). Reproduction of 
responses was done at and around the threshold level. The response threshold was defined as 
the lowest stimulation level at which the response for a specific stimulus waveform showed a 
reproducible peak, as judged subjectively by two experienced judges. Responses were stored 
in the PC for off-line statistical processing.  
Experiments  
Figure 2.1 shows a photograph a mouse in the experimental set-up. To enable positioning in 
the experimental set-up all animals were anesthetized shortly with a mixture of O2, N2O and 
2% halothane. Before ‘awake state’ recordings were started, at least a 20-minute time span 
was observed, allowing the mouse to fully recover from this momentary anesthesia.  
 
 
 
Figure 2.1: An awake mouse immobilized in the experimental set up. 
 
 
During hearing assessment, mice were placed in a sound-attenuating box (50 cm x 50 cm x 50 
cm) made out of plywood and with insides and all free surfaces covered with sound absorbing  
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foam rubber (see Figure 2.1). Tests were carried out in a quiet laboratory environment. 
During the recordings, the environmental sound level in the box complied with the NR10 
standard in the frequency range 3 kHz and up.  
In eight animals ABR waveforms were measured in both the awake as well as in the 
anesthetized condition in order to establish qualitative differences. When animals were 
assessed in both conditions on a particular day the awake condition was assessed first. 
For hearing assessment in the anesthetized state, a conventional method of anesthesia was 
used (120 mg ketamine + 7.5 mg xylazine per kg body weight I.P.). This sufficed for a 
minimum of 45 minutes duration of anesthesia allowing completion of the hearing 
assessment. The individual durations varied from 45 minutes to 90 minutes.  
During measurements body temperature was monitored via a copper-constantan thermocouple 
and a DC-Voltmeter, a set-up with a 0.5 degree resolution and calibrated against a 
conventional mercury thermometer between 32 and 44 °C. Body temperature was maintained 
constant with help of a heating bulb switching on when body temperature dropped by 0.5 
degree below 37 °C.  
In the same eight animals as mentioned before the response peak latencies and response 
thresholds were measured in both conditions as a function of stimulus repetition rate. In four 
additional animals, only the awake condition was assessed.  
The following outcome variables were recorded: Response waveforms in the awake and 
anesthetized condition, response waveforms as a function of duration of the post-stimulus 
time frame (being varied between 5 and 20 ms), response thresholds (dBpeSPL) (stimulus 
level was varied between 0 and 90 dBpeSPL), peak latencies (ms), and finally interpeak 
latencies (ms). Furthermore, for a frame duration of 5 ms, the repetition rate of stimulation 
was varied between 23 and 80 per second.  
Data processing 
Animal identification data were stored in a spreadsheet file (Excel). Data values of the 
experimental and outcome variables were stored in a database (Access), containing each 
measured response with its annotations, e.g. the peaks’ latencies. Statistical processing of the 
imported data was done with help of SPSS for Windows, version 11.0. Mean and median 
values, ranges, and standard deviations were calculated and tests of statistical significance of 
differences between various experimental conditions were done. Differences were considered 
to be statistically significant when p-values were below 0.02. 
 
   68
Results  
ABR waveforms of six mice for both the awake and anesthetized condition are shown in 
Figure 2.2. The upper trace in each panel was recorded in the awake condition and the lower 
trace under anesthesia. It appears from this figure that peak latencies increase and amplitudes 
decrease when animals are anesthetized. 
 
 
Figure 2.2: Examples of ABRs recorded at 90 dB nHL (normal Hearing Level) in six different mice. In each 
panel the ABR recorded in the awake state is the upper trace, and in the anesthetized state the lower one. In both 
states identical positive and negative peaks are identifiable, as indicated with connecting lines. In the 
anesthetized state amplitudes of response peaks are smaller and peaks are delayed as compared to the awake 
situation. The delay increases with peak number. The anesthesia affects the ABR of different mice differently. 
 
Post stimulus time frame duration and repetition rate 
Response waveforms to 80 dBpeSPL click stimuli are shown in Figure 2.3, for a short and for 
long post stimulus time frame duration. Both responses were acquired in the anesthetized 
condition. Peak V is the final peak present for both conditions and the response is flat after 
approximately 10 ms. For the awake condition the responses are similar in shape except for 
the differences already shown in Figure 2.2.  
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Figure 2.3: ABR recorded at 80 dBpeSPL in mouse 2 for two time-frame durations for post stimulus recording. 
No peaks are present at latencies above 10 ms. A repetition frequency up to 100 impulses per second can safely 
be used, without the risk of waveform distortion due to aliasing. 
 
 
Effects on (inter)peak latencies 
The overall response waveform did not change with stimulus repetition frequency in either 
condition. Table 2.1 shows the means and standard deviations of the absolute latencies of 
peak I through III and the interpeak latencies for different stimulus repetition frequencies, for 
both conditions. It is clear that in the anesthetized condition, latencies are longer and 
increasingly so with higher peak numbers. The differences between the mean values for the 
awake and anesthetized condition are all significant (Mann-Whitney U test, p<0.02).  
 
Figure 2.4: Boxplot showing, for a stimulus level of 80 dBpeSPL, vertically the ranges (whiskers), the 
interquartile ranges (boxes), and median values (horizontal bars in boxes) of the interpeak latency I to III at each 
stimulus repetition rate (horizontal), for the awake (open boxes) and the anesthetized condition (shaded boxes). 
 
Figure 2.4 shows a boxplot of median values, ranges, and interquartile ranges for the 
interpeak latency of peaks I and III for both conditions, as a function of stimulus repetition 
rate. In the awake condition, the absolute peak latencies increase significantly with stimulus 
repetition rate (linear regression analysis, p<0.02). However, the absolute increase is about the  
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Condition 
 
Awake Anesthetized 
Stimulus  
repetition  
rate 
(per second) Peak Mean Standard Deviation Mean 
Standard 
Deviation 
I 1.68 .05 1.87 .06 
II 2.36 .05 2.72 .12 
III 3.07 .07 3.80 .18 
IPL_I-II .68 .05 .85 .11 
 
23 
IPL_I-III 1.39 .07 1.92 .21 
I 1.68 .07 1.86 .06 
II 2.37 .05 2.76 .15 
III 3.11 .06 3.88 .21 
IPL_I-II .69 .04 .89 .15 
 
37 
IPL_I-III 1.43 .08 1.99 .21 
I 1.71 .07 1.86 .05 
II 2.37 .04 2.72 .10 
III 3.15 .07 3.95 .21 
IPL_I-II .66 .04 .86 .11 
 
53 
IPL_I-III 1.44 .06 2.11 .32 
I 1.74 .06 1.86 .05 
II 2.39 .04 2.72 .12 
III 3.17 .07 3.99 .34 
IPL_I-II .65 .05 .86 .11 
 
67 
IPL_I-III 1.45 .07 2.14 .40 
I 1.75 .08 1.87 .05 
II 2.42 .04 2.72 .11 
III 3.20 .11 3.95 .21 
IPL_I-II .67 .06 .85 .11 
 
80 
IPL_I-III 1.45 .08 2.09 .29 
 
 
Table 2.1: Per repetition rate of the 80 dBpeSPL click-stimulus, means and standard deviations are given for the 
latencies of peak I, II, and III, as well as for the interpeak latency between peaks II / III and I, for both the awake 
and anesthetized condition. The differences between the mean values for the awake and anesthetized condition 
are all significant (Mann-Whitney U test, p<0.02). 
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same for all 3 peaks considered. A linear regression analysis between interpeak latencies and 
repetition rate revealed no statistically significant correlation of interpeak latency with 
increasing stimulus repetition rate. In the anesthetized condition, neither peak latencies nor 
interpeak latencies increased significantly with stimulus repetition rate. 
 
Effects on ABR thresholds 
 
 
 
Figure 2.5: Examples of ABR patterns a mouse in the awake state, left panel, and in the anesthetized state, right 
panel. In the latter state the response amplitude is lower, the peak latencies are higher and the response threshold 
is also higher than in the awake state (55 and 15 dB nHL (normal Hearing Level) respectively). 
 
Response patterns for one animal in both the awake –left panel– and anesthetized –right 
panel– conditions are shown in Figure 2.5. The response thresholds are 15 and 55 dBpeSPL, 
respectively. The figure shows the largest difference found between an awake and an 
anesthetized condition in any animal. Between one and four response patterns were acquired 
for each mouse in each condition. Per mouse and per condition the mean, the lowest and the 
highest thresholds were calculated. Overall, the mean ABR threshold for awake mice was 
25.1 dB (s.d. 4.3 dB, s.e. 0.8 dB) whereas under anesthesia it was 33.1 dB (s.d. 8.6 dB, s.e. 
1.6 dB), i.e. an increase of 8.0 ± 1.8 dB. This increase is statistically significant (T-test, 
p<0.0005; Mann-Whitney, p<0.0005). It is clear that under anesthesia, thresholds are higher 
and more variable. Figure 2.6 shows a box plot of median values, ranges and interquartile 
ranges of the mean response thresholds as a function of stimulus repetition rate for both 
   72
conditions. Linear regression analysis failed to show a significant effect of the stimulus 
repetition rate on the response thresholds for both conditions. 
 
 
 
Figure 2.6: Ranges (whiskers), interquartile ranges (boxes), and median values (horizontal bars in the boxes) of 
the response threshold for both conditions and for increasing repetition rate of the stimulus. Linear regression 
analysis failed to show a significant relation between ABR-thresholds and repetition rate. 
 
Discussion 
In this study we evaluate the effects of ketamine/xylazine anesthesia on the outcomes of 
hearing assessment by ABR in mice, since this is the animal of choice for studying genetically 
induced hearing defects. Several past studies reported that ketamine induced increases in peak 
latencies in gerbil and rat without altering ABR thresholds (Church and Gritzke, 1987; Smith 
and Mills, 1989; Smith and Mills, 1991). 
We demonstrate that it is possible to record ABR waveforms and ABR thresholds in the 
awake mouse. The pedestal for immobilizing the animal in a sound field used in this study 
stays in place for at least 3-6 weeks, and in some animals considerably longer (up to 5 months 
in this series), and loosening of the pedestal occurred without apparent signs of distress and 
infection. Infections were very rare and could successfully be treated with locally applied 
antibiotic eye drops. 
Although we were successful in immobilizing the animals’ heads, both ears were free to 
move. Therefore in the awake condition sound perception may have been influenced by pinna 
orientation. This confound might theoretically be avoided with a closed sound stimulation 
system. We feel that in the awake animal such a system would cause ethically unacceptable 
discomfort and stress. 
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We compared the waveforms for the anesthetized condition with waveforms reported in the 
literature for other mouse strains (CD1: Le Calvez et al, 1998; CBA/CaJ:  Zheng et al 1999). 
From this comparison, we adopted a convention for peak labeling as much in line with 
existing literature as possible. For the FVB/N mouse strain that we used examples of 
waveform patterns are shown in Figures 2.2, 2.3, and 2.5. We inferred the peak identification 
for the awake condition directly from the anesthetized condition (see Figure 2.2). 
Subjective judgment of the ABR threshold, as used in this study, is conventional in clinical 
settings (e.g. Sininger, 1993; Watson et al., 1996). This method is also used in animal studies, 
although sometimes not specifically reported (e.g. Huang et al., 1995, Zheng et al., 1999). An 
objective method of determining peak presence and latency, by applying an absolute 
amplitude criterion, as used for example in Ou et al. (2000), is very suitable for responses 
recorded in the anesthetized condition, because the residual noise in the averaged response is 
lower than in the awake condition. In the latter condition the background noise in the 
averaged responses is due to myogenic potentials.  We estimated an objective method less 
suitable for this study than the subjective method, because the former will probably identify 
spurious peaks as response peaks.  
 
The threshold we found for the anesthetized condition is in line with results from the 
literature. Using click stimulation at a rate of 19.1 per second, Zheng et al. (1999) reported the 
ABR thresholds for the FVB/N strain to be 33 and 38 dB SPL, at 9 and 28 weeks of age, 
respectively. These findings correspond very well with the threshold we determined under 
anesthesia at ages 12-16 weeks, which was 33.1 dB. 
As could be expected in general, the effect of increasing the duration of the post-stimulus 
recording time frame is merely a lengthening of the response waveform (see Figure 2.3). For 
the FVB/N mouse strain used in this study, it is also clear that the response is flat after about 
10 ms. We concluded that the duration of the ABR-assessment could be reduced by a factor 
four to five by increasing the repetition rate of the stimulus up to 100 per second without 
risking significant waveform changes due to response aliasing effects. This is not necessarily 
true for other stimulation conditions than the clicks, e.g. for tone pips. In this study a 
maximum repetition rate of 80 impulses per second was used. 
For the awake condition, increasing the stimulus repetition rate causes a small but significant 
increase of absolute peak latencies, but not of interpeak latencies (see Table 2.1). The increase 
in absolute latencies is due to adaptation (Lasky 1997; Paludetti et al, 1983; Soucek and 
Mason, 1992), an effect that is thought to be caused by neural fatigue (Terkildsen et al, 1975). 
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For the anesthetized condition, this effect is not significant. The lack of statistical significance 
in the anesthetized condition is probably due to the higher dispersion of data in this condition 
(see Figure 2.4 and Table 2.1). There was a small effect of repetition rate on latency but it was 
largely overwhelmed by the variance due to anesthesia. 
In this series, the ABR threshold does not depend significantly on the stimulus repetition rate 
in the range of 23 to 80 per second. We are of the opinion that it is unlikely that the threshold 
will be lower at slower repetition rates.  
 
Importantly, however, response thresholds are significantly lower in the awake than in the 
anesthetized condition (difference of 8.0 ± 1.8 dB). Although ketamine has been demonstrated 
to affect ABR peak latencies and amplitudes in laboratory animals such as gerbils (e.g. Smith 
and Mills, 1989; Smith and Mills, 1991), to our knowledge, no effects on ABR thresholds 
have been described. One possible explanation for this could be that, whereas in the past in 
studies on the effect of anesthesia on ABR thresholds, occasionally 10 dB steps were used to 
obtain these thresholds (Smith and Mills, 1989), we used 5 dB steps. So, we conclude that the 
8 dB threshold increase is due to the anesthesia. We can however not exclude that this 
increase is partially due to pinna orientation by the awake animal. The use of anesthesia also 
significantly increases absolute latencies of peaks I through III, and interpeak latencies I-II 
and I-III. The increase in absolute latency of peak I is in contrast with the results reported by 
Smith and Mills (1989). The prolongation of peak I (originating from the cochlea and VIIIth 
nerve (Henry, 1979)) might be caused by ketamine induced alterations in conductance of n. 
VIII. Ketamine decreases resting membrane potentials, leading to a profound effect on 
electrical activity of nerve fibers and nerve endings in the brain (Shrivastav, 1977). 
Another important effect of the anesthesia on the ABR-threshold is increased variance of the 
data (see Figure 6).  So, for accurate studies of effects on the response thresholds, the 
increased variance in the anesthetized condition necessitates either a larger number of 
examined animals, a larger number of trials, or a better control of the depth of anesthesia.  
 
Conclusions 
With the fixation method used in this study, it is possible to measure ABRs in the awake 
mouse in free field stimulation. For the FVB/N strain used during this study we can 
furthermore conclude that: 
  75
1. ABR-peak latencies, interpeak latencies and ABR-thresholds are significantly 
increased in the anesthetized condition compared to the awake condition.  
2. The variance of peak latencies, interpeak latencies and thresholds is increased in the 
anesthetized condition. 
3. Increasing the stimulus repetition rate from 23 up to 80 per second causes a small but 
significant increase in absolute peak latencies in the awake condition only. However, 
in either condition the repetition rate has no significant effect on the overall ABR-
waveform, the ABR-threshold, or the ABR interpeak latencies. 
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“There’s not much point in finding a magic ring that lets you into other worlds, if you’re afraid to look 
at them when you’ve got there.” 
 
Uit ‘The magician’s nephew’, C.S. Lewis  
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Summary 
Patients with HDR syndrome suffer from hypoparathyroidism, deafness and renal dysplasia 
due to a heterozygous deletion of the transcription factor GATA3. Since GATA3 is 
prominently expressed in both the inner ear and different parts of the auditory nervous 
system, it is not clear whether the deafness in HDR patients is caused by peripheral and/or 
central deficits. Therefore, we have created and examined heterozygous Gata3 knockout 
mice. Auditory brainstem response thresholds of alert heterozygous Gata3 mice, analyzed 
from 1 to 19 months of age, showed a hearing loss of 30 dB compared to wild type 
littermates. Neither physiological nor morphological abnormalities were found in the 
brainstem, cerebral cortex, the outer or the middle ear. In contrast, cochleae of heterozygous 
Gata3 mice showed significant progressive morphological degeneration starting with the 
outer hair cells at the apex and ultimately affecting all hair cells and supporting cells in the 
entire cochlea. Together these findings indicate that hearing loss following Gata3 
haploinsufficiency is peripheral in origin and that this defect is detectable from early postnatal 
development on and maintains through adulthood. 
 
Keywords: GATA3, HDR, cochlea, deafness, degeneration, otic, mouse, hair cell, ABR, brain 
stem maturation 
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Introduction 
The zinc finger transcription factor GATA3 is essential for proper development of several 
tissues and organs during embryogenesis (Pandolfi et al., 1995). Gata3 knockout mice show 
aberrations of the nervous system, cardiovascular and lymphatic system, as well as of the liver 
and renal system (Lim et al., 2000; Pandolfi et al., 1995; Pata et al., 1999; Ting et al., 1996; 
van Doorninck et al.; 1999 Zheng and Flavell, 1997). Unless treated with catechol 
intermediates (Lim et al., 2000), homozygous Gata3 knockouts die between embryonic day 
(E) 10.5-11.5 (Pandolfi et al., 1995).  
The prominent role of GATA3 during development is also exemplified by the fact that 
haploinsufficiency of GATA3 in humans leads to HDR syndrome, which is characterized by 
hypoparathyroidism, deafness, and renal defects (Bilous et al., 1992; Van Esch et al., 1999; 
2000; Lichtner et al., 2000; Muroya et al., 2001). While the hypoparathyroidism and renal 
defects appear to be local defects (e.g. Lim et al., 2000), it remains to be demonstrated to what 
extent the deafness is caused by deficits in the peripheral and/or central auditory system. Both 
types of deficits may contribute to hearing loss, because GATA3 is prominently expressed 
during development in the ear as well as in the central nervous system (CNS). In the inner ear 
GATA3 is expressed in virtually all cell types that occur during otogenesis including inner 
hair cells (IHCs), outer hair cells (OHCs), and various supporting cells (Rivolta and Holley, 
1998; Debacker et al., 1999; Karis et al., 2001; Lawoko-Kerali et al., 2002). In the central 
auditory nervous system GATA3 is expressed in progenitor neurons in rhombomere 4 of the 
hindbrain that will form the cochlear and vestibular efferents (Pata et al., 1999; Karis et al., 
2001) and in higher order afferent neurons such as those that will form the inferior colliculus 
(van Doorninck et al., 1999; Karis et al., 2001). To date, it is not clear whether these cell types 
in the ear and the brain that abundantly express GATA3 during development continue to do 
so throughout adulthood. 
Here, we address the question of whether the deafness in HDR syndrome is caused by deficits 
in the peripheral and/or central auditory system by investigating heterozygous Gata3 mice as 
a model system. We investigated 1) whether the auditory brainstem responses (ABRs) of 
these mice show signs of peripheral and/or central deficits; 2) what cells in the ear and central 
auditory system express GATA3 through adulthood; and 3) whether these cells and their 
connections show morphological aberrations at the adult stage.  
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Materials and methods 
Mouse lines 
Heterozygous Gata3 knockout mice have one of their Gata3 alleles replaced either by an 
nlsLacZ reporter gene, which localizes β-galactosidase to the cell nucleus, or by a tauLacZ 
reporter gene, which allows β-galactosidase transport into axons (for construct details see 
(van Doorninck et al., 1999). The original F1 of 129/SvEvBrd x C57BL/6 Gata3-nlsLacZ 
mice were bred at least four times into FVB/N background, which is reported as a normal 
hearing mouse strain (Zheng et al., 1999) before being used in these experiments. 
Heterozygous mice were compared to wild type mice born from the same or a similar litter. 
Animal experiments were performed in accordance with the "Principles of laboratory animal 
care" (NIH publication No. 86-23, revised 1985) and the guidelines approved by the Erasmus 
Medical Center animal care committee (DEC; protocol No. 138-01-03). A few days before 
surgery and throughout experiments mice were kept in an inverted day/night cycle of 12 
hours.  
Surgery 
To test their hearing capacity, heterozygous Gata3 and wild type mice were prepared for 
longitudinal ABR measurements in the alert state. For surgery, animals were anaesthetized 
with a mixture of O2, N2O and 2% halothane and received an acrylic head fixation pedestal 
equipped with electrodes. Two platinum reference electrodes were placed in hand-drilled 
holes in both left and right occipital bones at the level of Crus2 of the cerebellum. A third 
stainless steel screw, which served as the active electrode, was fixed to the skull between the 
two parietal bones. Finally, a common ground electrode was drilled into either the left or the 
right frontal skull. All transcranial screws were covered with dental cement, in which a three-
poled connector was fixed. The two reference electrodes and the active electrode were 
soldered to this connector, while the common ground electrode was wired to a separate 
connector.  
ABR recordings  
ABR recordings were performed in 31 heterozygous Gata3 knockout mice and 25 wild type 
littermates at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 15, 16, 17 and 19 months of age. The ABRs were 
performed in alert mice, since anesthesia significantly prolongs ABR latencies and causes an 
upward shift of thresholds (our unpublished observations). Mice were immobilized by placing 
them in a plastic holder and fixing their pedestals under short-term anesthesia. A 10-minute 
interval was always taken between short-term anesthesia and ABR recordings. Each mouse 
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was tested alert in both binaural and monaural stimulation conditions. For monaural 
recordings, the left and right ears were reversibly plugged with silicon elastomer. As reported 
(Henry, 1979), plugging resulted in a 30-35 dB threshold elevation in the plugged ear. Sound 
stimuli were presented in a sound attenuated box in frontal free field condition with a one-
tweeter loudspeaker (Radio Shack Super Tweeter 40-1310B) at a constant 40 mm distance 
between the cone tip of the tweeter and the external auditory canals of the animal. We used 
the EUPHRA-I system (Erasmus University Physiological Response Averager) for stimulus 
control and response recording. This 2-channel response averaging system consists of a PC 
combined with components for stimulus presentation and response acquisition and averaging 
(DSP Motorola 56002, 32 MHz). Stimulus clicks were generated by the DSP board (duration 
50 µs; repetition rates 23 or 80 Hz), while stimulus tone bursts were generated by a Hewlett 
Packard 33120A signal synthesizer (carrier frequencies of 4, 8, 16 and 32 kHz; repetition rate 
of 80 Hz). The tone bursts had a rectangular envelope with 1 ms duration and either zero or π 
radians starting phase of the carrier (i.e. alternating polarity of the carrier). Five hundred 
accepted post-stimulus time frames were averaged. Artifact rejection level was set at 40 µV. 
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Figure 3.1: Representative example of an ABR test-retest pattern of a 7-month-old male wild type mouse. Five 
distinct peaks are generally observed. For reasons of clarity only the uppermost trace was labeled. Scale bars 
represent 2 µV at 100 and 80 dB SPL, 1 µV at 60-25 dB SPL and 0.5 µV for lower sound pressure levels, 
respectively. The ABR threshold for this mouse was estimated to be 10 dB SPL. 
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A Bruel & Kjaer sound level meter (2218 with 1613 octave filter set and a ½ inch 4134 
microphone) was used for acoustic calibration. Peaks were identified and manually labeled by 
one and reviewed by a second observer. Response thresholds were determined by lowering 
the stimulus level with 20 dB steps from 110 dB sound pressure level (SPL) until no response 
peaks were detectable, and by subsequently increasing it with 5 dB steps until the peaks 
reappeared (Huang et al., 1995). The ABR threshold was defined as the lowest stimulus level 
at which a response peak was reproducibly present (for example see Figure 3.1). Statistical 
description of the data and tests were done with SPSS for windows version 10.0. An effect 
was considered significant when P < 0.02. 
Histology 
For histological examination at the light microscopic level we processed and analyzed 25 ears 
and 7 brains of 11 heterozygous Gata3 and 10 wild type mice. Animals were between 1 and 
15 months of age. The animals were deeply anaesthetized with Nembutal and perfused 
transcardially with either 1% paraformaldehyde, 0.5% glutaraldehyde in 0.05M phosphate 
buffer or with 4% paraformaldehyde in 0.1M phosphate buffer. The first fixation protocol was 
used to optimize visualization of β-galactosidase activity in both the ear and brain (van 
Doorninck et al., 1999). The second protocol was used to process the brains for 
immunohistochemistry against acetyl choline transferase, serotonin and glutamic acid 
decarboxylase (for details see De Zeeuw et al., 1996; Jaarsma et al., 1997; van Doorninck et 
al., 1999). Brains were embedded in gelatin, cryosectioned, processed, mounted and cover 
slipped in a standard fashion (see Jaarsma et al., 1995). Counting of cell nuclei in Nissl 
stained sections was done on comparable brain sections of three mice for each genotype. 
Cochleae were postfixed in 1% osmium tetroxide for 1 hr, embedded in plastic (Durcupan 
from Fluka, Buchs, Switzerland), and dissected into 10 'quarter' turns (Bohne and Harding, 
1997). In the material of each consecutive ‘quarter’ both the length of the organ of Corti and 
the numbers of present OHCs, IHCs, and pillar cells were determined. In addition, the 
percentage of missing nerve fibers was estimated by extrapolation of the diameter of the 
bundles. N=4 cochleae for each genotype at 2 and 15 months of age, n=2 for each genotype at 
9 months. For developmental analysis, β-galactosidase activity was visualized in ten fetal 
cochleae, after which they were decalcified, embedded in paraffin, sectioned and 
counterstained with neutral red (Kharkovets et al., 2000).  
In situ hybridization 
Non-radioactive in situ hybridization with digoxigenin-labeled antisense Gata3 or LacZ 
probes (all around 800 nucleotides in length) was done according to Schaeren-Wiemers 
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(Schaeren-Wiemers and Gerfin-Moser, 1993) on inner ears of 1-, 5-, 7-, and 26-week-old wild 
type and heterozygous Gata3 mice. Nine-micrometer-thick cryosections of 
paraformaldehyde-fixed decalcified cochleae (Whitlon et al., 2001) were hybridized at 65ºC 
with either an exon 2-3 probe comprising the 5’ part of the Gata3 cDNA (EcoRI-XhoI) or an 
exon 6 probe containing the 3’ part of the Gata3 cDNA (HindIII-EcoRI) or an EcoRV-ClaI 
LacZ fragment containing the 5’ part of this gene as a negative control (when hybridized to 
wild type cochlear sections). Cochlea were counterstained with methyl green. 
 
Results 
Heterozygous Gata3 knockout mice show hearing loss 
To investigate whether heterozygous Gata3 knockout mice have a hearing defect, longitudinal 
ABR thresholds were determined for 31 heterozygous Gata3 knockout mice and 25 wild type 
littermates. Measurements were done with clicks and tone bursts of respectively 4, 8, 16, and 
32 kHz at ages ranging from 1–19 months under alert conditions in a total of 75 recording 
sessions. Figure 3.2 shows that both types of mice show the lowest ABR thresholds at 16 
kHz, and that thresholds increase with age in both groups. The average monthly increase was 
2.2 dB. As compared to wild type littermates, heterozygous Gata3 mice showed a significant 
threshold elevation of approximately 30 dB at virtually all frequencies and all ages (P < 0.01, 
Mann-Whitney). When all ABR thresholds at 32 kHz were analyzed an apparent convergence 
of regression lines was detected, this however was an artifact, due to a ceiling effect (the level 
of the loudest sound stimulus was 110 dB SPL): when analyzing only thresholds of mice 
under 10 months of age the constant 30 dB threshold difference between the two groups was 
observed as well. We did not observe any difference in thresholds due to different repetition 
rates of the stimulus (23/s and 80/s, top panels in Figure 3.2), due to gender differences, or 
between left and right ears (data not shown). The mean difference between binaural and 
monaural thresholds was 5.95 dB (0.02 dB, SEM), which is comparable to findings in man 
(Conijn et al., 1990). Thus the persistent hearing deficits found in the Gata3 mice appear to be 
reliable and specifically caused by the genetic mutation, and they indicate that the 
heterozygous Gata3 mice can serve well as a model for studying the cause of deafness in 
HDR syndrome.  
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Figure 3.2: Binaural thresholds (dB SPL) as a function of age (months) for click stimuli and 4, 8, 16 and 32 kHz 
pure tone conditions. Open circles indicate heterozygous Gata3 knockout mice and filled circles represent wild 
type controls. Note that due to overlapping data points the number of represented measurements may appear 
smaller than the actual number of measurements performed. Regression lines through wild type and 
heterozygous data points are shown. A reference line at 110 dB SPL indicates the maximum stimulus level. All 
panels demonstrate an approximate 30 dB threshold elevation in heterozygous Gata3 knockout mice as 
compared to wild type controls. 
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Expression of GATA3 in the inner ear and auditory parts of the CNS 
To learn whether and where Gata3 is expressed in the inner ear and/or auditory parts of the 
CNS during development and adulthood, we investigated β-galactosidase activity in mouse 
lines in which either an nlsLacZ (for labeling of cell nuclei) or a tauLacZ (for labeling of 
axonal connections) allele is inserted at the transcription start site of the Gata3 gene. Inner ear 
expression of Gata3 starts at E9 in the otic placode (Lawoko-Kerali et al., 2002) and by E18 
Gata3 driven β-galactosidase activity (GATA3-LacZ) was observed in both sensory and non-
sensory cell types including cells in the developing cochlear duct and spiral ganglion (SG) 
(Figure 3.3A). At postnatal day 1 GATA3-LacZ was abundantly expressed in nerve fibers, 
hair cells, pillar cells and supporting cells throughout the entire cochlea (Figure 3.3B). 
Although it was reported that Gata3 expression could not be detected by immunofluorescence 
in the adult sensory epithelium of the ear (Rivolta and Holley, 1998), we can easily detect 
GATA3-LacZ throughout adulthood. In adult cochleae GATA3-LacZ was found in neurons 
of the SG, outer and inner hair cells, and various supporting cells including Claudius’ cells, 
pillar cells, inner and outer sulcus cells, interdental cells and cells in the spiral prominence 
and ligament (Figure 3.3C). These expression profiles in the cochlea remained throughout 
adult life without any sign of reduced intensity at older ages. To verify the distribution 
patterns of GATA3-LacZ in the ear during young-adulthood and adult life we investigated its 
expression also with the use of in situ hybridization. We used two Gata3 probes recognizing 
different parts of the gene that gave identical results. In heterozygous mice, a LacZ probe that 
hybridizes to the LacZ sequence inserted in the Gata3 gene, gave results indistinguishable 
from both Gata3 probes (data not shown). We used this LacZ probe as a negative control in 
wild type cochlear sections (see Figures 3.3D,G). In 5-7-week-old animals, Gata3 mRNA was 
detected in the organ of Corti and surrounding cells (Figure 3.3E, H) and in the SG (Figure 
3.3E,I). The in situ hybridization experiments showed that Gata3 mRNA was strongly 
expressed in the cochlea from early life (P8) until half-a-year-of-age (the oldest age examined 
for in situ hybridization), without reduced expression levels at older ages. GATA3-LacZ 
staining therefore fully reproduces Gata3 in situ hybridization; both are detected in neurons of 
the spiral ganglion, outer and inner hair cells, Claudius’ cells, pillar cells, inner and outer 
sulcus cells, interdental cells and cells in the spiral prominence and ligament.  
No expression of GATA3-LacZ is found in the ossicles of the middle ear (data not shown). In 
the auditory parts of the CNS expression of Gata3 starts around E9 (Pata et al., 1999) and 
expression continues until adulthood and is observed in cell bodies and fibers in the superior 
paraolivary nucleus, nucleus of the lateral lemniscus, and inferior colliculus as well as in 
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efferent fibers in the cochlear nucleus (Figure 3.4). Similar to the expression in the inner ear, 
GATA3-LacZ expression in these neurons and axonal connections remained at high densities 
beyond the age of 1 year. 
In conjunction our data show that Gata3 is continuously expressed from early development on 
through adulthood in various parts of both the inner ear and central auditory nervous system. 
Thus, these temporal-spatial expression patterns leave open all possibilities to explain whether 
the hearing loss in heterozygous Gata3 mutants is caused by a peripheral or a central defect. 
 
Peak and interpeak latencies do not differ 
To find out whether auditory parts of the CNS of heterozygous Gata3 knockout mice were 
affected, we compared the latencies of their ABR peaks to latencies of ABR peaks of wild 
type littermates. Stimulus levels of 80 dB SPL or higher that were at least 30 dB above 
threshold levels were used for these comparisons. In the ABRs of both wild types and 
heterozygous Gata3 mutants usually 5 peaks (I to V) were readily discriminated (see also 
Figure 3.1). We aligned average peak I latencies obtained with frequency-specific stimulation 
(4, 8, 16 and 32 kHz) with those obtained with click stimulation to avoid frequency-dependent 
bias effects due to the tonotopy in the cochlea. The latencies of subsequent peaks were 
corrected with the same amount, leaving interpeak latencies unchanged. None of the latencies 
of the pooled data of the Gata3 mutants were significantly different from those obtained in 
wild types (for corrected average latencies see Table 3.1). In addition, interpeak latencies do 
not differ between heterozygous Gata3 and wild type control mice (e.g. P > 0.8 for peak I-III 
interpeak latencies, Student’s t-test).   
Interestingly, the interpeak latencies developed in both the wild types and mutants at a similar 
pace (Figure 3.5). In both cases these latencies were shortened by approximately 0.3 ms 
during the first 100 days. A similar maturation pattern can be observed in humans (Salamy, 
1984) and is likely due to increases of the diameter of the myelin sheaths during maturation of 
the nervous system, which results in faster axonal conductance and thus in a decrease of peak 
and interpeak latencies. Nonlinear regression analysis shows that interpeak latency I-III is 
significantly age-dependent (P < 0.0001, F-test) with an R-square of 0.21. The age-effect 
therefore explains 21% of the variance in the interpeak latency I-III data. Together these 
latency data show that the auditory parts of the  CNS in Gata3 mutants mature similar to  wild 
   90
A tauLacZ, P1B
wt, 5 weeksIIHC OHCG IHC OHCH
I
IHC OHC
StV
SLSG
SP
RM
wt, 5 weeksE F
 
 
Figure 3.3: (A-C) Expression of Gata3 visualized by β-galactosidase activity (blue staining) and (D-I) in situ 
hybridization (purple) in mouse cochleae. (A) Section through the cochlea of an E18.5 heterozygous GATA3-
nlsLacZ fetus. GATA3-LacZ expression is visible in and adjacent to the developing organ of Corti (OC) and in 
spiral ganglion (SG) cells. (B) Overview of a cochlea of a heterozygous Gata3-tauLacZ mouse at postnatal day 1 
(P1). (C) Cross section of a cochlea of a 4-month-old heterozygous GATA3-nlsLacZ mouse. β-Galactosidase is 
predominantly present in the cell nuclei. Tunnel of Corti (T), inner hair cell (IHC), outer hair cells (OHC), pillar 
cells (PC), and Claudius’ cells (CC) are indicated. (D, G) In situ hybridization on wild type cochlea hybridized 
with a LacZ probe (negative control). (E, H) Cochlea hybridized with a Gata3 probe shows Gata3 mRNA 
expression in IHCs, OHCs, various supporting cells, inner and external sulcus cells, spiral ganglion (SG) cells 
identical to LacZ staining. Note that G and H have a nuclear methyl green counter staining. (F) Schematic 
drawing of an adult cochlea to indicate the different cell types (Van Camp and Smith, 2004).(I) Detail of E, 
showing the presence of Gata3 mRNA in the cytoplasm of spiral ganglion cells. Scale bars: A, 250 µm; B, 400 
µm; C, 40 µm; D, E, 100 µm; G,H, I, 20 µm. BM Basilar membrane, DC Deiters’ cells, ESC External sulcus 
cells, HC Hensen’s cells, IDC Interdental cells, IPC Inner pillar cell, ISC Inner sulcus cells, SL Spiral limbus, 
OPC Outer pillar cell, RM Reissner’s membrane, SP Spiral prominence, StV Stria vascularis, TM Tectorial 
membrane.
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Figure 3.4: Distribution of Gata3 positive, β-galactosidase labeled fibers and neurons in various parts of the 
auditory system in the CNS of a 9-month-old heterozygous Gata3-tauLacZ mouse. (A) Overview of transverse 
section of the brainstem with labeled fibers in the cochlear nucleus (CN) and with both labeled cell bodies and 
fibers in the inferior colliculus (IC). (B) Magnification of IC labeling in (A). Note the patches of dense labeling 
in the external cortex of the IC (arrows). (C) Magnification of CN labeling in (A). The labeled fibers run through 
the ventral CN. (D) Both the lateral superior olive (LSO) and superior paraolivary nucleus (SPN) contains many 
labeled fibers and cell bodies. Scale bar: A, 500 µm; B-D, 100 µm. 
 
A
D
B
E
C
F
1
2
3OHC
IHC
PC
NF
* **
*
 
 
Figure 3.6: Light microscopic examinations of cochleae of wild type (A,B,C) and heterozygous mice (D,E,F) 
mice of 2 (A,D), 9 (B,E) and 15 (C,F) months of age. Of the 10 quarter pieces cut from the whole cochlea, the 
number 4 pieces are shown in this figure (apex is one, base is ten). Three rows of outer hair cells (OHC), a row 
of outer pillar cells with visible protruding necks and heads that are flanking the lighter stained heads of the inner 
pillar cell row (PC) and one row of inner hair cells (IHC) are indicated in (A). Whereas in (A) three distinct rows 
of OHCs can be seen, in (D) the pattern is irregular, this is due to missing OHCs and the appearance of 
underlying Deiters’ cells (lighter circles). A complete loss of all cell types is seen in 15-month-old heterozygous 
mice (F), whereas in wild type mice (C), NF, PCs and IHCs are missing sporadically and only OHCs are almost 
completely lost. Asterisks indicate missing pillar cells. Scale bar in A (for A-F) 20 µm. 
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type mice during postnatal development and that they reach the same functional level that is 
maintained until at least 1 year of age. 
 
Genotype Peak I Peak II Peak III Peak IV Peak V 
mean 1.72 2.52 3.32 4.25 5.75 Wild type 
s.d. .09 .14 .14 .24 .25 
mean 1.70 2.47 3.30 4.14 5.68 Heterozygous  
s.d. .11 .21 .20 .23 .24 
 
Table 3.1. Latencies of ABR peaks I to V of wild type and heterozygous Gata3 mice. 
ABR-peak I-V latencies, corrected for tonotopic effects (see Materials and methods), do not differ significantly 
between heterozygous Gata3 and wild type control mice. Differences in peak latencies would indicate 
dissimilarities in conduction velocity in the (auditory) brainstem between groups. Stimulus level was 80 dB SPL, 
and data were pooled over all frequencies, stimulus modes and age groups. 
 
 
 
 
Figure 3.5: Maturation of the I-III interpeak latencies as a function of age. Mean interpeak latencies were 
determined for ABR peaks elicited by stimulus levels of 80 dB SPL or higher that were at least 30 dB above 
threshold levels. The lines are the least squares fits with an inverse function through the data. Dotted line 
represents fit for wild type mice data and solid line indicates fit for heterozygous mice. No data points were 
available for heterozygous mice older than 300 days because the thresholds were too high. 
 
 
The inner ear, but not the brain, shows morphological abnormalities  
The threshold elevations and normal latencies of the ABRs described above show that the 
cause of hearing loss in Gata3 mutants is not central but peripheral, and that hearing loss 
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starts during early postnatal development and maintains through adulthood. To find out 
whether these physiological data are corroborated by morphological pathological phenomena, 
we investigated whether, when and to what extent the central auditory nervous system and ear 
show morphological aberrations. 
Nissl stained sections of the brains of heterozygous Gata3 mice of 1, 3 and 9 months old did 
not show any abnormality in cyto-architecture or cell counts when compared to wild types. 
Sections of the cochlear nucleus, superior olive, nucleus of the lateral lemniscus and inferior 
colliculus that were stained with antisera against a neurotransmitter (serotonin) and two 
neurotransmitter producing enzymes (acetyl choline transferase and glutamic acid 
decarboxylase) did not reveal any abnormal distribution or density of terminals (data not 
shown). Both macroscopic and light microscopic examination of the external and middle ear 
did not show any abnormality during development or adulthood (data not shown).  
In contrast, the inner ears of heterozygous mice showed clear abnormalities. In Figure 3.6 
mid-apical quarter pieces of cochleae of wild type and heterozygous Gata3 mice isolated at 
different ages are depicted. Cochleae of 2-month-old wild type mice showed an organized 
pattern of one row of IHCs and 3 orderly rows of OHCs (Figure 3.6A). The heterozygous 
mice at 2 months of age however, showed an irregular pattern with remnants of the 3 OHC 
rows while the nuclei of underlying Deiters’ cells became visible (Figure 3.6D). The stria 
vascularis and Reissner’s membrane appeared normal in heterozygous mice. At 1 month of 
age, OHCs in the mutant mouse and to a lesser extent their auditory nerve fibers were 
partially missing at the apex and this became more prominent with age (Figure 3.6). 
Quantitative analyses of the OHCs, IHCs, pillar cells and nerve fibers revealed a progressive 
loss of cells and fibers that significantly preceded and exceeded the loss in wild types (Figure 
3.7). During the same period, some degeneration occurred at the basal turn of the cochlea, but 
the level of this process was comparable to that in wild type mice (Figure 3.7). In 9-month-old 
mutants, all OHCs had disappeared, while in the wild types OHCs were only affected at the 
base of the cochlea (Figures 3.6B,E and 3.7B,E). Concomitantly, the IHCs, pillar cells and 
nerve fibers of the mutants substantially decreased in number at both the apical and basal 
turns. Finally, the organ of Corti of 15-month-old heterozygous Gata3 mice was almost 
completely degenerated including supporting cells, whereas wild type littermates still had 
normal numbers of IHCs, pillar cells and nerve fibers in the upper half of the organ of Corti 
(Figures 3.6C,F and 3.7C,F). Intermediate ages showed intermediate patterns of degeneration 
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Figure 3.7: Presence of outer hair cells (OHC, red squares), inner hair cells (IHC, yellow circles), pillar cells 
(PC, blue triangles), and absence of nerve fibers (NF loss, green circles), in cochleae of wild type (A,B,C) and 
heterozygous Gata3 (D,E,F) mice of 2 (A,D), 9 (B,E) and 15 (C,F) months of age (these data are from the same 
mice as shown in Figure 3.6). Markers indicate the percentage of cells present or the percentage of nerve fibers 
absent in the 10 different cochlear pieces, plotted against the distance to the apex of the analyzed cochlear part. 
Hair cells responsive to 4 kHz, 8 kHz, 16 kHz and 32 kHz tones are found at approximately 25%, 40%, 60% and 
75% distance from the apex respectively (Ou et al., 2000). 
 
 (data not shown). Thus, Gata3 haploinsufficiency-induced degeneration started at the apex 
and ultimately progressed into sensory epithelia in the middle turns of the cochlea. 
 
In sum, our morphological analyses showed no abnormalities in the central auditory regions, 
while clear degeneration was observed peripherally in the cochlea and hence confirm the 
physiological data that showed involvement of the peripheral but not the central auditory 
nervous system in Gata3 related hearing loss. 
 
Discussion 
Gata3-related hearing loss is cochlear in origin  
Mice with a mutation in one allele of the Gata3 gene may serve as a mouse model to study 
the involvement of GATA3 in different HDR disease phenotypes (hypoparathyroidism, 
deafness and renal dysplasia). Here we have addressed the question as to whether 
heterozygous Gata3 mice indeed suffer from deafness, and if so, whether this disorder is 
caused by deficits in the peripheral and/or central auditory system. This question turns out to 
be particularly pertinent as we showed with the use of in situ hybridization and a Gata3 
regulated LacZ reporter gene that Gata3 is expressed in several auditory components of both 
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the central and peripheral nervous system from embryogenesis until adulthood. We used a 
combination of physiological and histological techniques to analyze different auditory 
parameters in brain and ear. Our ABR measurements showed that Gata3 mutant mice suffer 
from sensorineural hearing loss similar to HDR patients (Bilous et al., 1992). The average 
threshold elevation in mutant mice was 30 dB at all ages ranging from 1 to 19 months.  
In both the mutants and wild type littermates we observed a mild form of age-related hearing 
loss, which is characterized by functional and morphological deficits that start at the base of 
the cochlea (high frequencies) and progress towards the apex (low frequencies) during life. 
This was unexpected since the genetic background of these mice was 94 % FVB/N and 
FVB/N has been reported to be a good hearing mouse strain (Zheng et al., 1999). However, 
we are confident that this form of hearing loss did not confound the deficit and phenotype that 
is caused by Gata3 haploinsufficiency, because the age-related hearing loss was equal in 
mutants and wild types, and because the dominant hair cell loss in the Gata3 mutants started 
at the apex of the cochlea instead of the base. 
To distinguish the impacts of a loss of GATA3 at the different neuro-anatomical levels we 
analyzed ABR peak latencies, because they are a measure for the conductance efficiency of 
the different auditory connections. ABR peaks I to V originate in the afferent auditory 
pathway between the cochlea and VIIIth nerve (peak I) and the inferior colliculus (peak V) 
(Henry, 1979). Comparisons of the peak and interpeak latencies of heterozygous Gata3 and 
wild type mice showed that the velocities of the different nerve conductances of the mutant 
mice were indistinguishable from those of wild type animals. The absence of a prolonged 
latency of peak I together with the absence of morphological defects in the middle ear bones 
exclude a middle or outer ear origin (van der Drift et al., 1988). The normal interpeak 
latencies indicated that the origin of deafness was not located in the central nervous system, 
which was confirmed by the absence of detectable abnormalities in the brain. In contrast, 
histological analysis of the cochleae in heterozygous Gata3 mice showed a gradual 
degradation of all cell types of the organ of Corti starting with the OHCs at the apex. At 15 
months of age the organ of Corti was completely degenerated. Together, these results indicate 
that the observed hearing defects in heterozygous Gata3 mice have a cochlear origin.  
 
Primary cause of deafness  
Our data clearly indicated that the hearing loss observed in Gata3 mutant mice is most likely 
caused by a cochlear deficit, however, the exact cellular cause of this deafness remains to be 
elucidated. Several observations suggest that a defect of the OHCs may be the primary cause 
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of deafness: First, the OHCs were the first type of cells in the Gata3 mutant mice that showed 
signs of degeneration. Second, the level of hearing loss corresponds well to that observed in 
other disorders with a degeneration of the OHCs. For example, the loss of OHCs in 
chinchillas induced by noise also causes a 30 dB permanent threshold shift (Hamernik et al., 
1989). Third, a loss of OHCs in other mutants such as the Prestin and Barhl1 knockouts and 
the Kit(W-v) and Jackson Shaker mouse mutants also causes comparable hearing deficiencies 
(Schrott et al., 1990a, 1990b; Kitamura et al., 1991, 1992; Dallos, 1996; Li et al., 2002; 
Liberman et al., 2002). Still, it should be noted that IHCs and pillar cells also express Gata3 
and that functional loss of these cells may also contribute to the hearing loss.  
We have shown abundant expression of Gata3 mRNA in the adult ear, either by the detection 
of Gata3 induced β-galactosidase or by direct in situ hybridization (Figure 3.3). However, 
GATA3 protein expression has been shown in mouse cochleae up till P0 by Holley and co-
workers but was no longer visible at P14 (Rivolta and Holley, 1998). As Gata3 mRNA is 
readily detectable but apparently subject to strong translational control, it remains a question 
whether GATA3 protein is too low to be detected in adult cochleae or no longer present. If 
GATA3 protein is not present in adult life, the hearing deficiency and progressive 
degeneration that we observed in heterozygous Gata3 mice are a result of developmental 
GATA3 shortage. An inducible Gata3 knockout mouse, that deletes GATA3 after birth, will 
be tested to distinguish between a developmental and maintenance problem. 
 
Does GATA3 haploinsufficiency cause cell-autonomous degeneration in the cochlea? 
Different cell types in the cochlea express GATA3 but it is not known whether the observed 
cellular degeneration is due to cell-autonomous loss of GATA3. The first cells in the Gata3 
mutant mouse to degenerate are OHCs followed by IHCs and pillar cells. This is reminiscent 
of the noise-induced hearing loss model in which outer hair cells are lost first and surrounding 
supporting and sensory cells degenerate as a secondary event (Bohne and Harding, 2000), i.e. 
non cell-autonomous. However, the noise-induced cell loss is rapid (days, Bohne and 
Harding, 2000) whereas the IHC loss we observed in the Gata3 mice lagged behind OHC loss 
by several months. Loss of OHCs (or OHC function) does not in itself cause loss of IHCs and 
pillar cells as several mouse mutants exist that show independent loss of OHCs and IHCs: 
The Barhl1 mouse mutant shows opposed gradients of hair cell loss with OHC degeneration 
from apex to base and IHC degradation from base to apex (Li et al., 2002). The Jackson 
Shaker mouse, which carries a mutation in the scaffold protein Sans (Kikkawa et al., 2003), 
shows degeneration of basal OHCs in the first weeks while basal IHCs degenerate only 3 
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months later (Kitamura et al., 1991; Kitamura et al., 1992). The KitW-v mouse mutant lacks 
almost all OHCs from birth onwards, but does not show any IHC or supporting cell 
degeneration (Sterbing and Schrott-Fischer, 2002). For these reasons, we think it likely that 
OHC, IHC, and pillar cell losses in the heterozygous Gata3 mice are cell-autonomous events. 
This would be in line with our expression data (Figure 3.3), which show that all three cell 
types express Gata3. However, cell non-autonomous events could play a role in the observed 
degeneration. To distinguish between these possibilities we will investigate (cochlear) cell 
type specific Gata3 knockout mice that will help to elucidate the exact role of each cell type 
in the observed cochlear degeneration.  
Cochlear cells are likely to be dependent on a number of downstream genes regulated by the 
transcription factor GATA3. They may include neurotrophin-like factor genes, similar to 
GATA3 regulated induction of interleukines in T-lymphocytes (Zhang et al., 1998) or 
neurotransmitter genes, similar to the defective serotonin and tyrosine hydroxylase expression 
in respectively Raphe nuclei and sympathetic ganglia in homozygous Gata3 knockout cells 
(van Doorninck et al., 1999; Lim et al., 2000). A reduced amount of neurotrophin-like 
substances would affect the correct development of the organ of Corti or its resistance against 
normal injury occurring throughout life.  
The present study analyzed the deafness phenotype in heterozygous Gata3 mice as a model 
system for the deafness of HDR patients. Our data show that Gata3 haploinsufficiency leads 
to a peripheral auditory defect. This finding opens the possibility for the development of local 
peripheral treatment for the hearing problems in HDR patients using for example virally 
mediated transfer of GATA3 or GATA3 target genes into the cochlea. 
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… 
Zo ging hij telkens een stap dichter naar de tor toe, tot hij voor zijn oor stond en tamelijk luid riep: 
“Tor.” 
Maar de tor sliep door. 
De mus wendde zich tot de eekhoorn en zei: “Hij slaapt onmeetbaar diep.” 
“Wat is  onmeetbaar?” vroeg de eekhoorn. 
“Ja…” zei de mus, “dat is bijvoorbeeld hoe warm de tijd is of wie er het meest van de lucht houdt of 
het jarigst is...” 
“O,” zei de eekhoorn. 
…. 
 
Uit ‘Misschien wisten zij alles’, Toon Tellegen, Em. Querido’s Uitgeverij B.V., 2005. 
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Summary 
Human HDR (hypoparathyroidism, deafness and renal dysplasia) syndrome is caused by 
haploinsufficiency of zinc-finger transcription factor GATA3. The hearing loss due to GATA3 
haploinsufficiency has been shown to be peripheral in origin, but it is unclear to what extent 
potential aberrations in the outer hair cells (OHCs) contribute to this disorder. To further 
elucidate the pathophysiological mechanism underlying the hearing defect in HDR syndrome, 
we investigated the OHCs in heterozygous Gata3-knockout mice at both the functional and 
morphological level. While the signal-to-noise ratios of distortion product otoacoustic 
emissions (DPOAE) in wild-type mice did not change significantly during the first half-year 
of live, those in the heterozygous Gata3 mice decreased dramatically. In addition, both light 
microscopic and transmission electron microscopic analyses showed that the number of 
OHCs containing vacuoles was increased in the mutants. Together these findings indicate that 
outer hair cell malfunctioning plays a major role in the hearing loss in HDR syndrome. 
 
Key words: DPOAE, OHC, vacuole, HDR syndrome, EM, hearing loss, GATA3 
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Introduction 
In 1992, HDR syndrome was first described as a new clinical entity, comprising 
hypoparathyroidism, deafness and renal dysplasia (Bilous et al., 1992).  
The sensorineural hearing loss in HDR patients can be both symmetric or asymmetric, and as 
tested by auditory brainstem response (ABR), conditioned orientation reflex tests or pure tone 
audiometry it ranges in level from 40 dB to 105 dB (Bilous et al., 1992; Fujimoto et al., 1999; 
Hasegawa et al., 1997; Lichtner et al., 2000; Muroya et al., 2001).  Although it is clear that 
hearing loss in HDR is usually somewhat more severe at the higher end of the frequency 
spectrum (Lichtner et al., 2000; Muroya et al., 2001), no systematic audiometric evaluation 
has yet been made, and the exact pathophysiological mechanism causing the hearing defect 
remains largely unknown. Genetically HDR syndrome is caused by haploinsufficiency of zinc 
finger transcription factor GATA3 (Van Esch et al., 2001a; Van Esch et al., 2001b; Van Esch 
et al., 2000), which in mice is essential for development of several tissues and organs 
including the lymphatic system, the sympathetic nervous system, brain, kidney, jaw and inner 
ear (Lim et al., 2000; Pandolfi et al., 1995, Pata et al., 1999;, Ting et al., 1996; van Doorninck 
et al., 1999; Zheng and Flavell, 1997). During development human and murine GATA3 is 
prominently expressed in virtually all cell types of the inner ear including inner hair cells 
(IHCs), outer hair cells (OHCs) and supporting cells as well as in various cell types of the 
central auditory system including neurons in the superior olive and inferior colliculus 
(Debacker et al., 1999; Karis et al., 2001; Lawoko-Kerali et al., 2002; Rivolta and Holley, 
1998; van der Wees et al., 2004;van Doorninck et al., 1999).   
In line with HDR syndrome in humans, heterozygous Gata3 mice show an elevation in their 
Auditory Brainstem Response-thresholds. Thresholds are elevated by approximately 30-dB, 
while no interpeak latency differences can be found. In addition Gata3 heterozygous mice 
showed extensive apical cochlear cell loss from young ages onwards, without any 
morphological abnormalities in the central nervous system.  This led us to conclude that 
hearing loss due to GATA3 haploinsufficiency is peripheral in origin (van der Wees et al., 
2004). Building upon the above-mentioned findings, and considering the fact that at light 
microscopical level outer hair cells (OHCs) degenerated first before subsequent loss of inner 
hair cells (IHC), pillar cells (PC) and nerve fibers (NF), we hypothesized that OHC 
malfunctioning could be an important factor causing hearing loss in GATA3 
haploinsufficiency. 
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The most accurate measure for testing OHC function are otoacoustic emissions (OAE’s) 
(Schrott et al., 1991). Otoacoustic emissions have been used in mice auditory research for a 
variety of purposes, amongst others to study age related hearing loss – AHL - (Jimenez et al., 
1999; Parham, 1997; Parham et al., 1999), noise induced hearing loss – NIHL - (Jimenez et 
al., 2001; Vazquez et al., 2001) and effects of hypothyroidism on OHCs (Li et al., 1999).  
Moreover, OAE’s have also been used for auditory phenotyping and to study effects of 
genetic mutations on the auditory system (Huang et al., 1995; Huang et al., 1998; Konrad-
Martin et al., 2001). 
To shed light on the potential role of dysfunction of OHCs in the hearing loss found in HDR 
patients, we investigated the function of these cells in heterozygous Gata3 mice. We 
investigated functioning of their OHCs by measuring the distortion product otoacoustic 
emissions (DPOAE) and by further analyzing the morphology of these cells at both the light 
microscopic and electron microscopic level at young ages (1 to 2 months). 
 
Materials and Methods 
Mouse lines/subjects 
Heterozygous Gata3 knockouts (129/C57BL/6 GATA3-nlsLacZ mice bred 6 to 8 times into 
FVB/N background) were compared to wild type mice from the same litter. Animal 
experiments were performed in accordance with the “Principles of laboratory animal care” 
(NIH publication No. 86-23, revised 1985) and the guidelines approved by the Erasmus 
University animal care committee (DEC; protocol No. 138-02-01). 
Light microscopy and electron microscopy 
Outer hair cell loss was analyzed at the light microscopic level in 24 cochleae of 7 
heterozygous Gata3 and 7 wild type mice, in the age range between 1 and 15 months. The 
animals were deeply anaesthetized with Nembutal and perfused transcardially with 4% 
paraformaldehyde in 0.1M phosphate buffer. 
Cochleae were post fixed in 1% osmium tetroxide for 1 hr, embedded in plastic (Durcupan 
from Fluka, Buchs, Switzerland), and dissected into 10 'quarter' turns (Bohne and Harding, 
1997). In the material of each consecutive ‘quarter’ both the length of the organ of Corti and 
the number of present OHCs was determined.  
A total of 11 cochleae (left and right ears) obtained from 3 mice of each genotype (of which 
one was 1 month old and two were 2 months old) were used for analysis of differences 
between heterozygous and wild type mice at light microscopical level. Cochlear pieces 
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containing those sections of the organ of Corti that are responsive to approximately 4, 16 and 
32 kHz were used for histological analysis (Ou et al., 2000). Semithin slices (1µm thick) were 
cut on a Leica Reicherts Ultratome and counterstained with a Toluidin blue-staining 
containing 1% Toluidin blue, 1% Methylene blue, 0,2% Sodiumhydroxide, 1% Borax 30% 
Ethanediol Ethyleneglycol and 70% MilliQ water. Slices were examined under a Leica DM-
RB microscope. Per cochlear piece 50 to 163 slices were examined. The number of OHCs 
containing vacuoles was scored and entered in Excel data-files, which were subsequently 
imported into an SPSS-data file. Statistical analysis of histological data was done using SPSS 
for Windows version 11.0. An effect was considered significant when p < 0.02. Non-
parametric (Mann-Whitney) tests were used to analyze the difference in numbers of outer hair 
cells containing vacuoles between genotypes. Apart from this, the effect of age and location 
of the OHC in the cochlea on this difference was analyzed.  
In order to assess possible additional signs of (outer) hair cell degeneration, such as 
mitochondrial changes, changes in endoplasmatic reticulum and disappearance of ribosomes 
ultrathin slices were cut for electron microscopy, and contrasted with uranyl acetate and lead 
citrate (Oei et al., 2003) of inner ears from three 2 months old mice for each genotype. Slices 
were analyzed using a Philips CM100 electron microscope.  
DPOAE-test procedure  
Per age group, genotype and gender at least 5 mice were subjected to DPOAE measurements 
(i.e. at least 20 mice were examined per age group). Measurements were performed both 
longitudinally and transversally (32 mice were tested once, 25 mice twice, 9 mice trice and 7 
mice four times). Animals were anesthetized with a mixture of 5% Fluothane, N2O and O2. 
After induction of anesthesia, mice were placed on a heating pad (Thermocomfort, Brisk BV, 
Venray, The Netherlands), to maintain constant body temperature. In each mouse the right 
and left ear were consecutively tested. Cerumen obstruction and infection were excluded prior 
to experiments by otoscopically inspecting ear canals and eardrums. Mice suffering from 
obvious outer- or middle ear problems were temporarily excluded from experiments. To 
equalize the anesthesia induced increase in middle ear pressure, the pars flaccida of the 
tympanum was perforated using a Microlance® needle. The success rate of this procedure 
was high. Occasionally however, the perforation was unsuccessful or closed during 
measurements, resulting in a decrease of signal to noise ratios of emissions. If so, a second 
tympanocentesis was performed. Repeated measurements (and ear drum perforations) in 
individual mice did not influence DPOAE levels; an illustrative example of this is given in 
Figure 4.1. Signal to noise ratios of two 5 months old mice are compared, one after a single, 
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and the other after four test sessions. Next, foam stripped Etymotic® ER10C-14C ear tips 
were fitted in the external ear canals to enable recording of DPOAE. 
 
 
 
Figure 4.1: DPOAE signal to noise ratios (dB) of two 5 months old wild type mice, open circles indicate results 
after a single measurement, closed triangles represent results after four test sessions. Data for both ears are 
represented. Repeated measurements and paracentesis in individual mice did not influence DPOAE levels. 
 
DPOAE measurements 
2f1-f2 DPOAEs were measured using a commercially available recording system (DP 2000 – 
Starkey). After introduction of the probe and prior to actual recordings calibration of the 
stimulation conditions was done over a 0.1-20 kHz frequency range. The primary frequency 
ratio (f2/f1) was 1.2 (Le Calvez et al., 1998b). The targeted primary tone levels, L1/L2, were 
65/55 dB SPL. Data were collected with f2 at 6.8, 8.0, 9.5, 11.3, 13.5 and 16.0 kHz. All 
experiments were performed in a quiet but not sound treated room. Recordings were repeated 
(at least 6 times). 
DPOAE data processing and analyses 
DPOAE data processing was done using SPSS for Windows version 10.0. Raw data, as stored 
in the database of the DPOAE recording system, were imported into SPSS-data files. Data 
were included for statistical analysis after a strict selection as to quality of calibration curves 
of both stimulus channels, on noise floor and stimulus condition quality during recordings. 
Symmetry criteria of the calibration curves of both loudspeakers in the probe were used for 
selection of good quality recordings. Furthermore, recordings with calibration curves showing 
a probable air leakage or occlusion of probe channels by the ear canal wall were excluded, as 
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were recordings with background noise levels over –2 dB SPL and recordings with 
stimulation levels differing too much from targeted levels (more than 15 dB). Finally only 
recordings with primary tone level differences ranging from –1 to 12 dB were included.  
 
 
f2 frequencies (kHz) and genotypes 
 
6.8 8.0 9.5 11.3 13.5 16.0 
 
 
age 
(months) 
 wt ht wt ht wt ht wt ht wt ht wt ht 
    1.0 8 9 9 11 9 11   1 6 9 9 11 
    2.0 7 10 7 11 7 11 2 2 6 10 6 10 
    3.0 9 12 10 12 10 12 3 2 9 12 10 12 
    4.0 9 8 10 8 10 8 5 3 6 8 9 8 
    5.0 11 10 11 11 11 11   5 11 10 11 11 
    6.0 11 10 11 10 11 10 3 4 11 10 11 10 
    7.0 5 8 7 9 7 9   3 5 9 7 9 
 
Table 4.1: Number of mice per age group, genotype and frequency (f2) after selection of data on DPOAE 
recording-quality criteria.  
For the f2 = 11.3 kHz only a limited number of data met the selection criteria, therefore this frequency was 
excluded from further statistical analysis. (wt; wild type, ht; heterozygous). 
 
Table 4.1 displays the number of mice per age group, genotype and frequency (f2) after strict 
selection of data. For the f2= 11.3 kHz target levels of the primaries often failed to meet the 
selection criteria. Therefore this frequency was excluded from further statistical analysis. 
Subsequently, of every individual mouse the emission with the best signal to noise ratio per 
age, per frequency, and per ear was selected for analysis. Since each individual mouse was 
measured on both ears, we analyzed ear effects prior to further analyses. Within individual 
mice a significant correlation existed between right and left ears (Pearson’s correlation 
coefficient = 0.81, significance < 0.0005).  Therefore data were aggregated for each mouse 
(means of right and left ears), at each age and frequency, for further analysis of genotype and 
gender influence. Statistical analysis of DPOAE-data was done using SPSS for Windows 
version 10.0. An effect was considered significant when p < 0.02. 
  111
Effects of genotype on signal to noise ratio’s were analyzed, as were age effects, and gender 
effects. 
 
Results 
Light microscopy  
Quantitative analyses of the OHCs revealed a progressive loss of apical outer hair cells in 
heterozygous mice from one month onward, significantly preceding and exceeding loss in 
wild types. At the same time some degeneration occurred at the basal turn of the cochlea, but 
the level of this process was comparable to that in wild type mice. By the age of 9-months, in 
mutants, nearly all OHCs had disappeared, while in the wild types OHCs were still only 
affected at the base of the cochlea (Figures 4.2a and b). Thus, Gata3 haploinsufficiency-
induced degeneration started at the apex and ultimately progressed into the middle turns of the 
cochlea. 
 
 
Figure 4.2: Presence of outer hair cells (OHC) in cochleae of wild type (A: upper panel) and heterozygous (B: 
lower panel) Gata3 mice of 1, 2, 5, 9 and 15 months of age. Markers indicate the percentage of cells present in 
the 10 different cochlear pieces, plotted against the distance to the apex of the analyzed cochlear part. Hair cells 
responsive to 4 kHz, 8 kHz, 16 kHz and 32 kHz tones are found at approximately 25%, 40%, 60% and 75% 
distance from the apex respectively (Ou et al., 2000). OHCs in both the apical and basal cochlear regions 
degenerate in heterozygous mice, and progressively so with age. Wild type controls in contrast, are only affected 
by (normal) loss of basal outer hair cells. (Previously, data were presented partially in ‘van der Wees et al., 
2004’) 
 
A 
B 
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To investigate effect of Gata3 haploinsufficiency on the morphological structure of outer hair 
cells from heterozygous Gata3 mice we analyzed semithin plastic sections and compared 
them to sections from wild types. We examined 1151 slices, representing 11 cochleae of 6 
mice, at light microscopic level. The estimated width of OHCs in the cochlear regions 
examined in our study was approximately 5 µm, so that a maximum of 5 semithin slices per 
OHC may have been included in histological analysis. No compelling differences between 
heterozygous mice and wild type controls were found other than numbers of OHCs showing 
vacuoles. OHCs in heterozygous mice contained vacuoles more often than those in controls, 
an illustrative example of this can be seen in Figures 4.3a and b. In heterozygous mice 
vacuoles were found throughout the cell, whereas when present in wild type mice they were 
predominantly seen in the apical region. 
 
 
 
Figure 4.3: Vacuolization in Gata3 heterozygous OHCs. Plastic sections of normal OHCs from a 2-months old 
wild type mouse (A) and of abnormal OHCs, with vacuoles in all three OHC rows, from a 2-months old 
heterozygous Gata3 mouse (B). Electronmicroscopy of a normal wild type (C) and a Gata3 +/- OHC (D) shows 
multiple vacuoles in the mutant OHC that otherwise looks normal. Panel E is a magnification of panel D and 
shows the irregular shape of the unfilled vacuoles that have a single layer membrane. Bars are 2 µm for panels 
A-D and 0.5 µm for panel E. 
  113
The difference in numbers of OHCs containing vacuoles was age-dependent: At one month of 
age this number significantly differed between genotypes for the first row of OHCs only 
(Mann Whitney, P < 0,02), whereas at two months of age the difference was significant 
(Mann Whitney, P < 0,02) for all three rows (see Figure 4.4a).  
 
 
 
  
 
 
Figure 4.4: Panel A: Percentages of cells containing vacuoles versus age and genotype (wt; wild type, ht; 
heterozygous). Numbers of OHCs containing vacuoles significantly differed between genotypes for the first row 
of OHCs at one month of age (^), at two months of age this difference was significant for all three rows (o). 
Analysis within genotypes demonstrated an increase in the number of cells with vacuoles in the second as 
compared to the first month in heterozygous mice. This increase was significant for all three rows of OHCs at P< 
0.02 (*). In wild types less than 10% of cells contained vacuoles. Error bars indicate 95% confidence intervals. 
A 
B 
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Panel B: Percentages of cells containing vacuoles versus age per genotype and cochlear localization. Analysis of 
influence of cochlear localization demonstrated the increase in the number of cells with vacuoles as described in 
heterozygous mice in Figure 4.4a, to be due to the highly significant increase in vacuoles in all rows of OHCs in 
the apical pieces in the second as compared to the first month of age (*) (Mann-Whitney, P< 0.001). No 
significant differences could be demonstrated in the mid-cochlear or basal pieces. Numbers of cells containing 
vacuoles in the cochlear apex, however differed significantly between genotypes, both at one (o) and two months 
(^) of age (Mann-Whitney, P<0,02). Error bars indicate 95% confidence intervals. A = apical, M = mid-
cochlear, B = basal. 
 
Analysis within genotypes demonstrated an increase in the number of cells with vacuoles in 
the second as compared to the first month in heterozygous mice. This increase was significant 
for all three rows of OHCs at P < 0.02 (see Figure 4.4a).  In wild types numbers of cells 
containing vacuoles were low constantly over the observed age-range. 
The significant age-dependent increase in affected OHCs in heterozygous mice is mainly due 
to the highly significant increase in vacuoles in all rows of OHCs in the apical pieces (Mann-
Whitney, P < 0.001). In the mid-cochlear pieces a similar trend was seen, but no significant 
differences could be demonstrated (see Figure 4.4b).  
In conjunction, our data show that GATA3-haploinsufficiency induces OHC degeneration, 
especially in the apical regions of the cochlea, in mice as young as one month of age. These 
deleterious effects increase with increasing age. 
 
Electron microscopy 
To closer examine the nature of the observed vacuoles in the OHCs, we investigated them at 
the ultrastructural level. The vacuoles were irregularly shaped and surrounded by a single 
layer membrane (Figures 4.3 d, e). The OHCs did not show any sign of apoptosis or 
immediate cell death such as pyknotic nuclei or abnormal mitochondria.  Thus, the first sign 
of GATA3-driven degeneration of OHCs seems to be the appearance of irregularly shaped 
vacuoles, which can be observed at both the light microscopic level and at electron 
microscopic level.  
 
Otoacoustic emissions 
Outer hair cell functionality was examined by measuring DPOAE levels in both Gata3 
heterozygous  and  wild  type mice  at  various  ages.  DPOAE  signal  to noise  ratios differed 
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Figure 4.5: 98% confidence intervals of DPOAE signal to noise ratios (dB SPL) at f2’s 6.8-16.0 kHz for wild 
type (discontinuous line) and heterozygous (continuous line) mice aged 1 to 7 months. At all ages and 
frequencies emissions in wild types were stronger than in heterozygous mice. At 7 months of age hardly any 
emissions could be generated in heterozygous knockouts, whereas signal to noise ratios in wild types remained 
fairly constant. Signal to noise ratios at 11.3 kHz are not represented graphically, since statistical analysis was 
unreliable due to small numbers of data (see Table 4.1). 
 
 
significantly between Gata3 heterozygous mice and wild types when data were pooled over 
all f2’s and ages (Mann-Whitney Test, P < 0.001) (Figure 4.5). When separate ages and f2’s 
were analyzed, this significance was consistent (at the P < 0.02 level) for groups larger than 6 
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(see Table 4.1), with the sole exception of 7 months old mice at 9.5 kHz (P = 0.023). 
Emission levels in the f2 frequency range from 6,8 kHz to 16,0 kHz remained fairly constant 
in wild type mice during the first seven months of life, whereas in the mutants signal to noise 
ratios rapidly decreased during this period (Figures 4.5 and 4.6).  At 7 months of age signal to 
noise ratios of DPOAEs in heterozygous mice no longer differed from 0 dB. Signal to noise 
ratios did not differ significantly between genders for pooled data (T-test, P > 0.2), or within 
specific age groups (T-tests, P > 0.02).  
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Figure 4.6: Signal to noise ratios (dB SPL) of 1-7 months old wild type and heterozygous mice in the f2 
frequency range 6,8 to 16,0 kHz. During the first seven months of life, emission levels remain fairly constant in 
wild type mice, whereas in heterozygous mice signal to noise ratios rapidly decrease. 
 
 
In sum, our acousto-physiological analyses demonstrated a rapid deterioration of OHC 
functionality in Gata3 heterozygous mice, starting apically in the cochlea and progressing 
onto its base. 
 
Discussion  
Here, we show that young heterozygous Gata3 mice generate abnormal Distortion Product 
Oto-Acoustic Emissions (DPOAEs) and that their outer hair cells (OHCs) are commonly 
affected by vacuoles. Together these data raise the possibility that dysfunctional OHCs form 
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one of the prime causes of hearing loss in these mutants. Since HDR patients, who suffer from 
the same haploinsufficiency as these mouse mutants, suffer from hearing loss as well, this 
pathological mechanism may also hold for HDR patients.  
 
Outer hair cells are affected by both histological and physiological aberrations  
Otoacoustic emissions (OAE’s) are the best means for testing OHC function in vivo (Schrott 
et al., 1991). In our present study Distortion Product Otoacoustic Emissions were recorded in 
1-7 months old Gata3 heterozygous mice and in age- and sex matched controls. In both 
genotypes the loudest emissions were found in the higher end of the frequency range (6.8 kHz 
- 16 kHz). Emission levels decreased rapidly over time in heterozygous knockout mice, 
whereas in wild type controls they remained fairly constant during the first 7 months of life. 
Signal-to-noise emission levels in the FVB/N controls in this study are equal to, or even 
slightly better than emission levels in the CBA/J mouse model, which is considered a well 
hearing strain until relatively late in life (Parham et al., 1999). During DPOAE-recordings we 
used gas anesthesia, since this type of narcosis provides flexibility (e.g. short-term 
anesthesia), despite the known increase in middle ear pressure caused by N2O, necessitating 
paracentesis. Moreover, we demonstrated that repeated measurements in itself did not 
influence DPOAE levels (Figure 4.1). Thus, in contrast to the commonly used intraperitoneal 
or intramuscularly anesthesia (e.g. Sun et al., 1999, Jimenez et al. 2001, Konrad-Martin et al., 
2001), gas anaesthesia may be quite feasible for (longitudinal) DPOAE-recordings. 
Heterozygous mice also differed from controls in numbers of OHCs containing vacuoles, 
increasingly so with age. Curiously, no gross abnormalities were found in other cochlear cell 
types expressing GATA3. Further histological analysis of OHCs by electron microscopy 
excluded other changes at the cellular level such as apoptosis. Vacuoles are frequently seen as 
the first signs of (hair) cell death (Vetter et al., 1996).  At two months of age the numbers of 
outer hair cells containing vacuoles in heterozygous mice were especially high in the apical 
region of the cochleae, which is responsive to frequencies of approximately 4 kHz (Ou et al., 
2000), whereas in the middle (responsive to 16 kHz) and basal regions (responsive to 32 kHz) 
these numbers remained low. These findings are in agreement with the outcomes of the 
DPOAE measurements, which showed that the loudest emissions were found in the vacuole-
free frequency regions. Thus, although the current data do not allow us to conclude that there 
is a direct causal relation between the deficits in DPOAEs and the occurrence of vacuoles in 
the OHCs, both findings suggest that functional deficits in OHCs may contribute to hearing 
loss in HDR syndrome.  
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Role of outer hair cells in hearing loss in HDR 
Our findings that GATA3 haploinsufficiency induces an age-dependent loss of OHC-function 
as well as concomitant histological anomalies in OHCs raise the question as to whether the 
OHCs can be held solely responsible for the hearing loss in HDR syndrome. Although at 
present it is not possible to answer this question conclusively, several findings suggest that we 
cannot exclude this possibility either. 
First, deficits in both DPOAEs and ABRs start to occur in the first few months of life (see 
also van der Wees et al., 2004).  
Second, DPOAE signal to noise ratios in heterozygous Gata3 mice as compared to controls 
are lower for all f2-frequencies in the 6,8–16,0 kHz range, agreeing with the fact that ABR-
thresholds in these mice were elevated for all tested frequencies (4-32 kHz) in the age-range 
of 1-19 months as compared to controls. Moreover, ABR-thresholds are worse at 4 kHz, 
compared to 16 kHz for ages up to 19 months, this corresponds to lower DPOAE-signal to 
noise ratio’s in the lower end of the frequency range described here. 
Third, ABR-thresholds in heterozygous mice are on average elevated by approximately 30 dB 
(van der Wees et al., 2004), which agrees well with numerous other animal models in which 
there is a presumptive selective deficit of the OHCs. For example, Kanamycin sulfate 
treatment, causing complete loss of OHCs, with preservation of IHCs, results in threshold 
shifts of 40 dB and more in chinchillas (Woolf et al., 1981). In the same species, the first 
approximate 30 dB of noise-exposure induced permanent threshold shifts is induced by 
primarily outer hair cell losses (Hamernik et al., 1989). On the other hand, neomycin in 
combination with acoustic trauma causes decreases in cochlear sensitivity amounting up to 62 
dB, averaged across all frequencies, in guinea pigs with losses of cochlear OHCs close to 
100% (Brown at al., 1978). Unfortunately, the effect of the used treatment on other cochlear 
cell types was not described. Finally, homozygous Kit W-v mice (Wv/Wv), which have 
normal IHCs but lack 98% of cochlear OHCs, have an elevation of ABR- thresholds up to 
about 50 dB, as compared to control mice (Schrott et al., 1990).  
It should be noted that the exact correlation between DPOAEs and ABR-thresholds remains 
to be established. DPOAEs were below the level of detection in laboratory animals such as 
mice and chinchilla’s when ABR-threshold shifts exceeded approximately 40 dB (e.g. Kakigi 
et al., 1998, Le Calvez et al., 1998a), however when tentatively correlating DPOAE levels to 
ABR-thresholds variances were fairly large and no significant correlation was established so 
far. When considering our data we find that the best DPOAE signal to noise ratios in 
heterozygous Gata3 mice were recorded in the upper half of the tested frequency spectrum 
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during the first months, when ABR-thresholds of corresponding frequencies (8 and 16 kHz) 
ranged approximately between 30 and 50 dB SPL. Moreover, in wild type controls DPOAE 
signal to noise ratios were high and remained fairly constant over the time span presented in 
this paper, where ABR-thresholds did on average not exceed 40 dB SPL during the first 7 
months of life for the 4-16 kHz range. 
Thus, taken together we can conclude that it appears likely that OHC dysfunction caused by 
GATA3 haploinsufficiency contributes to hearing loss in HDR syndrome, but it remains to be 
demonstrated whether it is the sole cause. 
 
Conclusions 
GATA3 haploinsufficiency is known to cause hearing loss in both humans affected by the 
HDR syndrome and mice. The goal of the present study was to elucidate the role of outer hair 
cells in this process. We demonstrated that GATA3 haploinsufficiency causes a rapid 
deterioration of OHC function in mice. Apical OHCs show early signs of cell degeneration in 
affected mice as young as one to two months in that they exhibit multiple vacuoles and 
produce abnormal emissions. We conclude that, outer hair cell malfunctioning can play a 
major role in the hearing loss in HDR syndrome. 
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“We still did not answer the questions that are important to us.” 
 
Paulo Coelho
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Summary 
Haploinsufficiency of zinc-fingertranscriptionfactor GATA3 causes the triad of 
hypoparathyroidism, deafness and renal dysplasia, known by its acronym HDR syndrome. 
The purpose of the current study was to describe in detail the auditory phenotype in human 
HDR patients and compare these to audiometrical and histological data previously described 
in a mouse model of this disease.  
Pure tone audiometry, speech audiometry, speech in noise, Auditory Brainstem Responses 
(ABR) and Transiently Evoked Otoacoustic Emissions (TEOAE) were measured in two 
patients affected by HDR syndrome. Both patients were affected by a moderate to severe 
sensorineural hearing loss. Speech reception thresholds were shifted and speech recognition in 
noise was disturbed. No otoacoustic emissions could be generated in either patient. Auditory 
brainstem response interpeak intervals were normal. 
The human and murine audiological phenotypes seem to correspond well. Hearing loss in 
HDR syndrome is moderate to severe, seems to be slightly worse at the higher end of the 
frequency spectrum and may be progressive with age. The absence of otoacoustic emissions 
and loss of frequency selectivity suggest an important role for outer hair cells in causing the 
hearing loss.  
 
Key words: HDR syndrome, GATA3, Audiometry, OHC 
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Introduction 
Hearing loss in combination with hypoparathyroidism and renal dysplasia was first described 
in patients in 1977 (Barakat et al., 1977). However, it was not until several years later that it 
was recognised as a specific clinical entity (Bilous et al., 1992). Since then the triad of 
hypoparathyroidism, deafness and renal dysplasia has been known by its acronym HDR 
syndrome. This syndrome is inherited as an autosomal dominant trait. Molecular genetic and 
deletion-mapping studies mapped the HDR gene to 10p 13/14 (Hasegawa et al., 1997; 
Lichtner et al., 2000), and identified that it was caused by abnormalities of the GATA3 gene 
(van Esch et al., 2000). 
Since the first description of HDR syndrome several papers reporting on the clinical features 
of the syndrome in individual patients or (small) groups of patients have been published (e.g. 
Mino et al., 2005; Muroya et al., 2001; Zahirieh et al., 2005). These patients, as tested by 
ABR (auditory brainstem response), conditioned oriented reflex tests or pure tone audiometry, 
were affected by either a symmetric or an asymmetric sensorineural hearing loss (ranging 
from moderate (40 dB) to profound (105 dB)). Hearing loss was usually more severe at the 
higher end of the frequency spectrum (Bilous et al., 1992; Fujimoto et al., 1999; Hasegawa et 
al., 1997; Lichtner et al., 2000; Muroya et al., 2001; Yumita et al., 1986). Hitherto, however, 
hearing loss in HDR patients has not been systematically evaluated, and no attempts have 
been undertaken to identify the underlying cause of the hearing loss.  
Previously we attempted to shed light on the pathophysiological mechanism causing the 
hearing defect in a mouse model of the syndrome. Our studies led us to conclude that hearing 
loss due to GATA3 haplo-insufficiency is peripheral in origin and that OHCs (outer hair cells) 
probably play a major role in the hearing loss in HDR syndrome (van Looij et al., 2005; van 
der Wees et al., 2004).  
Here, we describe in detail the hearing loss in two patients, one who was newly diagnosed 
with the HDR syndrome and one in whom the phenotypic spectrum has previously been 
described, however without a detailed description of audiometry (Beetz et al., 1997; van Esch 
et al., 2000). 
 
Case descriptions 
Case 1 
The clinical details of this 19-year old German boy have been previously reported (Beetz et 
al., 1997; van Esch et al., 2000). He is the first child to normally hearing parents. He has three 
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younger brothers with normal hearing. He had been affected by a multicystic right kidney and 
a dysplastic left kidney since infancy. When he first started attending kindergarten, his teacher 
suspected mental retardation. However, medical examination demonstrated his learning 
difficulties to be due to hearing loss, rather than retardation, and after being fitted with 
hearing aids at the age of 8 years, he performed well in school. At the age of eleven years he 
was affected by Lyme borreliosis, for which he was treated with intravenous antibiotics. 
Apart from this, he had no other risk factors for acquired hearing loss in his medical history. 
Throughout childhood he recurrently suffered from episodes of renal disease. A diagnosis of 
HDR syndrome was established after laboratory findings indicated hypoparathyroidism. 
GATA3 mutation analysis demonstrated a 465-513 deletion, resulting in a frameshift from 
codon 156 (van Esch et al., 2000).  
This case has been described previously by (Beetz et al., 1997; van Esch et al., 2000). 
 
Pure tone audiometry  
Pure tone audiometry was recorded, using a Madsen OB822 clinical audiometer and TDH-39 
earphones. A symmetric sensorineural hearing loss was found, ranging from 40 dB in the 
lower end of the tested frequency range, to approximately 65 dB at 4 kHz (Figure 5.1). 
Speech audiometry  
The shift of the speech reception threshold (50% speech recognition level) relative to normal 
was approximately 55 dB in the left ear, and approximately 60 dB in the right ear (Figure 
5.1). 
Speech in noise 
The speech in noise threshold (Freiburger Zahlentest) was 1.8 ± 0.6 dB for the left ear and 2.4 
± 0.6 dB for the right ear. This is about 6 dB worse than normal.  
ABR (Auditory Brainstem Responses)  
Auditory Brainstem Responses were recorded with  custom-made equipment, the EUPHRA-1 
system (Erasmus University Physiological Response Averager). When stimulating with 90 dB 
nHL clicks ABR peaks I (1.6 ms) through V (5.8 ms) were clearly present in both ears. 
Absolute latencies, as well as the I-III interpeak interval and the I-V interpeak interval were 
within the normal range (Figure 5.1).  
TEOAE’s (Transiently Evoked Otoacoustic Emissions)  
TEOAE’s were recorded using standard ILO88 equipment (Otodynamics). No transiently 
evoked otoacoustic emissions could be generated in either ear when stimulating with 81 dB 
peSPL (Figure 5.1). 
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Figure 5.1: Case 1, the uppermost panel displays pure tone audiometry; the right ear is displayed on the left and 
the left ear on the right side. 
The second panel represents speech audiometry. The third and fourth panel display ABR traces at 90 dB nHL for 
the right and left ear respectively. The fifth panel represents the TEOAE measurement for the right (left panel) 
and left (right panel) ear.  
See text for details. 
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Case 2  
A 33-year old Dutch female, had been affected by idiopathic hearing loss, for which hearing 
aids had been prescribed since the age of four. Apart from an isolated episode of otitis media 
in early childhood, her medical history did not reveal any risk factors for hearing loss, such as 
the use of ototoxic medication or a trauma of the head or ears. Both her parents and only sister 
had normal hearing. In her mid-twenties the patient started to suffer from cramp-like pains in 
her hands, and in her late twenties, she suffered from three generalised seizures due to 
hypocalcaemia that was secondary to hypoparathyroidism. 
The patient requested for genetic counseling, in the context of reproductive decision-making. 
She was noted to have suffered from a single episode of pyelonephritis several years earlier, 
and renal ultrasonography demonstrated an asymptomatic cyst in the right kidney. This was 
confirmed by an abdominal CT-scan. On the basis of these findings a diagnosis of HDR 
syndrome was considered. 
Figure 5.2: Detection of mutation in exon 3 of the Case 2 individual by DNA sequence analysis. 
DNA sequence analysis of a 33 year old individual (Case 2) revealed the insertion of a C at codon 135 of exon 3 
(indicated by arrow). This led to a frameshift that resulted in 193 missense amino acids from codon 136 to codon 
328, followed by a premature termination signal (Stop) at codon 329.  This change did not result in the alteration 
of a restriction enzyme site, hence was confirmed by repeat sequencing. This mutation is predicted to result in 
the loss of zinc-fingers 1 and 2 and haplo-insufficiency. Panel A shows a normal wild-type sequence of codons 
133-138 and panel B shows the mutant sequence of the Case2 individual, with insertion of a C (indicated by 
arrow) and resulting frameshift. 
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Venous blood was obtained after informed consent, as approved by the local ethical 
committee, and used to extract leukocyte DNA (Nesbit et al., 2004). Nine pairs of GATA3 
specific primers were used for PCR amplification of the six exons and ten intron-exon 
boundaries using 50 ng of genomic DNA as described (Nesbit et al., 2004). The DNA 
sequences of both strands were determined by Taq polymerase cycle sequencing and resolved 
on a semi-automated detection system (ABI 377XL sequencer, Applied Biosystems, Foster 
City, CA) (Nesbit et al., 2004). The DNA sequence abnormality, was confirmed by repeat 
sequence analysis, and was demonstrated to be absent in the DNA obtained from 55 
unaffected unrelated individuals, using methods previously described  (Nesbit et al., 2004).  
Chromosomal analysis demonstrated a normal female karyotype (46, XX), but GATA3 
mutation analysis demonstrated an insertion of a nucleotide C of codon 135 in exon 3 that 
resulted in a frameshift (Figure 5.2). This is predicted to lead to a missense peptide from 
codon 136 with a premature termination at codon 329, such that there is a loss of zinc fingers 
1 and 2. The mutation was not detected in either of her parents, and hence she represents a de 
novo mutation.   
 
Pure tone audiometry  
Pure tone audiometry was recorded, using a Madsen OB822 clinical audiometer and TDH-39 
earphones. A moderate to severe sensorineural hearing loss was demonstrated, that was most 
pronounced in the highest frequencies. Losses ranged from 45 dB HL at 250 Hz to a 
maximum of 75 dB HL at 4 kHz in the right ear and from 45 dB HL at 250 Hz and 500 Hz to 
a maximum loss of 85 dB HL at 8 kHz in the left ear. A mixed hearing loss was found only at 
250 Hz, with a conductive component of 30 and 20 dB for the right and left ear respectively 
(Figure 5.3).  
Interestingly, we were able to compare these data to audiograms made during childhood. The 
first audiogram at the age of eight years, revealed that she was affected by a flat, 
predominantly sensorineural hearing loss, with a conductive component of 10-20 dB on 
average, with thresholds ranging from 40-60 dB HL (Figure 5.4), thus it appears that in this 
patient the hearing loss is progressive with age, especially so in the higher end of the tested 
frequency range. 
Speech audiometry  
Speech recognition level thresholds as compared to normal were shifted by 50 dB and 60 dB 
for   the  right  and  left  ear  respectively.  Due   to  a  ‘plateau’  in  the curve,  100%   speech 
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Figure 5.3: Case 2, the uppermost panel displays pure tone audiometry; the right ear is displayed on the left and 
the left ear on the right side. 
The second panel represents speech audiometry. The third and fourth panel display ABR traces at 90 dB nHL for 
the right and left ear respectively. The fifth panel represents the TEOAE measurement for the right (left panel) 
and left (right panel) ear.  
See text for details. 
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recognition was attained only at the 110 dB sound level in the right ear, whereas in the left ear 
maximum of 85% speech recognition was attained at the 100 dB sound level (Figure 5.3). 
 
 
  
 
 
 
 
 
 
 
 
Figure 5.4: Pure tone audiometry of case two, at age eight. The left panel (a) represents the right ear; the right 
panel (b) represents the left ear. 
See text for details. 
 
Speech in noise 
Free field testing by the Plomp and Mimpen test (Plomp et al., 1979) without hearing aids for 
the right ear yielded an average signal to noise ratio of 0.7 dB, whereas for the left ear this 
ratio was –2.0 dB. The average binaural signal to noise ratio was 0.4 dB. 
ABR (Auditory Brainstem Responses)  
Auditory Brainstem Responses were recorded with custom-made equipment, the EUPHRA-1 
system (Erasmus University Physiological Response Averager). When stimulating with 90 dB 
nHL peaks III (3.9 ms and 4.0 ms, left and right ear respectively), IV and V (6.2 ms and 6.3 
ms, right and left ear respectively) were clearly present. The III-V interpeak interval was not 
prolonged. 
The absolute latency of peak V was prolonged for both ears. However, this was consistent 
with hearing thresholds as demonstrated by pure tone audiometry (Figure 5.3).  
TEOAE’s (Transiently Evoked Otoacoustic Emissions) 
TEOAE’s were recorded using standard ILO88 equipment (Otodynamics). No transiently 
evoked otoacoustic emissions could be generated in either ear when stimulating with 82-83 
dB peSPL (Figure 5.3). 
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Discussion 
The HDR syndrome is an autosomal dominant condition, defined by the triad 
hypoparathyroidism, deafness and hearing loss. Although phenotypic expression may be 
variable, it seems that hearing loss is a rather consistent feature, affecting the majority of 
patients (Muroya et al., 2001). So far, only few data have been published reporting the nature 
of the hearing loss in HDR patients. 
Presently, we describe in detail hearing loss in two patients affected by HDR syndrome. Both 
patients suffered from a moderate to severe sensorineural hearing loss, which was worse in 
the higher end of the tested frequency range. No increases in interpeak latencies were 
demonstrated by ABRs, indicating a probably peripherally hearing loss. Speech audiometry 
corresponded well with pure tone audiometry, however both patients performed poor on 
speech in noise tests. The latter finding suggests a reduced frequency selectivity, which may 
be due to a loss of outer hair cells (Harrison et al, 1981-a; Harrison et al., 1981-b). 
Interestingly, in neither patient TEOAEs could be generated. The combination of the above 
findings – hearing loss with reduced speech in noise performance, absent otoacoustic 
emissions and normal ABR waves - substantiates the suggestion that outer hair cells might be 
lost, or that their functionality is reduced. Taking into consideration the severity of the hearing 
loss in our patients and patients previously described in literature, it is likely that inner hair 
cells also play a role in the coming about of the hearing loss.   
When defining hearing loss due to a specific cause, it is important to exclude the influence of 
other possible risk factors for hearing loss. Our first case suffered from Lyme borreliosis at 
the age of eleven years, which may cause sudden hearing loss, although the causal 
relationship between the infection and sensorineural hearing loss is difficult to verify 
(Peltomaa et al., 2000). However, since the infection was adequately treated, and since 
hearing did not deteriorate in the peri-infectious period, it would seem that Borreliosis wasn’t 
a causative factor for the hearing loss in this patient. The second patient did not yield any risk 
factors for hearing loss other than one single episode of otitis media in early childhood, which 
is unlikely to have caused the progressive loss of hearing.  
In order to elucidate the underlying pathophysiology causing HDR syndrome we previously 
studied hearing loss in a mouse model of the disease. We demonstrated Auditory Brainstem 
Response-thresholds in heterozygous (+/-) Gata3 mice to be elevated by approximately 30-dB 
as compared to those in controls, in absence of interpeak latency differences (van der Wees et 
al., 2004). Apart from this, distortion product otoacoustic emission levels (f2 frequency range 
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from 6,8 kHz to 16,0 kHz) rapidly decreased during the first seven months of life in the +/- 
mutants, whereas in the wild type (+/+) mice they remained fairly constant (van Looij et al., 
2005). In addition, Gata3 heterozygous mice, showed early signs of outer hair cell 
degeneration, especially in the cochlear apex, at both light microscopic level and electron 
microscopic level, without any morphological abnormalities in the central nervous system. 
Outer hair cell loss was followed by an extensive loss of both inner hair cells and supporting 
cells. This degenerative process progressed in an apico-basal direction from young ages 
onwards, and in combination with a normal age-related basal cell loss, ultimately affected all 
cochlear hair cells and supporting cells (van Looij et al., 2005; van der Wees et al., 2004). 
These findings led us to conclude that hearing loss due to GATA3 haplo-insufficiency is 
peripheral in origin and that OHCs probably play a major role in the hearing loss in HDR 
syndrome.  
Mutant mouse models of hearing loss are very valuable in auditory research aimed at 
elucidating pathophysiological mechanisms underlying deafness and for gene identification 
by positional cloning, and often there is good agreement in pathology between mice and man 
(Steel, K.P., 1995). Occasionally however, differences in phenotypic expression occur 
between man and mice.  A well-known example of this is the MYO7A gene, mutations of 
which cause Usher 1B syndrome in man, but hearing loss and vestibular dysfunction without 
blindness in shaker-1 mice. It has been hypothesized however, that the absence of visual 
problems may be due to the time span needed for retinal degeneration to develop (Keats and 
Savas, 1999; Steel, 1995). Another illustrative example of different phenotypic expression is 
seen in Pompe’s disease; children affected by the classic infantile form of Pompe’s disease 
are affected by a moderate to severe hearing loss, whereas no differences in auditory function 
- as measured by ABRs - could be demonstrated between a knockout mouse model of 
Pompe’s disease and wild-type controls (Kamphoven et al., 2004).  
These observations indicate that cautious interpretation is required when comparing murine 
and human data. However, our present study data from HDR patients indicated that the 
audiological phenotypes are similar between man and mouse, even though histological data 
from human studies are not available. 
 
In conclusion, hearing loss in HDR syndrome is moderate to severe and it appears to be worse 
at the higher end of the frequency spectrum. Possibly, auditory functioning in HDR patients 
deteriorates with age. The hearing loss is brought about by disorders in the peripheral part of 
the auditory system and absence of otoacoustic emissions and loss of frequency selectivity 
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suggest a substantial causative role for outer hair cells, without however precluding a role for 
inner hair cells. Although no histological data of cochleae of patients affected by HDR 
syndrome are available to date, it appears that otological or at least audiological phenotypes 
between HDR patients and heterozygous Gata3 knock-out mice correspond well. 
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Chapter 6: 
General discussion 
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…  
“Morgen ga ik vliegen”, zei de slak. “Tenminste, ik ga eerst oefenen”.  
De mier liep naar huis en sliep die nacht slecht. 
De volgende dag betrapte hij zich erop dat hij telkens naar de lucht keek. Maar, dacht hij dan, vliegen 
kan hij nooit. Nooit! Dat bestaat niet!  
Laat in de middag kwam de slak voorbij, traag en stuntelig fladderend. Hij slingerde, botste tegen de 
toppen van grassprieten aan, helde soms vervaarlijk opzij. Maar hij vloog. 
Toen hij de mier zag wuifde hij en riep: “Kom jij ook vliegen? Het valt best mee. Je hoeft alleen maar 
op te stijgen.” 
De mier keek naar de grond en trapte met volle kracht tegen een losliggende wortel. 
 
Uit ‘Misschien wisten zij alles’ , Toon Tellegen, Em. Querido’s Uitgeverij B.V., 2005. 
  143
The last decennia great scientific progress has been made in the field of both syndromic and 
non-syndromic hereditary deafness. Studies of audiology, physiology, inner ear metabolism at 
molecular level and histology, as well as family, gene-linkage, and gene-identification studies 
have provided knowledge – and surely in the future will do even more so - about genotype-
phenotype correlations and the natural course of hereditary deafness. This knowledge is very 
important in clinical otological practice. It will contribute to the development and selection of 
guiding patterns for patients with hereditary hearing loss, and in the future possibly even to 
the development of new treatments of sensorineural hearing loss.  
 
The study described in this thesis was aimed at elucidating the nature of hearing loss in 
Hypoparathyroidism, Deafness and Renal dysplasia (HDR) syndrome. Although 
embryologically the kidneys develop from the intermediate mesoderm and the inner ears from 
the epidermal otic placode (Larsen, 1993) renal anomalies and hearing loss often co-occur. 
One possible pathophysiological mechanism causing both renal disease and hearing loss, may 
be the malfunctioning of transporters or channels - for e.g. chloride, bicarbonate, protons, 
sodium, potassium or water - that are found in both systems (as reviewed by Peters et al., 
2004). In Table 1.1 of the introduction of this thesis an overview of syndromes in which 
hearing loss and renal anomalies co-occur is given. From this table, we can conclude that 
disturbed endolymph homeostasis is at least responsible for the clinical features of Bartter 
syndrome and Distal Renal Tubular Acidosis (DRTA) with sensorineural hearing loss. For 
some of the remaining syndromes other common pathophysiological mechanisms can be 
discerned; metabolic accumulation is the cause of Fabry disease and Refsum’s disease, 
whereas BOR syndrome, Nager syndrome, Okihiro syndrome and Townes Brocks syndrome 
are caused by mutations involving transcription factors. 
When studying syndromes involving both the kidneys and the inner ears, one needs to bear in 
mind that although microarray hybridization analysis of gene expression in these organs 
suggests a relationship between the tissues at genomic level, genes in either organ may be 
over- or underexpressed as compared to the other (Liu et al., 2004). 
 
Experimental set-up: impact of anesthesia on audiometry 
In this thesis, we used a variety of techniques to study the nature of hearing loss in HDR 
syndrome in knock-out mice as well as in patients. Chapter 2 reports on a pilot-study, 
conducted in healthy laboratory mice, aimed at developing an objective and accurate method 
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to assess hearing acuity in these animals. One commonly used method of testing the auditory 
function of laboratory animals is the recording of auditory brainstem response (ABR) 
thresholds. In addition to providing hearing thresholds, ABR’s inform us on the functioning 
of the central auditory pathways up to the level of the inferior colliculus (Henry, 1979). In 
spite of previous publications, demonstrating an anesthesia (ketamine) induced increase in 
peak latencies in gerbil and rat (Church and Gritzke, 1987; Smith and Mills, 1989, 1991), 
possibly due to a decrease in resting membrane potentials of n. VIII (Shrivastav, 1997), ABR 
assessments in mice were invariably done in anesthetized animals (Henry, 2002; Huang et al., 
1995; Jero et al., 2001; Miller et al., 1998; Ou et al., 2000).  
We describe a surgical technique, allowing for ABR recordings in alert mice. With this 
technique longitudinal experiments can be performed without the need for repetitive 
prolonged general anesthesia, apart from the initial 45 minutes of anesthesia needed for 
surgery. We demonstrate that ABR thresholds are significantly elevated when recorded under 
general (ketamine/xylazine) anesthesia. We propose that this upward threshold shift is mainly 
due to a ketamine/xylazine effect, but we cannot exclude for sure the effects of pinna 
orientation. Furthermore, we show that general anesthesia causes a significant prolongation of 
ABR-peak latencies and I-III interpeak latencies as well as a decrease of the accuracy of peak- 
and interpeak latency, and threshold measurements. Therefore, our method as compared to 
conventional ABR recordings using subcutaneous needle electrodes, allows a more accurate 
evaluation of central auditory pathways up to the level of the inferior colliculus. This may be 
especially useful in (mouse models of) complex diseases, possibly affecting both the 
peripheral and central auditory system. Finally, it is demonstrated that the stimulus repetition 
rate can be as high as 80 per second without affecting ABR thresholds, interpeak latencies or 
waveforms.  
In addition to influencing auditory brainstem responses, high-dose ketamine anesthesia also 
affects otoacoustic emission (OAE) recordings, probably by alteration of middle ear dynamics 
(Hatzopoulos et al., 2002). Moreover, ketamine is not the only anesthetic agent known to 
influence middle ear pressure. Nitrous oxide and pentobarbital induce negative middle ear 
pressure in children (Chinn et al., 1997) and gerbils respectively (Zheng et al., 1997). In order 
to avoid the considerable influences of general anesthesia on audiological outcomes we tried 
to develop a way to record otoacoustic emissions in alert mice. Mice were anesthetized. Using 
a ventral approach, an incision was made between the mandibular angle and the middle of the 
clavicle. The neurovascular bundle and digastric muscle were carefully retracted, allowing for 
access to the tympanic bulla. The bulla was opened and carefully avoiding the stapedial 
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artery, an electrode was placed in the cochlear round window. This electrode was diverted 
subcutaneously and connected to a head fixation pedestal (described in chapter 2). The round 
window electrode allowed us to record electrical variations of the intracochlear potentials. 
These variations result from outer hair cell activity, amongst other sources. In conventional 
electrocochleography one of the extracted components of these variations of potentials is 
called cochlear microphonics. The waveform of this component is almost an electrical 
analogue of the acoustic waveform of the stimulus used to generate it, hence it’s name. Under 
stimulation conditions used for generating distortion product otoacoustic emissions, we 
expected that spectral analysis of the potential variations would reveal activity at the 
frequencies of the two stimulation tones (‘the microphone signal’), but also at the frequencies 
of the distortion products generated in the cochlea. This approach would enable electrical 
recording of the distortion products, including the 2f1-f2 distortion product (usually recorded 
acoustically in the outer ear canal as the distortion product emission). 
Apart from being rather time-consuming, unfortunately this method proved to be successful in 
only a small percentage of cases. This may have been due to difficulties we experienced in 
securing a stable electrical connection to the cochlea. Therefore, otoacoustic emissions in 
laboratory mice were eventually recorded using a mixture of 5% Fluothane, N2O and O2. 
Fluctuations in middle ear pressure – and concomitant fluctuations in signal strength of 
otoacoustic emissions – were prevented by perforating the pars flaccida of the tympanic 
membrane using a Microlance® needle (chapter 4). 
 
Evaluation of hearing in a murine model of HDR syndrome 
HDR syndrome is caused by haploinsufficiency of transcriptionfactor GATA3. The effects of 
Gata3 haploinsufficiency on hearing in mice are described in chapters 3 and 4. Over a one-to-
nineteen months age-range, heterozygous Gata3 knock-out mice show a significant ABR-
threshold elevation (approximately 30 dB), as compared to wild-type littermates. This 
threshold elevation is present at all tested frequencies. Both the heterozygous knock-outs and 
the wild type controls are affected by an age-related hearing loss, causing an average monthly 
increase in ABR-threshold of 2.2 dB.  
In addition ABR- peak-and interpeak latencies were compared. Neither differed significantly 
between genotypes. The above findings led us to suggest that the hearing loss observed in the 
mutant mice is most likely caused by a peripheral – i.e. cochlear - deficit. This suggestion was 
substantiated by the fact that in the knock-out mice the outer hair cell (OHC) function, as 
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tested by distortion product otoacoustic emissions (DPOAEs), rapidly deteriorates during the 
first seven months of life.     
 
Cochlear histology in a murine model of HDR syndrome     
The auditory system of Gata3+/- mice and wild types was not only studied 
electrophysiologically, but also histopathologically. Heterozygous Gata3 mice show a 
progressive morphological cochlear degeneration starting with apical OHCs from one month 
onwards that ultimately affects all hair cells and supporting cells in the entire cochlea, as well 
as the nerve fibers. This type of degeneration is rare, but has also been described in mice 
deficient for the Barhl1 homeobox gene (Li et al, 2002.). In addition to the apical 
degeneration only found in the knock-out mice, some mild age-related morphological deficits 
starting at the cochlear base and progressing in a baso-apical direction, were demonstrated in 
both the affected mice and their control littermates (chapters 3 and 4). 
The first sign of GATA3-driven degeneration is the appearance of irregularly shaped vacuoles 
in all three rows of outer hair cells. These vacuoles can be observed at both the light – and 
electron microscopic level (chapter 4). 
 
Correlation between audiometric and histological data in a murine model of 
HDR syndrome 
In chapters 3 and 4 of this thesis we have demonstrated a Gata3 haploinsufficiency induced 
hearing loss in heterozygous knock-out mice. Since Gata3 is prominently expressed during 
different developmental stages in various parts of both the inner ear and the central auditory 
nervous system, one of the most apparent questions to be answered was whether Gata3 
haploinsufficiency induced hearing loss is peripheral or central in origin. ABR-recordings 
demonstrated a threshold shift in heterozygous knock-out mice, however without affecting 
interpeak latencies, indicating a peripheral deficit. The absence of morphologic abnormalities 
in the central auditory pathways supports this notion. GATA3 is not expressed in the middle 
ear ossicles, and no absolute ABR peak latency differences were demonstrated, suggesting 
that the hearing loss is caused by cochlear disorder. This was confirmed by our histological 
studies, demonstrating an extensive loss of OHCs – both sensors and mechanical feedback 
amplifiers – followed in time by a loss of inner hair cells (IHCs), pillar cells (PCs) and nerve 
fibers (NFs).  
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The lowest ABR-thresholds in both types of mice were found at 16 and 8 kHz, frequencies 
that are respectively perceived at 60 and 40 percent distance of the cochlear apex. This is very 
much in agreement with the histological findings in the knock-out mice, who show both an 
apical and basal age-related cochlear degeneration. The constant ABR-threshold difference 
between genotypes at 4 kHz, in this respect however, is unexpected and sofar unexplained. 
When comparing ABR-thresholds to DPOAE signal to noise ratios, we find both the lowest 
ABR-thresholds and the best DPOAE signal to noise ratios at 16 kHz. Furthermore we find 
that disappearance of DPOAEs corresponds with an approximate ABR-threshold shift of 40-
60 dB. This threshold shift is most probably for the greater part caused by OHC loss. 
However, the literature on the contribution of OHCs to hearing thresholds is not fully 
conclusive (as reviewed in the discussion section of chapter 4), and a contribution to this shift 
of e.g. IHC loss cannot be excluded.   
 
Hearing loss in HDR syndrome, a comparison of mice and men 
In Chapter 5 of this thesis, we describe the results of extensive audiometric testing of two 
human HDR patients. A moderate to severe, (probably) age-related hearing loss is 
demonstrated. Although this hearing loss affects all frequencies, it is slightly more 
pronounced in the higher end of the tested frequency spectrum. We compare the audiometric 
results obtained from the two patients to those from heterozygous Gata3 knock-out mice 
(described in chapters 3 and 4). Based on the similarities in hearing loss between the two 
species, the loss of frequency selectivity in combination with normal auditory brainstem 
interpeak latencies in man and the histological data obtained from the mice, we conclude that 
the otological, or at least the audiological phenotypes between the two species seem to 
correspond well.  
Mouse models of hearing loss for reasons discussed earlier in this thesis, today have become 
indispensable for basic auditory research. In some instances mouse mutations are identified 
even before the detection of the human disorder (e.g. Melchionda et al., 20012), whereas in 
others the detection of a human ‘deafness gene’, induces the development of a murine knock-
out model. Overviews of available mouse models have been published in several review 
papers (e.g. Ahituv et al., 2002; Morton 2002; Petit, 2006). However, the phenotypes, 
including the degrees of hearing loss, caused by a given mutation, may occasionally differ 
considerably between humans and mice. In Chapter 5 we describe two well-known examples 
                                                 
2 E.g. Myo6 and it’s associated phenotype were described in Snell’s Waltzer Mice before the identification of 
humans affected by DFNA22 
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of this phenomenon; Usher 1B syndrome and Pompe’s disease. These differences might result 
amongst others from modifications in corresponding proteins, compensatory mechanisms, or 
different evolutionary developments (Petit, 2006). Finally, modifier genes, genes influencing 
the expression or function of other genes and thus accounting for phenotypic differences 
observed in a given disease, may be of influence in both inter- and intraspecies variability.   
 
Suggestions for future research 
In this thesis we have studied the nature of GATA3 haploinsufficiency induced hearing loss by 
audiometric and histopathologic experiments. In order to fully understand the exact 
pathophysiological mechanisms leading to the cochlear degeneration and consequent hearing 
loss in HDR syndrome it would be beneficial to define all target genes of GATA3 and their 
functions and possible interactions with other genes. Recent studies have commenced in 
doing so. For example, a microarray analysis comparing gene expression levels of otic 
epithelia at an early vesicle stage between Gata3 -/- and wild type mice, identified 250 up-
regulated and 63 down-regulated genes in the mutants. Amongst the up-regulated genes were 
gap junction membrane channel protein beta2 (Gjb2), encoding connexin 26, essential for the 
formation of intercellular membrane channels (gap junctions), and Epha4 and Ephb4, 
encoding receptors that are involved in migration, adhesion and repulsion in multiple 
developmental events. In contrast secreted phosphoprotein 1 (Spp1), an extracellular matrix 
protein mediating cell-matrix interactions, cell-adhesion and cellular signaling, was down-
regulated. Taking together these observations Lilleväli et al. suggested that cell motility in 
Gata3 -/- otic epithelium is changed (Lilleväli et al., 2006). The same group suggested a 
regulatory relationship between Gata3 and fibroblast growth factor Fgf10 (Lilleväli et al., 
2006; Lilleväli et al., 2007). Furthermore, GATA3 was recently demonstrated to regulate the 
transcriptional activity of tyrosine hydroxylase through interaction with yet another 
transcriptionfactor; CREB, prompting Hong et al. to propose a role for GATA3 in the 
development of the sympathetic nervous system (Hong et al., 2006). Although the 
abovementioned studies, amongst several others, shed light on some of the functions and 
interactions of GATA3, a lot remains to be unraveled. 
In chapter 4 we have described EM findings in OHCs of 2 months old heterozygous knock-
out mice and healthy controls. It would be interesting to extend the examined age range, both 
to examine possible changes occurring at the ultrastructural before the occurrence of vacuoles 
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as well as to record the changes occurring hereafter. It would also be interesting to perform 
SEM, to closer examine the stereocilia. 
In addition to the above, it would be (clinically) relevant to perform extensive audiometry in a 
larger group of patients, preferably of different age groups, allowing us to create age related 
typical audiograms (ARTA’s). 
 
General considerations regarding the future of basic auditory research 
The discussion of this thesis would not be complete, without shortly addressing some exciting 
new developments in basic otologic research.  
The primary cause of hearing loss is damage to or death of cochlear hair cells, as it also is in 
the syndrome described in this thesis. In contrast to birds and other non-mammalian 
vertebrates, mammals lack the capacity to regenerate sensory hair cells and consequently lose 
their cochlear hair cells through apoptosis when ageing or when exposed to severe damage 
such as noise exposure or exposure to ototoxic drugs. Although recently great advances have 
been made in the treatment of sensorineural hearing loss, in both the preventative (protein 
kinase inhibitors protecting against acoustic trauma and ototoxicity) and prosthetic (e.g. 
middle ear implantable hearing assistive devices, cochlear implants, hybrid devices and 
auditory brainstem implants) field (e.g. Holley, 2005; Murugasu, 2005), preliminary results of 
studies on regenerative therapies – aimed at repairing or replacing damaged hair cells – 
suggest that a cure for sensorineural hearing loss might no longer be an utopia in the future. 
Today, three different approaches aimed to develop regenerative therapies of hearing loss; 
stem cell transplantation, gene manipulation and gene therapy. In short, stem cells are cells 
with the capacity to develop into multiple cell types, the fate of the progeny of these cells is 
dependent on the microenvironment in which the cells reside. Current stem-cell related 
studies are for example aimed at finding ‘niches’ (groups of undifferentiated and multipotent 
stem cells) in the ear and at means to make stem cells differentiate into specific target cell 
types. Gene manipulation studies examine the possibility to interfere with cell cycle 
inhibitors, blockers that down-regulate mitosis in sensory epithelium and thus establish a 
mature, non-proliferating sensory epithelium. Finally, gene therapy is the delivery and 
(regulated) expression of a gene in a specific cell or tissue aimed producing a therapeutic 
effect in this cell or tissue. The cochlea seems quite well suited for this type of therapy, being 
isolated from the rest of the body by the blood-labyrinth barrier, and with endocochlear fluids 
permitting liquids to rapidly reach the entire cochlea. Genes may be delivered either by means 
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of viral vectors or in liposomes. Focus has mainly been on the Drosophila atonol Atoh1 gene, 
and its murine and human homolog, Math1 and Hath1 respectively. The results obtained so 
far are promising: Adenoviral expression of Hath1 in rats initiated robust regeneration of hair 
cells, whereas Math1 gene transfer induced both structural and functional recovery of 
cochlear hair cells in vivo in guinea pigs (Atar et al., 2005; Holley, 2005; Izumikawa et al., 
2005; Matsui et al, 2005; Van de Water et al, 1999) 
It seems that some of the above studies make “the ability to cure sensory defects, a tangible 
goal that is now within our reach” as stated by Atar and Avraham in 2005.  
 
Conclusions 
One of the objectives of this thesis was to develop means to test hearing in alert laboratory 
animals and to evaluate the effects of anaesthesia on audiometry outcomes. In chapter 2 we 
describe a surgical technique, allowing us to measure ABRs longitudinally in alert mice. 
Moreover, we describe a significant anesthesia induced upward shift of ABR thresholds as 
well as a significant prolongation of ABR-peak latencies and I-III interpeak latencies.  
The main goal of this study, however, was to assess whether the auditory system of 
heterozygous Gata3 mice is a proper model for that of patients affected by the HDR 
syndrome. We have demonstrated that Gata3 haploinsufficiency causes a peripheral, cochlear 
hearing loss in mice, and that malfunctioning and degeneration of OHCs plays a major role in 
the coming about of this hearing loss. In addition, we have demonstrated a moderate to severe 
cochlear hearing loss in human patients, with a proposed substantial causative role for OHCs. 
We conclude that the otological or at least the audiological phenotypes between HDR patients 
and heterozygous Gata3 knock-out mice correspond well, and that hearing loss in HDR 
syndrome is mainly caused by OHC malfunctioning and degeneration, however without 
precluding a role for inner hair cells. 
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Hearing loss and deafness are major health issues. Estimations are that over 70,000,000 
people worldwide are unable to participate in normal verbal communication due to auditory 
handicaps. In the Western world, the reduction of the proportion of exogenous or 
environmental cases of deafness - due to vaccination schemes, use of antibiotics, and 
knowledge about rhesus antagonism - has led to a relative increase in genetic cases; inherited 
causes are now believed to represent over 60% of deafness cases in children.  
A commonly used classification of genetic hearing loss is that of syndromic versus non-
syndromic or isolated. Several hundreds of syndromes with hearing loss have been described 
today. Hearing loss in one of these syndromes, HDR syndrome, is extensively analyzed in 
both affected mice and human patients in this thesis. HDR syndrome is an autosomal 
dominant disorder, characterized by hypoparathyroidism, sensorineural hearing loss and renal 
dysplasia, although the phenotypic expression may be quite diverse.   
 
Chapter 2 reports on a pilot-study, conducted in healthy laboratory mice, aimed at developing 
an objective and accurate method to assess hearing acuity in these animals. 
The auditory function of laboratory animals is commonly tested by the recording of auditory 
brainstem responses (ABRs). These responses provide hearing thresholds, as well as 
information on the functioning of the central auditory pathways up to the level of the inferior 
colliculus. In the past it was demonstrated that anesthesia induced an increase in ABR- peak 
latencies in gerbil and rat. In order to avoid anesthesia-effects we developed a surgical 
technique allowing longitudinal ABR recordings in alert mice. We demonstrated that 
ketamine/xylazine anesthesia induced a significant upward shift of ABR thresholds as well as 
a significant prolongation of ABR-peak latencies and I-III interpeak latencies. In addition, we 
showed that the accuracy of peak- and interpeak latency, and threshold measurements 
decreases under general anesthesia. Finally, we demonstrated that the stimulus repetition rate 
can be as high as 80 per second without affecting ABR thresholds, interpeak latencies or 
waveforms. 
 
HDR syndrome is caused by haploinsufficiency of transcriptionfactor GATA3. The effects of 
Gata3 haploinsufficiency on hearing in mice are described in chapters 3 and 4.  
Over a one-to-nineteen months age-range and at all tested frequencies, heterozygous Gata3 
knock-out mice showed a significant ABR-threshold elevation, of approximately 30 dB, as 
compared to wild-type littermates. Both the heterozygous knock-outs and the wild type 
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controls were affected by an age-related hearing loss, causing an average monthly increase in 
ABR-threshold of 2.2 dB.  
No significant differences in ABR- peak-and interpeak latencies between genotypes were 
found. The above findings suggest that the hearing loss observed in the mutant mice is 
probably caused by a peripheral – i.e. cochlear - deficit. This was substantiated by the fact that 
in the knock-out mice the outer hair cell (OHC) function, as tested by distortion product 
otoacoustic emissions (DPOAEs), rapidly deteriorates during the first seven months of life.     
 
In addition to the electrophysiology, chapters 3 and 4 describe the histopathology of the 
auditory system of Gata3 knockout mice and wild types.  
From one month onwards, heterozygous Gata3 mice showed a progressive morphological 
cochlear degeneration starting with apical OHCs and ultimately affecting all hair cells and 
supporting cells in the entire cochlea, as well as the nerve fibers. In addition some mild age-
related morphological deficits starting at the cochlear base and progressing in a baso-apical 
direction, were demonstrated in both the affected mice and their control littermates. 
The first sign of GATA3-driven degeneration is the appearance of irregularly shaped vacuoles 
in all three rows of outer hair cells that can be observed at both the light – and electron 
microscopic level. 
 
In Chapter 5 of this thesis, the results of extensive audiometric testing  - by means of pure 
tone audiometry, speech audiometry, speech in noise, ABR and Transiently Evoked 
Otoacoustic Emissions (TEOAE) - of two HDR patients are described. We demonstrated a 
moderate to severe, (probably) age-related hearing loss that affected all frequencies, but was 
slightly more pronounced in the higher end of the tested frequency spectrum. ABR interpeak 
latencies were normal, but both patients performed poor on speech in noise tests and in 
neither patient TEOAEs could be generated. These results suggest that hearing loss in HDR 
syndrome is probably due to loss of, or a reduced functionality of outer hair cells. A role a 
role for inner hair cells however, cannot be precluded. 
 
We conclude that Gata3 haploinsufficiency causes a peripheral, cochlear hearing loss in both 
mice and men and that hearing loss in HDR syndrome is mainly due to OHC malfunctioning 
and degeneration, however without precluding a role for inner hair cells. 
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Samenvatting 
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Geschat wordt dat wereldwijd meer dan 70.000.000 mensen door een auditieve handicap niet 
kunnen participeren in normale mondelinge communicatie. Dit maakt slechthorendheid en 
doofheid een gezondheids- en economisch probleem van aanzienlijk belang. In de westerse 
wereld is er, onder andere dankzij de invoering van vaccinatieschema’s, het beschikbaar 
komen van (steeds betere) antibiotica en de toegenomen kennis over rhesusantagonisme, de 
laatste decennia een afname geweest van het percentage patiënten die doof of slechthorend 
zijn door een exogene oorzaak. Hierdoor is er een relatieve toename van het percentage  
ziektegevallen met een genetische oorzaak opgetreden; meer dan 60% van ernstige 
slechthorendheid en doofheid bij kinderen wordt tegenwoordig toegeschreven aan een 
erfelijke oorzaak.     
Erfelijke slechthorendheid wordt vaak onderverdeeld in syndromale en niet syndromale, of 
geïsoleerde slechthorendheid. Er zijn inmiddels honderden syndromen beschreven, waarbij 
slechthorendheid onderdeel van het ziektebeeld is. In de experimenten beschreven in dit 
proefschrift wordt de slechthorendheid binnen een van deze syndromen, namelijk het HDR 
syndroom, uitgebreid geanalyseerd, zowel in een muismodel van de aandoening als in 
menselijke patiënten. Het HDR syndroom is een autosomaal dominant overervende 
aandoening, die zich wisselend kan presenteren, maar waarvan de belangrijkste kenmerken 
hypoparathyreoïdie, perceptieslechthorendheid en nierdysplasie zijn. 
 
In hoofdstuk 2 wordt een pilot-study beschreven, die tot doel had een objectieve en accurate 
methode te ontwikkelen om het gehoor van laboratoriummuizen te onderzoeken. Het gehoor 
van proefdieren wordt veelal onderzocht met behulp van hersenstamaudiometrie (brainstem 
evoked response audiometry - BERA). Met deze methode wordt informatie verkregen over 
zowel gehoorsdrempels, als over het functioneren van de centrale gehoorbanen tot op het 
niveau van de colliculus inferior. In het verleden, werd aangetoond dat het gebruik van 
anesthesie in ratten en woestijnratten een toename gaf van BERA-latentietijden. Teneinde 
deze anesthesie-geïnduceerde effecten te vermijden ontwikkelden wij een techniek, die het 
mogelijk maakt longitudinaal BERA’s te meten in wakkere muizen. We demonstreren dat 
narcose met de in proefdieren vaak gebruikte middelen ketamine en xylazine, een significante 
BERA-drempel vehoging teweeg brengt, evenals een significante toename van BERA-piek 
latentietijden en van het I-III interpiek interval. Daarnaast laten wij zien dat de 
nauwkeurigheid van piek-, interpiek- en drempelmetingen afneemt onder algehele anesthesie. 
Tenslotte tonen we aan dat de ‘stimulus repetition rate’ (de frequentie waarmee de stimulus 
die de BERA induceert wordt gegeven) kan worden opgehoogd tot 80 per seconde, zonder de 
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BERA-drempel, de interpiek latenties of het golfpatroon te veranderen - hiermee kan een 
aanzienlijke tijdswinst worden behaald tijdens het meten van BERA’s in wakkere muizen. 
 
Het HDR syndroom wordt veroorzaakt door haplo-insufficiëntie van de transcriptiefactor 
GATA3. Het effect van deze genetische afwijking op het gehoor van muizen beschrijven wij 
in hoofdstuk 3 en 4. 
BERA-drempels van heterozygote Gata3 knock-out muizen in de leeftijd van 1 tot en met 19 
maanden zijn bij alle onderzochte frequenties significant (ongeveer 30 dB) hoger dan die van 
gezonde controle muizen. Daarnaast vertonen zowel de heterozygote knock-out muizen als de 
controle muizen een leeftijdsgerelateerd gehoorsverlies; maandelijks neemt de drempel met 
gemiddeld 2.2 dB toe. Tussen de genotypen bestaan geen significante verschillen in piek- en 
interpiek latentietijden.  
De hierboven beschreven bevindingen tonen aan dat het gehoorsverlies in de mutante muizen 
wordt veroorzaakt door een perifere, en specifieker een cochleaire afwijking. De snelle 
achteruitgang de van buitenste haarcelfunctie in de knock-out muizen gedurende de eerste 
zeven levensmaanden, zoals wij aantoonden met behulp van otoacoustische emissies, levert 
hiervoor nog verder bewijs. 
 
Naast electrofysiologische experimenten beschrijven wij in hoofdstuk 3 en 4 ook de 
histo(patho)logie van het auditieve system van heterozygote Gata3 knock-out en controle 
muizen. 
Heterozygote Gata3 knock-out muizen vertonen een met de leeftijd progressief cochleair 
celverlies. Het eerste teken van de door GATA3 haplo-insufficiëntie veroorzaakte degeneratie 
zijn onregelmatig gevormde vacuoles in alle rijen buitenste haarcellen, die op zowel licht- als 
electronenmicroscopisch niveau te zien zijn. De degeneratie treedt al op vanaf de eerste 
levensmaand en betreft in eerste instantie alleen de apicale buitenste haarcellen, maar later 
alle haarcellen, steuncellen en zenuwvezels in de cochlea.  
Daarnaast worden in zowel de aangedane als de controle muizen normale leeftijdsafhankelijke 
veranderingen gezien. Deze veranderingen treden aanvankelijk op aan de basale zijde van de 
cochlea, maar breiden zich met het toenemen van de leeftijd uit in apicale richting.  
 
In hoofdstuk 5 van dit proefschrift beschrijven we het gehoor van twee menselijke HDR 
patiënten, dat wij onderzochten met behulp van toonaudiometrie, spraakaudiometrie, spraak 
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testen in ruis, BERA metingen en otoacoustische emissie metingen (Transiently Evoked 
Otoacoustic Emissions -TEOAE). Wij demonstreren in deze patiënten een matig tot ernstig, 
vermoedelijk leeftijdsafhankelijk gehoorsverlies. Alle onderzochte frequenties zijn 
aangedaan, maar het verlies is het meest uitgesproken in de hoge tonen.  
De BERA interpiek latenties zijn niet afwijkend, maar otoacoutische emissies zijn niet 
opwekbaar en beide patiënten scoren slecht bij spraakverstaan in ruis. Alle resultaten in 
ogenschouw nemend, kunnen wij stellen dat gehoorsverlies binnen het HDR syndroom 
vermoedelijk wordt veroorzaakt door verlies of minder functioneren van buitenste haarcellen, 
een rol voor de binnenste haarcellen kunnen wij echter niet volledig uitsluiten. 
 
Wij concluderen dat GATA3 haplo-insufficiëntie zowel in muizen, als in mensen een perifeer, 
cochleair gehoorsverlies veroorzaakt. Het gehoorsverlies bij HDR syndroom wordt vooral 
veroorzaakt door verminderd functioneren en degenereren van buitenste haarcellen, maar 
binnenste haarcellen spelen mogelijk ook een rol.  
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gesprekken hebben misschien wel evenveel bijgedragen aan mijn wetenschappelijke vorming 
als alle experimenten uit dit boekje bij elkaar.  
Beste Eddy, dank voor je hulp bij mijn perikelen met de computer en vooral ook voor enorme 
stapels floppy’s (zo lang heeft het dus geduurd..) en later CD-rommetjes waarin je voorzag. 
 
Beste Nienke Homans, enorm bedankt voor je hulp bij het meten van de patiënten uit 
hoofdstuk 5. Juergen Kiessling, thank you very much for performing the speech audiometry 
tests in our German patient. Beste Michael Brocaar en Teun van Immerzeel bedankt voor alle 
technische ondersteuning die jullie hebben geboden, in mijn ogen zijn jullie magiërs. Beste 
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Hans Verschuure, dank voor de waardevolle adviezen die je in de loop der jaren hebt 
gegeven. 
 
Beste Janine Felix, hoewel het stuk dat wij samen hebben geschreven niet in mijn boekje is 
terechtgekomen, wilde ik je hier toch bedanken voor de gezellige uurtjes schrijven, submitten 
en re-submitten. Het was een plezier om met je samen te werken, ik wens je erg veel succes 
‘over twee weken’. 
 
Beste Hans, Fred en Marieke, dank jullie wel voor alles wat ik van jullie leer tijdens de 
otogenetica spreekuren. 
 
Beste Hans van der Ham, dank voor je hulp bij de handjes op de kaft! 
 
De mensen, die ik hieronder nog wil bedanken hebben wellicht in de strikste zin van het 
woord weinig van doen gehad met de totstandkoming van dit boekje, maar zij zijn wel 
degenen die de afgelopen jaren een essentiele bijdrage hebben geleverd aan mijn ‘emotionele 
welbevinden’, en zonder hen zou dit boekje er dus zeker niet zijn geweest!! 
 
BW-vriendjes, lieve Beatrijs, Cristel, Danny, Diederik, Els, Hester, Jan, Marieke, Martijn en 
Simone, jullie zijn het beste ‘clubje’ wat er is. Simplement penser à vous me fait déjà rire, als 
ik soms weleens had willen huilen, hoefde ik alleen maar aan jullie te denken en dan moest ik 
vanzelf al weer lachen. BW-93 geil, ik mag wel zeggen supergeil!  
Lieve Mareille, eigenlijk ben jij, door toedoen van onze wederzijdse ouders, al mijn 
vriendinnetje vanaf het moment dat jij werd geboren. Dit is zonder discussie het makkelijkste 
‘levenslang’ wat er bestaat! Lieve Michiel en Ad en Lotje, dank dat jullie mijn ‘reservegezin’ 
zijn, ik had me geen lievere surrogaat vader, moeder en broertje kunnen wensen. Babette, ik 
dacht heel eventjes dat het niet meer mogelijk zou zijn nieuwe vriendjes te maken na mijn 
dertigste, maar het kan dus toch – op vrijdag heb ik altijd al weer zin in de volgende 
donderdagavond! 
Lieve Frouke, dank voor je vriendschap en alle diepgravende – maar soms ook 
oppervlakkiger (‘hippe kleertjes zijn ook belangrijk’) - gesprekken die we voerden. Nog nooit 
heb ik zoveel over mezelf geleerd als tijdens ons verblijf in Botswana, en dat is grotendeels 
jouw verdienste. Michiel, als een vriendinnetje een man uitkiest die zo gezellig is als jij, voelt 
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dat als een bittergarnituur bij een goede zondagmiddagborrel. Lieve ‘frog and king’, nu dit ei 
is gelegd ben ik helemaal klaar voor eindeloze zomers in Toscane! 
Lieve Petnoi, al meer dan 25 jaar zijn we vriendinnetjes. Hoewel ik de laatste tijd nog wel 
eens de neiging heb gehad onder te dompelen in het werk en weg te zinken in een droevige 
soort sociale laksheid, was er aan jou gelukkig nooit te ontkomen (“lieve Mar, op de 
onderstaande 30 data kan ik, wanneer kan jij?”)! Andere vriendinnetjes van het Kennemer, 
dank dat jullie er al zo lang gewoon zijn. Lieve Muup, dank je voor de welgemeende interesse 
die je altijd toont (jij bent denk ik de enige die ooit aan mij heeft gevraagd hoe het nou 
eigenlijk is om dokter te zijn, over het antwoord moest ik best nog wel even nadenken). 
Tijdens Thom Pain had ik continue zin om spontaan in ovationeel applaus uit te barsten – in 
september kun je mij zien ‘nagelbijten’! Lieve Roos, ik weet heel zeker dat meer mensen 
jouw boek gaan lezen dan het mijne. Ik vind je een grotere held dan Eva Hart! Lieve Leen, ik 
krijg al kippevel van ontroering als ik aan jouw pianospel denk, fijn dat het de laatste tijd zo 
goed met je gaat! Lieve Annerose, jouw meiskes zijn prinsesjes, goed gedaan! 
Lieve Sahand, wat mis ik soms de ‘troost-koop-sessies’ in je winkeltje tijdens mijn 
compensatiedagen in dienstweken. Maar veel meer nog mis ik het dat een van mijn liefste 
vriendinnetjes niet meer halfverwege mijn huis en het station woont! Vroeger zei ik altijd dat 
jij het duiveltje was, dat op mijn linkerschouder voor wat leven in de brouwerij zorgde, maar 
ik heb me vergist, want je bleek toch een engeltje te zijn! 
Lieve, mooie en hippe dametjes van het goede leven, dank voor de avondjes ongecompliceerd 
eten, drinken, lachen en dansen, waarna ik altijd weer voor weken ‘opgeladen’ was. Lieve 
Amy en Nadine; thanks for never (ever) taking ‘no’ for an answer. Lieve Amy, bijpraten met 
jou had op mij al een therapeutische werking, lang voor je besloot psychiater te worden! 
Lieve Cariña, ook al zien we elkaar de laatste jaren maar weinig, ik ben er trots op dat jij al 
sinds we bij juf Beijer op de kleuterschool zaten mijn vriendinnetje bent. Wijsheid komt niet 
altijd uit boeken en veel academici zouden nog heel wat van jou op kunnen steken!  
Lieve Veer en Caro, wat vond ik het erg dat jullie stopten met de opleiding, maar wat ben ik 
ik ook trots dat jullie die knoop hebben weten door te hakken. Ik vind het een eer om “lid te 
zijn” van het tuttenclubje. Nu gebleken is dat - in elk geval de Randstedelijke -  afstanden 
geen belemmering hiervoor vormen, hoop ik dat we door zullen gaan met onze etentjes tot 
lang nadat we grijs en rimpelig zijn geworden! 
Lieve Guy, wat is het altijd gezellig als je er bent – ik ben op het moment dat ik dit schrijf nog 
aan het bijkomen van het diner (lees: slemppartij) op de Rotterdam van afgelopen vrijdag (het 
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is nu zondagavond)! Het lijkt me heerlijk om over niet al te lang eens te kunnen komen 
uitrusten in je hotel op de Filipijnen. 
Lieve Ronneke Goossens, dank je wel voor alle gezellige jaren in Zandvoort. Vooral ook 
bedankt dat je me hebt laten zien dat medisch het alleronderste uit de kan halen niet per se de 
beste behandeling hoeft te zijn. 
Lieve tante Ronneke, jij bent er het levende bewijs van dat het niet om de kwantiteit maar om 
de kwaliteit gaat. Ik vind je een beetje gek en excentriek, heel mooi, maar vooral erg lief. Ik 
ben zo trots dat jij mijn tante bent! En, hoewel ik weet dat je er niet echt van houdt boeken te 
krijgen, hoop ik dat dit exemplaar toch een plekje in je kast krijgt (er staat ergens ook nog een 
leuk fotootje van me in...)... 
Lieve Frank en Emmy, Rob en Mimi, Hans en Jenny, ‘familie krijg je en vrienden kies je’ 
zegt men wel eens, maar mijn vader en moeder kunnen zo goed kiezen, dat jullie voor mij net 
familie zijn!  
 
Lieve (oud)-assistenten van de Rotterdamse KNO, jullie maken werken minstens tweemaal zo 
leuk!  
 
Veel dank komt natuurlijk ook mijn paranimfen dr. W.P.A. Kelders, drs. M.L. Tan en drs. 
C.M. Lut toe.  
Lieve Willem en Liane, wat bijzonder dat collega’s zulke dierbare vrienden kunnen worden! 
Lieve Willem, vanaf dag één was jij mijn maatje op het lab. Hoewel onze onderzoeken elkaar 
maar zijdelings raakten, was het voor ons absoluut noodzakelijk meerdere malen per dag 
diepgravend intercollegiaal overleg te plegen – soms was er zelfs een indicatie voor een 
spoedconsult (bijvoorbeeld die keer dat jij, op zoek naar een cadeau voor Gilles -ja, jij bent 
ook heel leuk!-, volledig verstrikt was geraakt in het web van designbureaulampen). Met veel 
plezier heb ik me door jou meerdere malen laten rondslingeren in je ‘dark room’, helaas 
waren de daarbij verkregen resultaten voor jou niet altijd even bruikbaar (met name omdat je 
‘eye-link’ er wat moeite mee had mijn pupillen en mijn wimpers te onderscheiden – waarvoor 
oprechte dank aan de firma E. Lauder). Wat fijn dat we nu eindelijk, op een dag na een jaar 
later, de rollen kunnen omdraaien! 
Lieve Liane, lieve Tan. Na een korte overlap met Willem werd jij mijn grootste steun en 
toeverlaat op het lab. Ik zou wel honderd dingen tegen je kunnen zeggen, maar ik denk dat 
deze boodschap het beste overkomt: Als onze vriendschap een verjaardag zou zijn, zou ik een 
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heel bord dropveters of spaghetti eten! September wordt de mooiste maand van dit jaar, let op 
mijn woorden! 
Lieve Nienke, dank voor je altijd luisterende oor, voor je oprechte interesse, voor je 
ontluisterende nuchterheid en voor je hilarische, alles relativerende humor. Jij bent echt een 
vriendinnetje in de breedste zin van het woord. Het is een ongekende luxe om 3 paranymfen 
te hebben; ik vind het een eer dat jij er daar een van wilt zijn! 
 
Lieve pappa en mamma, in dit boekje staan een heleboel woorden (vele daarvan worden niet 
eens door de spellingscontrole herkend), maar alle dingen die ik weet, die echt belangrijk zijn, 
heb ik van jullie geleerd. Wie uit zo’n warm nest komt als dat van jullie, draagt die warmte 
voor altijd met zich mee. Dank jullie wel voor wie jullie zijn en voor wat jullie geven, dit 
boekje is voor jullie! 
Lieve Vis, jij bent mijn beste vriendje, met jou wil ik nog jaren praten en lachen. Je bent mijn 
life-saver, als jij er niet was geweest was ik ergens gedurende de afgelopen jaren van de 
honger of slaap omgekomen! Jij bent de gezelligste disgenoot, wat fijn binnenkort ook thuis 
weer eens aan de eettafel te kunnen zitten, als die ontdaan is van alle ‘promotie-rotzooi’. Jij 
bent mijn fijnste reisgezel, ik wil nog minstens 980 plaatsen met je zien! Je bent mijn liefste 
liefde: Ik kan niet wachten op de rest van ons leven! 
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“The only reason for time is so that everything doesn’t happen at once.” (A. Einstein). 
 
 
Marjolein Annigje Johanna van Looij werd op 14 juni 1975 in Haarlem 
geboren. In 1993 behaalde zij het eindexamen gymnasium ß aan het 
Kennemer Lyceum te Overveen. In datzelfde jaar begon zij met de 
studie Biomedische Wetenschappen aan de Rijksuniversiteit Leiden, 
maar een jaar later maakte zij de overstap naar de studie Geneeskunde. 
Tijdens haar studie was zij als student-assistent verbonden aan de 
afdeling anatomie en werkte zij als gids voor het anatomisch museum. 
Haar afstudeeronderzoek “Chimaerism after Allogenic Bone Marrow Transplantation in 
Relation to Relapse – A study of mixed chimaerism in DNA isolated from stored blood 
smears” deed zij aan de afdelingen antropogenetica en paediatrische haemato-oncologie van 
het LUMC. Na het doorlopen van de reguliere co-schappen liep zij haar keuze-coschap in het 
Deborah Retief Memorial Hospital, Mochudi, Botswana. 
Zij was, na het behalen van het artsexamen, korte tijd werkzaam als AGNIO heelkunde in het 
Diaconessenhuis in Leiden. Sinds mei 2001 is zij als “AGIKO”  verbonden aan de afdeling 
KNO-heelkunde van het Erasmus MC. Onder begeleiding van dr. G.A. van Zanten, Prof. dr. 
L. Feenstra en Prof. dr. C.I. de Zeeuw werkte zij op de afdeling neurowetenschappen aan het 
onderzoek dat heeft geleid tot dit proefschrift. Op 1 juli 2008 hoopt zij haar opleiding tot 
KNO-arts te voltooien. 
De auteur woont samen met André Vis. 
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List of abbreviations 
ABR   Auditory Brainstem Response 
AEP   Auditory Evoked Potentials  
AHL  Age-related Hearing Loss 
ARTA  Age Related Typical Audiograms 
ASD  Atrial Septal Defect  
ATP  Adenosine Triphosphate 
BOF   Branchio-Oculo-Facial (syndrome) 
BOR  Branchio-Oto-Renal (syndrome)  
BRESEK Brain anomalies, Retardation , Ectodermal dysplasia, Skeletal  malformations, ear/eye 
anomalies, Kidney dysplasia/hypoplasia and reflux 
BRESHECK  Brain anomalies, Retardation , Ectodermal dysplasia, Skeletal malformations, 
Hirschsprung disease, ear/eye anomalies, cleft palate/cryptorchidism, Kidney 
dysplasia/hypoplasia and reflux 
CEOAE’s  Continuous Evoked Otoacoustic Emissions 
CNS  Central Nervous System 
CS I  Classical Cockayne Syndrome 
CS II  Type II Cockayne Syndrome 
CSF  Cerebro Spinal Fluid 
CVA  Cerebro Vascular Accident 
dB  Decibel 
dBHL  Decibel Hearing Level (biological scale)  
dB SPL  Decibel Sound Pressure Level (environmental scale) 
DDAVP Desamino-D-Arginine Vasopressin 
DIDMOAD  Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and Deafness 
DFN  X-linked non-syndromic deafness 
DFNA  Dominant non-syndromic deafness  
DFNB  Recessive non-syndromic deafness 
DFNM  Modifying non-syndromic deafness 
DGCRI  DiGeorge Critical Region I 
DGCRII DiGeorge Critical Region II 
DNA  Deoxyribonucleic Acid 
DPOAE Distortion Product Otoacoustic Emission 
DRTA   Distal Renal Tubular Acidosis  
EM  Electron Microscopy 
FA  Fanconi Anemia 
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FCS  Familial Cold autoinflammatory Syndrome  
FISH   Fluorescence In Situ Hybridization  
Fgf   Fibroblast growth factor  
FMD   Fronto Metaphyseal Dysplasia 
FOG  Friends Of GATA 
GATA   A/T GATA A/G 
GBM  Glomerular Basal Membrane 
Gjb2  Gap junction membrane channel protein beta2  
HDR   Hypoparathyroidism, Deafness, Renal dysplasia 
Ht  Heterozygous 
IHC  Inner Hair Cell  
MIDD  Maternally Inherited Diabetes mellitus and Deafness  
MNS   Melnick-Needles Syndrome 
MWS  Muckle-Wells Syndrome 
NIHL  Noise Induced Hearing Loss 
NF  Nerve Fiber 
NOMID  Neonatal Onset Multisystem Inflammatory Disease  
OAE  Otoacoustic Emission 
OAVS  Oculoauriculovertebral spectrum 
OHC  Outer Hair Cell  
OPD   Oto-Palato-Digital syndrome 
PI   Peak I 
PII  Peak II 
PIII  Peak III 
PIV  Peak IV 
PV  Peak V  
PC  Pillar Cell 
PNS  Peripheral Nervous System 
PTH  Parathyroid Hormone 
SFOAE’s Stimulus Frequency Otoacoustic Emissions 
SOAE’s Spontaneous Otoacoustic Emissions  
TEOAE’s Transient Evoked Otoacoustic Emissions 
TIA  Transient Ischemic Attack 
TM  Tectorial Membrane 
VSD  Ventricular Septal Defect. 
Wt  Wild type 
 
